# ARA-290 (cibinetide): a fragment of erythropoietin that acts on nerves, not on blood

slug: ara-290 · https://miscsubjects.com/a/ara-290 · tags: peptide, ara-290, cibinetide, neuropathy, disc · updated 2026-08-06T07:53:46.499Z

Six randomised, placebo-controlled trials have put this compound into people and measured what happened. Three hit the thing they set out to change. Three missed.

> **The number most people need first: the trials gave 4 mg a day. Public reports of self-use run 250 to 1,000 mcg a day — four to sixteen times less, and below the lowest arm of the only dose-ranging trial ever run, which itself missed at 1 mg. Whatever the trials showed, almost nobody is taking that dose.** Nothing else written up on this site has that record. This is the one compound here whose evidence starts in people rather than in rats.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.
The compound is ARA-290, also written cibinetide. It is eleven amino acids in a row, copied off one face of a hormone your kidneys already make — erythropoietin, the hormone that tells bone marrow to build red blood cells. That hormone does a second job as well: it keeps injured cells from dying and helps damaged nerves grow back. The two jobs run through two different docking points on the cell. ARA-290 was cut out of the parent molecule to hit the repair one and miss the blood one. It does not raise your red cell count and it does not carry erythropoietin's clotting risk.

If you have burning feet, numb toes, electric jabs in the legs at night, or skin so sensitive that a bedsheet hurts, this is the compound in this library with the most human data behind it. What follows is what was given, to whom, at what dose, what moved and what did not, where the measurements stop, and the arithmetic that decides whether the dose you can actually buy is anywhere near the dose that was tested. That last answer is short: it is not. What people take sits four to sixteen times below anything a trial has ever given.

[[embed:source:s25]]

## Two jobs, one hormone, and a peptide cut to do only one of them

The reasoning that produced ARA-290 runs in five steps, and each step is a published result rather than a guess.

1. Erythropoietin tells bone marrow to make red blood cells. It does that by clamping two identical erythropoietin docking points together. This is the effect that makes the hormone a doping agent and a stroke risk.
2. Erythropoietin also keeps injured tissue alive and helps it rebuild. That was seen in stroke, in kidney damage, in heart damage and in nerve damage, decades before anyone knew why.
3. The two effects are not the same signal. Brines and Cerami showed that the repair effect runs through a different docking point entirely: one erythropoietin subunit joined to a second protein called CD131. They named the pair the innate repair receptor.

[[embed:source:s8]]

4. Because the two docking points are built differently, the two effects can be pulled apart by design. A molecule shaped to fit the repair pair, but too small to clamp the blood pair, would rebuild tissue without touching the marrow.
5. The part of erythropoietin that faces outward and does the repair binding is called the helix B surface. An eleven-residue peptide that reproduces that surface, with its front end looped shut so enzymes cannot chew it, is ARA-290 — also written pHBSP.

[[embed:source:s9]]

What that produces is not a weaker dose of erythropoietin. It is a different molecule that physically cannot reach the docking point erythropoietin uses to thicken your blood.

## What is dying back, and what would have to grow for it to stop hurting

Small-fibre nerve damage is a degeneration story with a specific shape, and the whole case for this compound is that it acts on one particular link in it.

**What is breaking down.** The nerve endings that carry pain, temperature and sweating signals are the thinnest fibres in the body — unmyelinated C fibres and thinly wrapped A-delta fibres. They end in your skin, in your cornea, in the lining of your gut. They are the furthest thing from the cell body that keeps them alive, so they are the first to die back when anything goes wrong upstream.

**What makes it break down faster.** Two drivers, and they are different diseases. In sarcoidosis, immune cells clump into granulomas and the inflammation eats the fibres. In diabetes, high blood sugar starves and poisons them from the inside. Both drivers keep working while the fibre is trying to survive, which is why removing the driver matters more than any repair signal.

**What the pain actually is.** As fibres die back, the ones left behind fire without being touched. That is why the pain is burning, electric and worse at night rather than sharp and located. The pain is not a measure of how much nerve you have left. It can rise while fibres are still dying and fall while fibres are still gone.

**What would have to grow.** New fibre, sprouting from the surviving stump outward, re-entering the skin. That is a slow, expensive process for a cell, and it is switched off by the same inflammation that caused the damage. Two things have to happen: the surviving cell has to not die, and it has to be given the signal to extend.

**What this compound does to that chain, and how strongly the evidence holds at each step.** It switches on a repair receptor that only assembles on damaged cells — shown directly in cells and animals, strong. Switching it on stops injured cells killing themselves and quiets the immune cells around them, dropping IL-6, IL-12 and TNF-alpha — shown in cells and animals, strong. Quieting that inflammation lets fibres regrow — shown in people, in two randomised trials, by counting fibres, moderate. Regrown fibres make the pain better — shown once, weakly, and missed twice. That last link is the weak one and it is the one you care about.

[[embed:source:s6]]

## The receptor only exists where there is damage

The repair docking point is not sitting on healthy cells waiting to be switched on. The erythropoietin subunit and the CD131 subunit sit apart until injury, inflammation or metabolic stress brings both to the cell surface at the same time. Only then does the pair exist. Only then is there anything for ARA-290 to bind.

Daniel Culver of the Cleveland Clinic, who ran the largest trial, described the assembly to a room of patients in plain terms: a subunit "comes out of the inside of the cell and comes up and joined its partner, joins the beta common receptor here on the surface the cell and it makes this dimer, this two-headed receptor."

[[embed:source:s28]]

Two things follow from that, and both are practical.

The drug does something where there is damage and nothing where there is not. That is the mechanical reason its safety record across the trials is as clean as it is — there is no receptor for it to act on in healthy tissue.

And the size of any effect is capped by how much damaged tissue is putting the receptor out. A person with nothing wrong should expect to feel nothing at all. That is not a disclaimer; it is what the trials found. Eleven of the diabetic subjects in the 2015 trial had normal corneal nerve counts at the start. They had nothing to repair, and their numbers did not move.

## Six trials in people: three hit, three missed

Every registered or published human study of ARA-290 and cibinetide, with the result stated the way the trial stated it.

| Trial | Registration | n | Who was enrolled | Dose and route | Length | What it set out to change | Result |
|---|---|---|---|---|---|---|---|
| Heij 2012 pilot, Leiden | Reported in Mol Med 2012; no NCT number | 22 (12 active / 10 placebo) | Sarcoidosis with small-fibre nerve symptoms | 2 mg into a vein, three times weekly | 4 weeks | Safety; change in the small-fibre symptom score | **Hit.** Symptom score −11.5 ± 3.04 against −2.9 ± 3.34 on placebo, p < 0.05. Pain and fatigue scores improved equally in both arms — no separation |
| Dahan 2013, Leiden | Investigator-run, single centre | 38 (21 active / 17 placebo) | Sarcoidosis with confirmed loss of small nerve fibres | 4 mg under the skin, daily | 28 days | Change in the number of nerve fibres in skin or cornea at day 28 | **Split.** Corneal fibre count rose significantly. Fibres in a lower-leg skin sample rose 0.38 ± 0.48 per mm, 7.2% above their own starting point, not significant. Symptoms, temperature sensing and 6-minute walk all improved |
| Culver 2017 Phase 2b, Cleveland Clinic and Leiden | NCT02039687 | 64, 16 per arm | Sarcoidosis with lost small nerve fibres and nerve pain | 1, 4 or 8 mg under the skin, daily | 28 days | Change in corneal nerve fibre area at day 28 | **Hit at one dose only.** Above placebo: 109 µm² at 1 mg (not significant), 697 µm² at 4 mg (p = 0.012), 431 µm² at 8 mg (not significant). Newly sprouting fibres in skin, tagged with GAP-43, rose in the 4 mg arm, p = 0.035. Pain in the moderate-to-severe subgroup: p = 0.157, missed |
| Brines 2015, Leiden / Karolinska / Manchester | NTR3858 | 49 enrolled, 48 analysed, 24 per arm | Type 2 diabetes with painful nerve damage in the feet and legs | 4 mg under the skin, daily, self-injected | 28 days dosing, 56 days follow-up | Side effects and blood work; change in HbA1c; change in symptom scores | **Hit.** HbA1c −0.16% at day 28 and −0.21% at day 56, against −0.01% and +0.21% on placebo, p = 0.002. The PainDetect score improved significantly. Corneal fibre count +2.6 ± 1.0 per mm² in the subgroup that started abnormal (n = 18, p = 0.02) against +0.7 on placebo |
| Cerit 2015, Leiden | NCT02070783 | 36 healthy volunteers | Healthy adults, in a task that predicts antidepressant action | 2 mg, single dose | One dose, read at one week | Brain response to fearful against happy faces; reading emotional expressions | **Missed.** Some shift in emotional processing, nothing in mood or symptoms. The authors wrote that the effects "do not unequivocally support an antidepressant-like profile" |
| Lois 2020, Queen's University Belfast | NCT06626971 / EudraCT 2015-001940-12 / ISRCTN16962255 | 9 recruited, 8 finished | Swelling at the back of the eye from diabetes, retinal thickness above 400 µm | 4 mg under the skin, daily, self-injected | 12 weeks | Change in best-corrected vision and retinal thickness at week 12 | **Missed, then stopped early.** Vision −2.9 ± 5.0 letters, retinal thickness +10 ± 94.6 µm, retinal sensitivity −0.53 ± 1.9 dB, tear production −0.13 ± 7.7 mm. The vision questionnaire score rose 2.7 ± 3.1 |

[[embed:source:s1]]

[[embed:source:s2]]

[[embed:source:s17]]

[[embed:source:s3]]

[[embed:source:s23]]

[[embed:source:s21]]

[[embed:source:s22]]

[[embed:source:s20]]

A seventh trial was registered and never reported: NCT01933529, a Karolinska study in prediabetes and type 2 diabetes, planned for 24 people, still listed as status unknown against a finish date of December 2015.

[[embed:source:s24]]

Across all six trials, about 132 people have received the real drug rather than placebo. The longest anyone has taken it under observation is 12 weeks, and that was the trial that failed.

## Three of the four wins came out of one disease

Three of the four positive results sit inside a single condition, which changes how far you can read them across to anything else.

In sarcoidosis, the small-fibre damage is driven by the immune system. Clumps of inflammatory cells damage the thin fibres that carry pain, temperature and sweating signals. Unlike diabetes, the damage is often not worst at the far end of the limb — it comes in patches rather than the glove-and-stocking pattern. About half of sarcoidosis patients with small-fibre damage carry the inflammatory protein signature of the far-end-worst form.

The people enrolled were not mild cases. In the Phase 2b, more than 80% were already on painkillers, about two-thirds were on nerve-pain drugs, most were taking around two drugs a day for it, and, in Culver's words, "usually not achieving very good benefits." Their skin fibre counts at the start were roughly half those of healthy people the same age and sex.

The diabetes trial is the one win outside sarcoidosis, and its nerve result was a subgroup result. Eleven of the diabetic subjects already had corneal nerve counts within one standard deviation of normal — they had nothing measurable to repair. The +2.6 fibres/mm² gain belongs to the 18 subjects who were genuinely abnormal to start with.

[[embed:source:s4]]

## They counted the nerves in a microscope instead of asking how it felt

What makes this data set unusually believable is not the pain scores. It is where they pointed the camera.

Your cornea has more nerve endings per square millimetre than anywhere else on your body, and they sit a few hundred microns under a clear window. A confocal microscope photographs that mesh in a conscious patient in a few minutes — no numbing, no cutting, no biopsy. Software then counts the fibres per square millimetre, the branch points, the total length, and the number the Phase 2b used: corneal nerve fibre area, meaning how much of the picture is nerve.

What that buys you, against the alternatives:

- **Against a pain questionnaire.** Pain scores moved in every arm of every trial. Culver's summary of the Phase 2b was that "every single group had improvements including the placebo." A photographed count of nerve fibres does not respond to hope.
- **Against a skin biopsy.** Counting fibres in a punch of skin is the reference method, but it needs holes cut in you at several time points, is read in a handful of specialist labs, and in this drug's own trials was the measure that failed to separate from placebo twice. The corneal picture picks up regrowth better.
- **Against a nerve conduction test.** Those read the big insulated fibres. Small-fibre disease is invisible to them, which is why so many people with burning feet are told their nerve test was normal.

[[embed:source:s19]]

The Phase 2b then did the thing that turns a stand-in measurement into a real one. It checked whether the eye moved with the rest of the body. Change in corneal nerve fibre area tracked change in newly sprouting GAP-43-tagged fibres in skin, ρ = 0.575, p = 0.025, and change in how far people could walk in six minutes, ρ = 0.645, p = 0.009. The eye, the skin and the legs moved together.

Culver stated the limit of that logic himself, and it is the honest caveat on the entire programme: "heaven forbid that you're measuring something that affects a surrogate endpoint but it doesn't have anything to do with the clinically meaningful endpoint, because then you might end up with a medication that is beneficial to something we measure but not beneficial to how you feel, function or survive."

He reported the durability problem just as plainly. Twenty-eight days of injections produced a measurable gain at day 28, and then: "By day 56 some of that goes back to the baseline... it looks like 28 days is probably not going to be enough to maintain a durable benefit."

[[embed:source:s28]]

## Where the trial record stops

If your problem is sciatica from a disc, you have a different injury from everyone in these trials. Here is exactly what carries across and what does not.

| Feature | Sarcoid small-fibre damage (trial population) | Diabetic nerve damage (trial population) | A nerve root squeezed by a disc |
|---|---|---|---|
| What started it | The immune system, clumping into granulomas | High blood sugar | Mechanical squeezing, plus chemical burn from the soft centre of the disc leaking onto the root |
| Which fibres | Thin unmyelinated C and A-delta | Thin fibres first, thick ones later | Thick insulated motor and sensory fibres of the root, plus thin ones |
| Where it is felt | Often patchy, not worst at the far end | Far-end-worst, glove and stocking | Along one or two nerve root bands |
| Inflammation in the picture | Central to the disease | Present | Present — disc material against a root sets off TNF-alpha, IL-1beta and immune cells in the spinal cord |
| Is something still physically pressing | No | No | Yes, and it stays there |
| ARA-290 evidence | Three trials, two positive main results | One positive trial, subgroup result on nerve counts | None |

The row that carries across is the inflammation row. Root pain is not purely a squeezing problem: contact between disc material and a nerve root sets off an inflammatory cascade in the spinal cord, and the immune cells there are a large part of what keeps the pain going. That is exactly the target ARA-290 was shown to hit in a mechanical nerve injury. In rats whose nerve was cut in the spared-nerve-injury model, ARA-290 at 3–60 µg/kg on days 1, 3, 6, 8 and 10 reduced pain from light touch and from cold out to 20 weeks, and the animals given 30 µg/kg showed no rise in spinal immune cell activity at all.

[[embed:source:s5]]

Spared nerve injury is a surgical, mechanical cut — closer to a squeezed root than either trial population is. That is the strongest bridge available, and it is a rat.

The row that does not carry across is the squeezing row, and it was put as a question by someone reading the same evidence:

[[embed:source:s31]]

Nothing in the ARA-290 record touches ongoing pressure. The peptide does not widen the gap the nerve is passing through, does not shrink a bulge, and does not change a joint. Every trial population had an injury with no mechanical cause left to remove. If something is still pressing on your root, you have a driver this drug cannot reach.

Searching the trial registry for the spine returns nothing. ClinicalTrials.gov holds four studies under "cibinetide" and four under "ARA-290", and they are the same four: sarcoidosis, type 2 diabetes, depression, swelling at the back of the eye. No sciatica trial. No disc trial. No trial in a pinched nerve root of any kind.

## The tested dose is about twelve vials a month, and almost nobody takes it

The number that governs everything practical about this compound is 4 mg a day.

It came out of a crossover study of how the body absorbs and clears it, run inside the Dahan 2013 trial. Blood levels above 1.3 ng/mL were treated as the working range, and the total exposure above that line was 65 ng/mL×min for 2 mg into a vein, 23 for 2 mg under the skin, 59 for 4 mg under the skin and 249 for 6 mg under the skin. Only the 6 mg dose was significantly different from the others. The 4 mg subcutaneous dose was picked because it reproduces the into-a-vein exposure that had already worked, in a form you can inject at home.

A separate run in healthy volunteers gives the shape of the curve. Four milligrams under the skin peaks at about 3 ng/mL in the blood — roughly 2.4 nmol/L — and is half gone in about 20 minutes. Injected into a vein, it is half gone in about 2 minutes.

[[embed:source:s35]]

A drug that clears in twenty minutes, injected once a day, looks like a contradiction. It is not. Binding the repair receptor starts a gene programme inside the cell, and that programme keeps running for days after the peptide itself is gone. Collino and colleagues titled their review of exactly this "flipping the molecular switch", and it is why effects in animals last weeks after five injections.

[[embed:source:s18]]

Then the arithmetic that decides whether any of this is within reach.

A 28-day course at 4 mg a day is 112 mg of peptide. Research-grade ARA-290 is sold in 5 mg and 10 mg vials. So one trial-equivalent month is eleven to twelve 10 mg vials, or twenty-three 5 mg vials.

Nobody buys that. The doses described in public reports run 250 to 1,000 mcg a day — a quarter of a milligram to one milligram, against the four milligrams every successful trial used. That is four to sixteen times less. Say it as bluntly as it deserves: the dose people take has never been tested in a person for anything, and it sits below the lowest arm of the only dose-ranging trial ever run, which itself missed at 1 mg.

## Mixing a vial, in numbers a syringe can read

The trials injected 4 mg in 0.5 mL. That is 8 mg per mL, and it is worth copying because it fills exactly half an insulin syringe.

The arithmetic, one step at a time:

1. Take a 10 mg vial. 10 mg is 10,000 mcg.
2. Add 1.25 mL of bacteriostatic water, slowly, running it down the inside wall of the vial. Do not shake. Swirl until it is clear.
3. Concentration = 10,000 mcg ÷ 1.25 mL = **8,000 mcg/mL**.
4. A U-100 insulin syringe holds 1 mL across 100 marks, so one mark is 0.01 mL.
5. Mcg per mark = 8,000 mcg/mL × 0.01 mL = **80 mcg per mark**.
6. The 4 mg trial dose = 4,000 mcg ÷ 80 = **50 marks = 0.5 mL**, the exact volume injected in the diabetes trial.

Other fills, same arithmetic:

| Vial | Bacteriostatic water | Concentration | Mcg per mark | Marks for 4 mg | Marks for 1 mg | Marks for 500 mcg | Marks for 250 mcg |
|---|---|---|---|---|---|---|---|
| 5 mg (5,000 mcg) | 1.0 mL | 5,000 mcg/mL | 50 | 80 | 20 | 10 | 5 |
| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 200, two injections | 50 | 25 | 12.5 |
| 10 mg (10,000 mcg) | 1.25 mL | 8,000 mcg/mL | 80 | 50 | 12.5 | 6.25 | 3.1 |
| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 80 | 20 | 10 | 5 |
| 10 mg (10,000 mcg) | 2.5 mL | 4,000 mcg/mL | 40 | 100, a full syringe | 25 | 12.5 | 6.25 |

For sub-milligram doses, use the weaker fills. At 8,000 mcg/mL a 250 mcg dose is three marks on the barrel, and three marks is not a measurement, it is a guess.

The rest of the regimen, as the trials actually ran it:

- **Where it went.** Under the skin. Diabetes-trial subjects injected their own front thigh, moving the spot each day. The sarcoidosis trial used upper leg or lower belly and reported no stinging and no irritation at the site.
- **How often.** Once a day. The only human schedule that was not once a day was the 2 mg into-a-vein pilot at three times weekly, and it was dropped because you cannot run a vein line at home.
- **How long.** 28 days in five of the six trials, 12 weeks in the sixth. There is no human data on any schedule longer than 12 weeks.
- **How long until anything moved.** Symptom scores separated from placebo by week 4 in the pilot. Corneal nerve fibre area separated at day 28. Both drifted back toward the starting point by day 56 once the injections stopped.
- **What it was mixed in.** The trial formulation was 20 mmol/L sodium phosphate buffer at pH 6.5 with 1% sucrose and 4% D-mannitol — a buffered, sugar-stabilised solution, not plain water.

## Once water goes in you have four weeks

| State | Temperature | How long it is good for |
|---|---|---|
| Sealed dry vial | 2–8 °C, out of the light | Months, to the manufacturer's date; −20 °C for long holding |
| Mixed with bacteriostatic water | 2–8 °C | About four weeks, set by the 0.9% benzyl alcohol preservative |
| Mixed with plain sterile water | 2–8 °C | One session. No preservative, no second needle entry |
| Mixed, left on the counter | 20–25 °C | Treat it as spoiled |
| Mixed, then frozen | −20 °C | Do not. Freezing and thawing clumps short peptides |

At 4 mg a day a mixed 10 mg vial lasts two and a half days, so the four-week clock never bites at trial dosing. At 250–500 mcg a day the clock is the thing that decides how the vial gets split, and most of the vial will expire before you use it.

## One death, four serious events, and no change in the blood counts

The safety claim that matters here is narrow and specific: ARA-290 does not act on the blood-building docking point, so it should not raise red cell production. The trials tested that, and it held.

- **Dahan 2013, n = 38.** "No medically significant deviations were noted in the general blood chemistry or hematology assessments." No serious events during dosing or across 12 weeks of follow-up. No pain or irritation at the injection site. One person on ARA-290 had a moderate event: 14 kg of weight loss over several months. The placebo arm had three moderate events — diarrhoea, irritability, light-headedness.
- **Brines 2015, n = 48.** No meaningful drug-related change in red cells, platelets or white cells. Four serious events happened in the ARA-290 arm. Two were judged unlikely to be related. Two were judged possibly related: one subject on daily furosemide developed worsening borderline kidney failure and stopped at day 15, and one subject was hospitalised for poor blood supply to a leg two weeks after the last dose and then died of a heart attack, which the safety committee judged unrelated to treatment. Non-serious events ran 64 in the ARA-290 arm against 66 on placebo.
- **Culver 2017 Phase 2b, n = 64.** One person had a serious event that led to stopping the drug, judged "possibly related at all". No deaths. Culver's reading: "there's no clear-cut serious or even not very serious adverse effects that occur very frequently with the medication", qualified in the same breath by "we're analysing small numbers of patients here so we'll need a larger trial to really answer the question."
- **Lois 2020, n = 9.** "No serious adverse events/reactions or anti-cibinetide antibodies were seen" across 12 weeks, the longest human exposure on record.
- **Heij 2012, n = 22.** "No safety concerns were raised by clinical or laboratory assessments."

[[embed:source:s16]]

Whether the immune system reacts to it — meaning whether the body starts making antibodies against the injected peptide — was tested in the diabetes trial and in the eye trial. Neither found any. For an injected peptide that is a real question, and it has now been answered twice, at small numbers.

State the limits exactly. About 132 people have had the real drug. Nobody has taken it beyond 12 weeks under observation. The mechanism is switching on a survive-and-repair signal, which is a reason for caution if you have an active cancer, and no trial has looked at that. And the one death on record happened in a diabetic group averaging 63 years old, where a heart attack two weeks after the last injection is what the underlying disease produces anyway — which is why it was judged unrelated, and why 48 people can neither rule it in nor rule it out.

## Two regulators gave it orphan status, then the company shut

| Date | Authority | Action | Condition |
|---|---|---|---|
| 7 October 2013 | European Commission / EMA | Orphan designation EU/3/13/1191 | Treatment of sarcoidosis |
| 28 October 2014 | FDA | Fast Track designation | Small-fibre nerve damage in sarcoidosis |
| 5 July 2016 | FDA | Orphan Drug designation | Treatment of sarcoidosis |
| 29 August 2016 | European Commission / EMA | Orphan designation EU/3/16/1721 | Preventing graft loss in pancreatic islet transplant |
| May 2017 | Cleveland Clinic and Leiden | Phase 2b published; main result met at 4 mg | Small-fibre nerve damage in sarcoidosis |
| 2016–2017 | Belfast Health and Social Care Trust | Eye trial run, then stopped at n = 9 | Swelling at the back of the eye from diabetes |
| April 2019 | EMA | Orphan sponsorship moved to Araim Pharmaceuticals Europe Limited, Ireland | — |

[[embed:source:s14]]

[[embed:source:s27]]

[[embed:source:s26]]

Orphan designation and Fast Track are not approvals. Culver told the patient audience exactly what was still missing: "a phase 2b trial does not equal approval of a medication you must have a phase three trial and sometimes two phase three trials in order for the FDA to approve a medication for commercial distribution." He added, in the same breath, "I don't know if a phase three Cibinetide trial will happen."

It did not. No Phase 3 was ever started, in any condition. Araim Pharmaceuticals, of Tarrytown, New York, stopped operating, and the four registry entries now read completed, terminated or status unknown. Cibinetide is approved nowhere, for anything.

That leaves no pharmaceutical supply at all. What circulates is research-grade material, and an eleven-residue peptide with a looped front end is not the easiest thing to make correctly. A third-party purity run and a mass-spectrometry identity check on the specific batch is the only evidence that a vial holds what the label says.

[[embed:source:s30]]

## What the people taking it report, counted

Five public accounts of ARA-290 are catalogued on this page. Three are first-person reports from someone who took it. Two describe improvement. One is a person eight weeks into a course with no result yet. None report nothing happening. None report harm. The remaining two accounts are a sceptic asking a question and a reader quoting the trial numbers back.

Three is not a denominator. Say that plainly rather than dressing it up: for BPC-157 and KPV there are dozens of first-person reports and they can be counted into a rate. Here there are three, and a rate built on three people is noise. Everything below is labelled anecdotal and is here for one reason — it is the only record of what this compound does at doses and durations no trial ran.

**Reported improvement, 2 of 3.**

[[embed:source:s13]]

That account describes 500 mcg under the skin into the outer hip near the pain, about six hours of tiredness afterward, and then: "I went from 3 weeks of being unable to put on pants or get in the car without stabbing pain, to zero pain." The same writer settled on roughly 400 mcg a day across four months — a tenth of the trial dose, for four times the longest trial.

[[embed:source:s32]]

**Under way, no result yet, 1 of 3.**

[[embed:source:s33]]

**Not a personal report — a question, and a reading of the trial.**

[[embed:source:s31]]

[[embed:source:s34]]

The public accounts agree on one thing and are silent on another. They agree that burning, tingling and sensitivity in the feet and legs are what got better. They are silent on nerve root pain: nobody is reporting a resolved pinched root, and nobody is reporting any kind of controlled comparison.

One report belongs here because it came from inside a trial rather than off a forum. Culver, quoting a Phase 2b participant: "Hey I just went to the mall all afternoon and I haven't done that for many, many years. I'm able to do much more than I was ever able to do." That person's 6-minute walk distance was one of the numbers that moved with the corneal nerve count.

## Where it sits next to the other compounds here

BPC-157 and TB-500 have animal evidence in tendon, ligament and muscle, and no controlled human trial in any of those tissues. ARA-290 is the mirror image: almost nothing preclinical in muscle or tendon, and the only randomised, placebo-controlled human trials in this whole group, every one of them aimed at nerve.

So the division of labour in a disc protocol is clean. The others are aimed at the tissue around the nerve. This one is aimed at the nerve. The framework is laid out on the disc-stack, herniated-disc and degenerative-disc-disease pages.

[[embed:source:s29]]

## What is settled, what missed, and what nobody has measured

| Status | Statement |
|---|---|
| Settled | An eleven-amino-acid peptide reproducing one face of erythropoietin, which switches on the EPOR/CD131 repair receptor and not the blood-building one |
| Settled | In small-fibre nerve damage from sarcoidosis, 4 mg a day under the skin for 28 days raised corneal nerve fibre area 697 µm² above placebo, p = 0.012, in a randomised trial of 64 people |
| Settled | The same dose raised the count of newly sprouting GAP-43-tagged fibres in skin, p = 0.035, and those changes moved with 6-minute walk distance |
| Settled | In type 2 diabetes, 4 mg a day for 28 days improved HbA1c against placebo, p = 0.002, and improved the PainDetect symptom score significantly |
| Settled | No meaningful change in red cells, platelets or white cells in any trial that measured them |
| Settled | Half gone in about 20 minutes under the skin and about 2 minutes into a vein, with the biological effect lasting days |
| Settled | Orphan designation in the US and EU, Fast Track in the US, and no approval anywhere |
| Missed | The count of nerve fibres in a skin sample did not separate from placebo in either sarcoidosis trial that measured it |
| Missed | Pain in the moderate-to-severe subgroup of the Phase 2b, p = 0.157 |
| Missed | Swelling at the back of the eye from diabetes — no change in vision or retinal thickness at 12 weeks, trial stopped at n = 9 |
| Missed | Antidepressant activity in a healthy-volunteer model |
| Untested | Any effect on sciatica, root pain or a nerve compressed by a disc. No trial has been run |
| Untested | Whether gains hold after the injections stop — the day-56 numbers show they partly reverse |
| Untested | Whether sub-milligram doses, which is what circulates, do anything at all |
| Unknown | Safety past 12 weeks, in anyone |
| Unknown | What it does in an active cancer, given that the target is a survive-and-repair receptor |
| Unknown | Whether a research-grade vial holds correctly made peptide, without a purity and mass-spectrometry run on that batch |

*Cibinetide is not an approved drug in any country and has no pharmaceutical supply. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:bpc-157]]

[[embed:tb-500]]

[[embed:wolverine-stack-ara-290]]

[[embed:herniated-disc]]

[[embed:degenerative-disc-disease]]

[[embed:what-are-peptides-herniated-disc]]


## Sources

1. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study — https://pubmed.ncbi.nlm.nih.gov/23168581/
2. Phase 2 Dose Ranging Study of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Sarcoidosis — https://clinicaltrials.gov/study/NCT02039687
3. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain — https://research.manchester.ac.uk/en/publications/cibinetide-improves-corneal-nerve-fiber-abundance-in-patients-wit/
4. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — https://pubmed.ncbi.nlm.nih.gov/25387363/
5. ARA 290 produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response — https://pmc.ncbi.nlm.nih.gov/articles/PMC3928087/
6. A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets — https://pubmed.ncbi.nlm.nih.gov/26683514/
7. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin — https://pubmed.ncbi.nlm.nih.gov/20660739/
8. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor — https://pubmed.ncbi.nlm.nih.gov/15456912/
9. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin — https://pubmed.ncbi.nlm.nih.gov/18676614/
10. ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor — https://superpower.com/guides/ara-290
11. Cibinetide Seems to Regenerate Nerve Fibers, Improve Pain in Sarcoidosis Patients — https://sarcoidosisnews.com/news/cibinetide-seems-to-regenerate-nerve-fibers-improve-pain-in-sarcoidosis-patients/
12. ARA 290 for Nerve Pain & Regeneration (first-person account) — https://diaryofrecovery.com/ara/
13. Araim Pharmaceuticals Receives FDA Orphan Drug Designation for ARA 290 (sarcoidosis) — https://www.prnewswire.com/news-releases/araim-pharmaceuticals-receives-orphan-drug-designation-from-the-us-fda-for-ara-290-for-the-treatment-of-sarcoidosis-300293773.html
14. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (Dahan 2013, Mol Med, PMID 24136731) — https://pubmed.ncbi.nlm.nih.gov/24136731/
15. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (Culver 2017, IOVS, PMID 28475703) — https://pubmed.ncbi.nlm.nih.gov/28475703/
16. Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin (Collino 2015, Pharmacol Ther, PMID 25728128) — https://pubmed.ncbi.nlm.nih.gov/25728128/
17. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy (Brines 2018, Sci Rep, PMID 29549285) — https://pubmed.ncbi.nlm.nih.gov/29549285/
18. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action (Cerit 2015, Eur Neuropsychopharmacol, PMID 26431906) — https://pubmed.ncbi.nlm.nih.gov/26431906/
19. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema (Lois 2020, J Clin Med, PMID 32674280) — https://pubmed.ncbi.nlm.nih.gov/32674280/
20. NCT06626971 - The Use of ARA290 for the Treatment of Diabetic Macular Oedema (TERMINATED, n=9) — https://clinicaltrials.gov/study/NCT06626971
21. NCT02070783 - Cognitive and Neural Effects of ARA290 (Leiden University Medical Center, n=36) — https://clinicaltrials.gov/study/NCT02070783
22. NCT01933529 - Effects of ARA 290 in Prediabetes and Type 2 Diabetes (Karolinska, status unknown) — https://clinicaltrials.gov/study/NCT01933529
23. EU/3/13/1191 - EMA orphan designation for cibinetide for the treatment of sarcoidosis — https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1191
24. EU/3/16/1721 - EMA orphan designation for cibinetide for prevention of graft loss in pancreatic islet transplantation — https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721
25. Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy (28 October 2014) — https://www.prnewswire.com/news-releases/araim-pharmaceuticals-given-fda-fast-track-designation-to-ara-290-for-the-treatment-of-sarcoidosis-associated-small-fiber-neuropathy-280635872.html
26. Webinar transcript: Small Fiber Neuropathy and ARA-290 Results - Dr. Daniel Culver, Cleveland Clinic, 17 May 2017 (Foundation for Sarcoidosis Research) — https://www.stopsarcoidosis.org/wp-content/uploads/SFN-ARA290.pdf
27. ARA 290 for treatment of small fiber neuropathy in sarcoidosis (van Velzen 2014, Expert Opin Investig Drugs, PMID 24555851) — https://pubmed.ncbi.nlm.nih.gov/24555851/
28. Araim Pharmaceuticals: Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis (2017) — https://www.prnewswire.com/news-releases/araim-pharmaceuticals-cibinetide-ara-290-regenerates-small-nerve-fibers-and-improves-neuropathic-clinical-symptoms-in-the-orphan-disease-of-sarcoidosis-300452818.html
29. X - @vedichi_ (Steady State), 16 July 2026 - anecdotal, skeptical — https://x.com/vedichi_/status/2077787145238913472
30. X - @NewsDeskOne (Scratch Off), 17 July 2026 - anecdotal, positive — https://x.com/NewsDeskOne/status/2077929820760019113
31. X - @BarbaraPaden (Barbara Paden), 26 June 2025 - anecdotal, in progress — https://x.com/BarbaraPaden/status/1938281042944872509
32. X - @0xTrenbolone, 10 July 2026 - anecdotal, cites the trial record — https://x.com/0xTrenbolone/status/2075641254810198018
33. Brines 2015 full text: pharmacokinetics, injection volume and adverse events in the type 2 diabetes trial (PMC4365069) — https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/


---

# TB-500 (Thymosin Beta-4)

slug: tb-500 · https://miscsubjects.com/a/tb-500 · tags: peptide, tb-500, thymosin-beta-4, disc · updated 2026-08-06T07:45:10.431Z

Your body already makes the thing this vial is named after. It is a protein called thymosin beta-4, 43 amino acids long, and almost every cell you have releases it — platelets dump it into a fresh wound, and the cells that clean up damage make more of it. Its job is to hold loose actin, the material a cell builds its own skeleton out of, so the cell can change shape and crawl toward the injury.

Here is the evidence state, and it decides how to read everything after it. Randomised trials of the seven-amino-acid fragment sold as TB-500: none completed, none running, none finished and unpublished. The number of people who have ever been given that fragment in a study, by any route, is nought, so there is no established dose for it, no measured blood level in a person, and no side-effect rate from a trial. One record on ClinicalTrials.gov names TB-500 — NCT07487363, first posted March 2026 — and its own public summary opens by saying it is a fictional example of a registry-style record. The controlled human evidence that does exist belongs to a different molecule, the 43-amino-acid parent protein thymosin beta-4, and it was given as eye drops or a skin gel: three completed dry-eye trials totalling 1,618 people, a nine-person dry-eye trial, an 18-person trial in a nerve-damaged cornea, and two 72-person skin-ulcer trials. Add the Chinese full-length programme and another 236 people have had the parent protein into a vein. None of that is tendon, ligament, muscle, fascia, cartilage or disc, and in twenty years no sponsor has registered a musculoskeletal trial of either molecule. The animal record is rats, mice, rabbits and horses, and its strongest single result is eight rats an arm with a stitched Achilles tendon. What has never been measured in a person is the thing in the vial.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

What is sold as "TB-500" is not that protein. It is a seven-amino-acid piece cut out of the middle of it — positions 17 through 23 — with a chemical cap welded onto the front end. Written out it is Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, or Ac-LKKTETQ for short. The studies on the vendor page were nearly all run on the 43-amino-acid protein. The powder in the vial is nearly always the seven-amino-acid piece.

That is the single most useful fact on this page, so it goes first. Everything else — the dosing arithmetic, the horse blood levels, the rat tendons, the anti-doping ban, the cancer numbers, what 31 people who injected it say happened to them — reads differently once you know the evidence and the product are two different molecules.

## What is breaking down, and what would have to be built back

Take the two injuries that bring people here.

A tendon is rope. Type I collagen fibres, laid down in parallel, bundled, and anchored into bone. It goes wrong slowly: the fibres lose their parallel order, the cells inside stop laying down good collagen and start laying down disorganised patch material, and tiny vessels grow in where they do not belong while the tissue overall stays starved of blood. That last part is the whole problem. A tendon has very little blood supply, so the cells and oxygen needed to rebuild it arrive slowly, and the repair loses the race against the next load you put through it.

A disc in your spine is worse. The soft centre of the disc holds water under pressure; the tough outer ring contains it. With age and load the centre dries out, the ring cracks, the height drops, and the joints above and below start taking force they were not built for. A disc has almost no blood supply at all in its middle — nutrients seep in slowly through the bone above and below it. Nothing in the body repairs more slowly than the middle of a disc. [[degenerative-disc-disease|What degenerating discs actually do]] and [[herniated-disc|what a herniation actually does]] are covered separately.

So the chain that breaks tissue down looks like this: load exceeds repair, the cells switch from building rope to building patch, blood supply stays too thin to feed either, the patch scars instead of remodelling, and the tissue ends up weaker — so the same load now breaks it faster.

Anything that would build it back has to hit one of five links. This is the frame to hold every claim below against.

| Link in the chain | What would have to happen | Does the evidence reach it |
|---|---|---|
| Blood supply | more small vessels feeding the injury | strong for the 43-amino-acid protein in animals, and the seven-amino-acid piece is the part that does it |
| Cells arriving | repair cells crawl into the damage instead of sitting at the edge | strong in a dish and in rodent skin, never measured in a human tendon |
| Collagen quality | new rope laid parallel, not patch laid crossways | one rat Achilles study, eight animals in the arm |
| Less scar | fewer of the contracting cells that turn repair into scar | real for the full protein, and it runs through a piece the vial cannot make |
| Inflammation settling | fewer inflammatory signals, so repair can start | shown for the full protein, not for the fragment |

## The vial and the studies contain different molecules

Two products sit side by side on the same shelf at the same 10 mg strength — one labelled "TB-500", one labelled "TB-500 / Thymosin Beta-4" — and nothing on either label tells you which molecule is inside. This is not a technicality.

| | Thymosin beta-4 (the natural protein) | "TB-500" as sold |
|---|---|---|
| Length | 43 amino acids | 7 amino acids (positions 17–23) |
| Sequence | the whole protein | Ac-LKKTETQ |
| Weight | ~4,963 daltons | 889.01 daltons |
| Front end | bare | capped with an acetyl group |
| Catalogue numbers | recombinant or synthetic full-length | CAS 885340-08-9, UNII QHK6Z47GTG, PubChem CID 62707662 |
| Tested in people | yes — eye drops, skin gel, heart | never, by any route |
| Can it release Ac-SDKP | yes, cut off the front end | no, it comes from the wrong part of the protein |
| Official drug name | recombinant human thymosin β4 | it does not have one |

Where the fragment came from is documented. In 2003 a group cut the protein apart looking for the smallest piece that still grew new blood vessels, and found it: those seven amino acids, and nothing shorter. Peptides missing the seven were dead. The seven on their own worked at about 50 nanomolar. Adding loose actin at 5 to 50 nanomolar switched the effect off completely, which proves the activity comes from grabbing actin rather than from docking into a receptor.

[[embed:source:s1]]

That is the honest origin story. The fragment is real, it does one real thing, and one thing is not the same as everything the parent protein does.

## A regulator wrote the mismatch down in July 2026

The Pharmacy Compounding Advisory Committee briefing package is the only document from a government agency that examines TB-500 as a substance. It says in plain terms that the two are not interchangeable, and it names the marketing error.

[[embed:source:s22]]

Three findings in that package change how everything else reads.

**Nobody has been given it and measured.** The agency searched the published literature through March 2025 and reports that "no articles were found in which TB-500 was administered to humans." The people who nominated it supplied no clinical data and no record of anyone taking it, by any route. The agency's safety verdict is the word "unknown" — not clean, not dangerous, unknown.

**The cap on the front end is not a detail.** The wound-healing papers vendors point at used the *uncapped* seven amino acids, LKKTETQ. FDA states that capping the front end "irreversibly alters their charge, hydrophobicity, and size," and that what the uncapped version does "cannot be directly extrapolated" to TB-500. Change the electrical charge and the water-repelling behaviour of a molecule whose entire job is sticking to another molecule, and you have changed the thing that matters.

**The one time anybody tested TB-500 itself in a dish, it did nothing.** In a scratch test — you scrape a line across a sheet of skin-building cells and time how fast they close it — TB-500 free base "appeared to be devoid of wound-healing properties." Its breakdown product, capped LKKTE, at 50 micrograms per millilitre did close the scratch by a small but real amount. That leaves open the possibility that TB-500 is a delivery form for a shorter piece. Nobody has tested that either way.

The same package records that the nomination itself carried a molecular formula that was wrong and a CAS number matching neither the free base nor the acetate salt. It also records where TB-500 actually came from commercially: a 2011 veterinary preparation sold to make racehorses and racing greyhounds perform better.

## Seven amino acids are enough to pull one lever

The proposed mechanism runs in five steps. None of it is special injury machinery. It is the ordinary business of a cell changing shape, happening where tissue is being rebuilt.

1. **Holding loose actin.** The protein grabs free actin building blocks, one molecule to one molecule. A held block cannot join a growing strand, so the cell keeps a stock of ready parts instead of a stiff finished mesh.
2. **Releasing it on command.** Letting those blocks go where and when the cell wants lets it extend a strand in one direction and push. Holding is not blocking. It is stockpiling, and the stockpile is what makes movement in a chosen direction possible.
3. **Crawling.** A cell that can build a leading edge crawls. Skin cells crossed a filter two to three times faster with as little as 10 picograms of the protein present. The cells that line blood vessels do the same thing.
4. **New blood vessels.** Those seven amino acids are the piece that does this, and this is the only step where the fragment is the active part rather than a bystander. Vessel-lining cells crawl, sprout, and form tubes.
5. **Inflammation settling down.** The full 43-amino-acid protein reduces the number of inflammatory cells at a wound and turns down three inflammatory signals — TNF-alpha, interleukin-1β and interleukin-6.

[[embed:source:s28]]

Steps 3 and 4 were measured together in the original rat wound work. Applied to the skin or injected into the belly cavity, the full protein grew the skin surface back over the wound 42% faster at four days and 61% faster at seven, with more collagen and more vessels in the treated wounds than in the salt-water controls.

[[embed:source:s2]]

Step 4 is the step that matters for the tissue you are worried about. Tendon, ligament, the sheet of tissue around muscle, and the disc in your back all share one problem: not enough blood. A mechanism aimed at growing vessels is aimed at the actual bottleneck. That is a good argument on paper. It is also where the argument stops, because nobody has grown a vessel into a human tendon with this and measured it.

## Why it gets run with BPC-157, and what happened when somebody tested that

[[bpc-157|BPC-157]] and TB-500 are sold as a pair because their proposed mechanisms sit at different points in the same repair sequence.

| | TB-500 / thymosin beta-4 | BPC-157 |
|---|---|---|
| What it grabs | the pool of loose actin building blocks | the grip machinery a cell uses to hold a surface (FAK and paxillin) |
| How it reaches blood vessels | the seven-amino-acid piece makes vessel-lining cells crawl and sprout | raises the main vessel-growth receptor and the nitric-oxide pathway |
| Level it acts at | supplying the cell's internal skeleton | grip and growth signals |
| Tissue where it is best evidenced | cornea, skin wound (as the full protein) | rat tendon, ligament, gut |
| Route used in the studies | on the surface, into the belly cavity, implanted locally | into the belly cavity, by mouth, locally |

The theory is that one supplies the machinery for moving and the other supplies the signal telling cells where to move. It is coherent. It has been tested head to head exactly once, and the pairing failed.

[[embed:source:s25]]

Thirty-two male Sprague-Dawley rats, twelve weeks old, about 330 grams each, had the Achilles tendon cut through and repaired, then four weeks of injections into the belly cavity, in four groups of eight: BPC-157 at 10 micrograms per kilogram per day, TB-500 at 60 micrograms per kilogram per day, both together, or nothing.

TB-500 on its own was the arm that reached statistical significance. Maximum load before the tendon failed: p < 0.05. Total Bonar score, which grades how normal the tissue looks under a microscope: p = 0.016. Movin score, a second grading scale: p = 0.017. A collagen stain showed the most orderly type I collagen in the TB-500 group. A protein stain found no real difference between groups in how much type I collagen was being made.

And the combination "did not confer additional benefits compared to either agent alone." The synergy the pair is sold on did not appear in the one experiment that looked for it.

## The scar-tissue claim comes off a piece this fragment cannot produce

A large share of the "breaks up scar tissue and adhesions" marketing traces back to Ac-SDKP, a four-amino-acid piece that calms inflammation and reduces scarring, released from the parent protein.

Getting it out takes two enzymes working in order. First an enzyme called meprin-alpha cuts the front section of the protein into pieces under 30 amino acids long. Then a second enzyme, prolyl oligopeptidase, snips Ac-SDKP off. Neither enzyme can do it alone.

[[embed:source:s29]]

Now put the two facts side by side. Ac-SDKP comes off the **front end** of the protein. TB-500 is positions **17 to 23** — the middle. The four-amino-acid piece cannot be made from it at any dose, by any enzyme, in any tissue. Every scar-reduction claim built on Ac-SDKP belongs to the 43-amino-acid protein and does not carry over to what is in the syringe.

There is a separate scar result for the full protein that does not depend on Ac-SDKP, and it is a good one. In rats, 100 micrograms of the protein delivered on days 2, 3 and 4 through implanted sponges produced wounds at day 14 with very few myofibroblasts — the contracting cells that pull a wound closed into a scar — and very few of their internal tension fibres. The collagen bundles were longer and thicker, and under polarised light they glowed the yellow-red of mature collagen where the untreated wounds glowed the green of immature patch material. Stopping cells from turning into myofibroblasts is the mechanism behind "repair instead of scar."

[[embed:source:s27]]

The 100 micrograms went into the wound on a sponge. It was the full protein. Neither of those matches a milligram injected into belly fat.

## Sort the whole literature by tissue and the tendon row is one rat study

Somebody counted the entire field. A 2026 scoping review from an orthopaedics and rehabilitation group at the University of Utah screened 1,772 records and included 80 studies.

[[embed:source:s10]]

Their findings, in their own words: the evidence is "weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500"; "direct musculoskeletal tissue categories such as tendon, ligament, muscle, cartilage, and spine/intervertebral disc were comparatively sparse"; and "human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study."

One study out of eighty tested the molecule that is actually sold.

| Tissue | Best study | Species and model | n | Molecule | How it was given | Result |
|---|---|---|---|---|---|---|
| Tendon | Biçer 2026 (PMID 42542926) | rat, Achilles cut and repaired, 4 wk | 32 (8 per arm) | TB-500 | into the belly cavity, 60 µg/kg/day | load to failure up, p<0.05; Bonar p=0.016; adding BPC-157 gave nothing extra |
| Tendon (cells) | Wu 2020 (PMID 31753373) | human stem cells from fat, on a woven scaffold | in a dish | full protein | released over 28 days from the scaffold | more crawling, more cells multiplying, cells turned into tendon cells |
| Ligament | Xu 2013 (PMID 23523891) | rat, knee ligament cut through, 4 wk | not stated | full protein | 1 µg in 100 µL of fibrin glue, placed in the gap | even fibre bundles, significantly stronger repair |
| Muscle | Tokura 2011 (PMID 20880960) | mouse, injured muscle plus cultured muscle cells | living animal and dish | full protein | the animal's own | the protein rises early after injury and pulls muscle cells toward the damage |
| Skin wound | Malinda 1999 (PMID 10469335) | rat, full-thickness wound | not stated | full protein | on the skin and into the belly cavity | surface regrown 42% faster at 4 d, 61% at 7 d, 11% more wound contraction |
| Scar | Ehrlich 2010 (PMID 20536458) | rat, implanted sponge, day 14 | not stated | full protein | 100 µg, days 2–4, into the wound | scar-pulling cells suppressed, mature collagen |
| Heart | Bock-Marquette 2004 (PMID 15565145) | mouse, coronary artery tied off | not stated | full protein | belly cavity or into the heart, every third day | heart cells survived, pumping function improved |
| Cornea | Sosne 2015 (PMID 25826322) | human, severe dry eye | 9 patients (18 eyes) | full protein, 0.1% | eye drops, 6×/day, 28 d | discomfort down 35.1%, p=0.0141; surface staining down 59.1%, p=0.0108 |
| Cornea | Sosne 2022 (PMCID PMC9820614) | human, nerve-damaged cornea, Phase III | 18 (10 vs 8) | full protein, 0.1% | eye drops, 5×/day | day 29: 60% healed vs 12.5%, p=0.0656; day 43: 50% vs 0%, p=0.0359 |
| Nerve | Morris 2010 (PMID 20627173) | rat, stroke from a clot | not stated | full protein | whole-body | better neurological recovery, nerve sheaths rebuilt, nerve fibres remodelled |
| Disc and cartilage | — | — | — | — | — | nothing, for either molecule |

[[embed:source:s19]]

Read the "Molecule" column before you read the "Result" column. Ten of the eleven rows are the 43-amino-acid protein.

## The best tendon result that exists is eight rats an arm, injected into the belly

That sentence deserves its own heading, because it is the single strongest piece of evidence in the world for the thing people buy TB-500 to do.

It ran four weeks. It was a rodent. The dose went into the abdominal cavity, not under the skin. The authors call their own study "exploratory" and stop at calling both compounds "candidate adjuncts to tendon repair, pending dose-optimization and longer-term studies." Nothing in it supports a milligram-per-week injection under the skin of a person, and the authors do not claim it does.

The delivery problem is out in the open in the tendon-engineering literature, which is itself a signal: the people who study getting this peptide into a tendon do not expect an injection into belly fat to do it. When the full protein was loaded into spun polymer yarns it released steadily over 28 days and pushed human stem cells taken from fat toward becoming tendon cells — they crawled more, multiplied more, and switched on tendon genes together.

[[embed:source:s30]]

The scaffold is the point. Somebody built a 28-day slow-release fibre to hold the peptide at the tendon, because holding it there is the hard part.

## The ligament study worked because the peptide was put in the wound

The rat knee-ligament study gets summarised as "TB-500 heals ligaments." What it actually did was place 1 microgram of the full-length protein, carried in 100 microlitres of fibrin glue, directly into a ligament that had just been cut through. Local. Held in place by a carrier. One microgram. A different molecule.

[[embed:source:s11]]

The paper opens by noting that as of 2013 nobody had ever published on this protein in ligament repair at all.

## In muscle, your body already sends this signal after an injury

The muscle result is not a treatment result, and it is worth understanding why.

Injuring a muscle causes the muscle itself to make more thymosin beta-4 — in the fibres that are regenerating, and in the blood-cell-making cells that move into the damage. The protein then acts as a chemical attractant, pulling muscle precursor cells toward the injury. Both the ordinary protein and its oxidised form sped up closure and pulled cultured muscle cells across a gap. Precursor cells taken from adult muscle followed the oxidised form.

[[embed:source:s26]]

So the pathway is real in skeletal muscle, and your body switches it on by itself when you tear something. What has never been tested is whether adding more from outside improves a strain. No study has asked that question.

## Every controlled result in a person is an eye or a skin wound

Here is the entire human record for the 43-amino-acid protein, sorted by tissue. None of it is muscle, tendon, ligament or disc.

**Eyes — the only place the numbers turned positive.** A nine-patient dry-eye trial reported eye discomfort down 35.1% and surface damage staining down 59.1% against the vehicle drops.

[[embed:source:s18]]

[[embed:source:s45]]

A Phase III trial in nerve-damaged cornea randomised ten patients against eight. Complete healing at four weeks was 60% versus 12.5%, p = 0.0656 — which misses the usual cutoff for calling a result real. At day 43 it was 50% versus 0%, p = 0.0359, which clears it.

[[embed:source:s32]]

Three completed Phase 3 dry-eye trials sit behind those: ARISE-1 with 317 patients, ARISE-2 with 601, and ARISE-3 with 700, the last finishing in October 2021. Total: 1,618 people. There is still no FDA approval.

**Skin — completed, but safety was the question being asked.** The pressure-ulcer trial enrolled 72 patients on gel at 0.01%, 0.02% and 0.1% by weight, once daily for up to 84 days. The main question was safety and tolerance. Healing was a secondary question.

[[embed:source:s3]]

A matching 72-patient trial in leg ulcers from poor vein drainage completed on the same design.

[[embed:source:s4]]

[[embed:source:s5]]

Two more were stopped early: one in the blistering skin disease epidermolysis bullosa, 30 patients, and one in corneal wounds in diabetic patients after eye surgery, 12 patients.

[[embed:source:s13]]

**Heart — withdrawn twice, then restarted in another country.** The animal finding that started the programme is specific: the protein forms a complex with two other proteins, PINCH and integrin-linked kinase, which switches on the survival signal Akt. After a coronary artery was tied off in mice, heart muscle cells survived better and the heart pumped better.

[[embed:source:s31]]

[[embed:source:s9]]

The Phase 1 safety study in healthy volunteers was designed around single rising intravenous doses of 42 mg, 140 mg, 420 mg and 1,260 mg. It never enrolled anybody. The reason on the record: "Study never initiated due to contract manufacturing issues."

[[embed:source:s34]]

The Phase 2 heart-attack trial behind it was also withdrawn with zero patients enrolled. The only heart programme still producing human data is a Chinese full-length recombinant product called NL005: a Phase 1a in 54 healthy volunteers that established the highest tolerated dose, measured how fast the body cleared it, and checked whether the immune system made antibodies against it, then a Phase 1b in 30 people and two completed Phase 2 trials in heart attack.

[[embed:source:s33]]

Look at the dose scale in that withdrawn Phase 1 design. Milligram quantities of the full protein, dripped into a vein, in a hospital, under a protocol, are not the same object as 2.5 mg of a seven-amino-acid fragment injected under the skin of a belly at home — even though both are written in milligrams.

## One registry record names TB-500, and it says it is made up

Search ClinicalTrials.gov for TB-500 and you get exactly one interventional record where the intervention is TB-500 itself: NCT07487363, "TBRIDGE-CV," sponsor listed as Hudson Biotech, first posted March 2026.

Its summary reads, word for word: "This fictional study is an example of a ClinicalTrials.gov-style record."

[[embed:source:s35]]

It is a demonstration template. Its intervention description has an unclosed bracket. Its dose field says the levels "are not provided in this public example." Any page that cites NCT07487363 as proof TB-500 is in human trials is citing a placeholder — and that citation will keep appearing, because it is the only registry entry that looks like the thing people want to find.

## Nothing has ever been injected into a person and measured

One row, stated plainly, because the tables above allow no other reading.

There is no human trial of TB-500. None finished, none running, none registered. Every controlled human result belongs to the 43-amino-acid protein, given as eye drops or a skin gel, for dry eye, a nerve-damaged cornea, or a long-standing skin ulcer. For tendon, ligament, muscle, fascia, cartilage or disc, the count of human trials is zero for both molecules.

If you are asking "is this proven for my tendon" — no. Not partly proven, not proven in a small way. The study has never been run.

That is one row on this page, not the page. Everything else here is what is actually known.

## Mixing the vial, in numbers a syringe can read

A freeze-dried vial holds a fixed mass of powder. The strength is whatever the water you add makes it, and the volume you inject follows from that. Insulin syringes are marked in units, where 100 units is 1 millilitre, so one unit is 0.01 mL.

Take the common 10 mg vial and add **2 mL of bacteriostatic water**:

- 10 mg ÷ 2 mL = **5 mg per mL**
- 1 mL is 100 units, so 100 units holds 5 mg
- **1 unit = 0.05 mg = 50 micrograms**

| Dose you want | Volume | Units on a 100-unit insulin syringe |
|---|---|---|
| 250 mcg | 0.05 mL | 5 units |
| 500 mcg | 0.10 mL | 10 units |
| 1 mg | 0.20 mL | 20 units |
| 2 mg | 0.40 mL | 40 units |
| 2.5 mg | 0.50 mL | 50 units |
| 5 mg | 1.00 mL | 100 units (the whole syringe) |

Add 5 mL instead and you get 2 mg/mL. Now 1 unit is 20 micrograms, and a 2.5 mg dose is 125 units — more than one syringe holds, so a single dose takes two injections. That is why 2 mL is the practical fill for a 10 mg vial: it puts every commonly used dose inside one syringe.

The mechanics, in order. Wipe the rubber stopper with alcohol and let it dry. Draw up the water. Angle the needle so the water runs down the inside glass wall instead of jetting straight onto the powder. Swirl until it goes clear. Do not shake. Shaking tears peptide molecules apart and makes them clump together, and clumping is the exact mechanism behind the immune-reaction concern further down this page.

## Every dose ever given in a study, and where yours would sit

No dose-finding study of TB-500 exists. Not in any species, at any dose. The loading-then-maintenance schedule that circulates online has no source under it: no trial produced it, no blood-level study calibrated it, no regulatory filing contains it. The nomination sent to FDA specified a formulation — 3 mg/mL, "Subcutaneous and/or Intramuscular Injection" — and specified no dose at all.

What does exist is every dose that has actually been given in a study, and the list is short enough to print in full.

| Study | Molecule | Species | Route | Dose | Schedule |
|---|---|---|---|---|---|
| Biçer 2026, Achilles repair | TB-500 | rat | into the belly cavity | 60 µg/kg/day | daily, 4 weeks |
| Ho 2012, blood levels | TB-500 | horse | under the skin | 10 mg total | one dose |
| Rahaman 2024, scratch test | TB-500 | cells in a dish | in the culture fluid | 50 µg/mL | one exposure |
| Xu 2013, knee ligament | full protein | rat | into the wound, in fibrin glue | 1 µg | once, at surgery |
| Ehrlich 2010, sponge implant | full protein | rat | implanted locally | 100 µg | days 2, 3, 4 |
| Philp 2003, punch wound | uncapped LKKTETQ | mouse | on the skin | 0.01% in buffer | day 0 and 48 h |
| Bock-Marquette 2004, heart attack | full protein | mouse | belly cavity or into the heart | not fixed | every third day |
| NCT00382174, pressure ulcers | full protein | human | gel on the skin | 0.01%, 0.02%, 0.1% by weight | once daily, up to 84 days |
| NCT01393132, dry eye | full protein | human | eye drops | 0.1% solution | 6× daily, 28 days |
| NCT02600429, cornea | full protein | human | eye drops | 0.1% solution | 5× daily, 43 days |
| NCT00743769, heart (withdrawn) | full protein | human | into a vein | 42 / 140 / 420 / 1,260 mg | single rising doses, never run |

Read the route column and count. Two doses in the entire record went under the skin: one of them was a horse, and the other does not exist. Every human dose ever given was put on a surface — a cornea or a wound bed — and none of them was TB-500.

The one animal musculoskeletal study that came out positive on placement put 1 microgram directly into the wound in a glue carrier. The schedules people run use milligrams injected into belly fat and expect them to reach a tendon in the shoulder. Those are not the same treatment scaled up. They are different treatments.

Three route facts are settled. There is no oral form that works, because your gut digests it. Under the skin and into the muscle are the routes the formulation was submitted for. Injecting into or right beside the injured structure — the route in the one positive animal result — is not the route almost anybody uses.

## Ten milligrams under the skin of a horse peaked at 0.08 nanograms per millilitre

The only measurement of TB-500 in the blood of a living animal, in any species, comes from thoroughbred geldings given 10 mg of the free base under the skin.

Blood concentration peaked at 0.05 to 0.08 nanograms per millilitre, somewhere between 60 and 120 minutes after the injection. Between 6 and 10 hours it could no longer be measured at all. It broke down by losing amino acids one at a time off the tail end: Ac-LKKTET, then LKKTE, then LKKT, then LKK, then LK.

Two things follow from that, and both change how you would take it.

**Dosing every three or four days has nothing behind it.** Schedules that space injections out are usually defended by saying TB-500 has a long half-life. A compound that cannot be detected in blood 6 to 10 hours after a 10 mg dose does not have a long half-life. Whatever else might justify spacing doses out, measured persistence in the blood is not it — and no half-life for TB-500, in any species, has ever been published as a number.

**Sub-nanogram blood levels off a 10 mg dose is a very small exposure.** For scale: the concentrations at which this peptide and its breakdown products do anything measurable in a dish are in the tens of micrograms per millilitre. That is four to five orders of magnitude higher than what a 10 mg injection produced in a horse.

## The 28-day rule comes from the water, not from the peptide

- Freeze-dried powder: keep at 2–8 °C, or freeze it for long storage. Keep it out of light.
- Mixed with **bacteriostatic** water, which contains 0.9% benzyl alcohol as a preservative: 2–8 °C, commonly cited as good for about 28 days. That 28 days is the preservative's specification. It is not a stability figure anybody measured on this peptide.
- Mixed with **sterile** water, no preservative: one use, discard after a single draw.
- Do not freeze and thaw it once it is in solution.

There are no pharmacopeial stability data for either form of TB-500. FDA's own finding is that TB-500 free base "is not physically and chemically well characterized," and that tests for contaminants, clumping, microbial contamination and bacterial endotoxin are missing from the public data and from vendor Certificates of Analysis.

## How long each measured effect actually took to appear

Every timeline anybody can quote belongs to a study, and they cluster tightly.

| What was measured | Time to effect | Study |
|---|---|---|
| Skin surface regrown over a wound | 4–7 days | Malinda 1999 (rat) |
| Collagen maturing, scar-pulling cells suppressed | 14 days | Ehrlich 2010 (rat) |
| Cornea healing | 29–43 days | NCT02600429 (human) |
| Dry-eye signs and symptoms | 28 days | NCT01393132 (human) |
| Ligament strength | 28 days | Xu 2013 (rat) |
| Tendon load to failure | 28 days | Biçer 2026 (rat) |
| Long-standing skin ulcer healing | 84 days | NCT00382174 (human) |

The musculoskeletal readouts all sit at four weeks in rodents. Rat tendon repairs faster than human tendon, and the human version of that four-week endpoint has never been measured. Any statement about how long you should expect to wait is a rat's timeline stretched across a species gap, for a molecule the rat got into its abdominal cavity.

There is a second problem with judging this by how you feel. Tendon problems get better on their own over months. That is the ordinary course, with no treatment at all. If you improve on that timescale you cannot separate the compound from time, from having backed off the load, and from everything else that changed in the same window.

## The cancer objection has real numbers behind it

The vessel-growing and cell-crawling machinery that would plausibly help a healing tendon is the same machinery a tumour uses to grow and spread. That is not a hypothetical. It has been measured in living animals.

[[embed:source:s20]]

Forcing a melanoma cell line to overproduce thymosin beta-4 gave a mean 2.3-fold increase in how far the cells crawled (95% CI 1.9–2.7, p<.001), a mean 4.4-fold increase in blood vessels inside solid tumours (95% CI 3.3–5.5, p<.001), and roughly four times as many tumour deposits in the lungs — 46.7 against 10.9. The authors concluded that thymosin beta-4 may drive tumour spread by switching on cell crawling and new vessel growth.

The paper shares an author with the wound-healing and vessel-growth work. The helpful finding and the harmful finding come from the same laboratory and the same mechanism. That is not a scandal. It is what an honest mechanism looks like when you follow it in both directions.

Three qualifications, all of them real.

- The experiment used a virus to force a melanoma line to overproduce the protein. It did not give a seven-amino-acid fragment at the doses a person injects. It establishes that the risk is mechanically plausible and open. It does not establish a proven human hazard.
- The literature runs both ways and depends on the cancer type. In multiple myeloma, this protein behaves as a tumour suppressor, and lower levels of it predict a worse outcome.

[[embed:source:s21]]

- No cancer-causation study of TB-500, in either form, has ever been run. FDA states that outright.

The defensible position is a specific exclusion, not a ban on the compound. Active cancer, or a significant cancer history, is a reason not to use this — because the risk is unmeasured in the direction that would hurt you and the benefit is unproven. That is a bad trade regardless of how the mechanism eventually resolves.

The wider literature supports that framing rather than either extreme. The protein is reported to help liver tumours in children spread, and to drive colon cancer cells to crawl through a specific signalling route, while in multiple myeloma losing it predicts a worse course. The effect depends on the tumour, which is exactly why no blanket reassurance is available in either direction.

## What is in the vial has never been tested for the things that could hurt you

Separate from cancer, and specific to injecting a substance nobody has characterised:

| Risk | Where it stands |
|---|---|
| The immune system reacting to it | FDA: TB-500 "may pose a significant risk" here, "potentially amplified by aggregation as well as potential peptide-related impurities" |
| Peptide contaminants | not characterised in public data or in vendor Certificates of Analysis |
| Bacterial endotoxin | not tested in public data |
| Clumped peptide | not tested in public data |
| Microbial contamination | not tested in public data |
| Cancer causation | no studies exist |
| Reports of harm after sale | the FDA adverse-event database returned zero reports for TB-500 |

The zero in that last row is not reassurance, and reading it as reassurance is the mistake this page most wants you to avoid. There is no legal human market for TB-500, so there is no channel through which a report could be filed. FDA's food and cosmetics system held two cases mentioning "blended TB-500 and BPC-157," with no safety assessment attached to either. No surveillance produces no data, and no data looks identical to safety if you do not check which one you are looking at.

Nobody has published an independent purity or endotoxin audit of the consumer TB-500 market. Searching for one returns vendor pages claiming 99% purity and nothing that tested the claim. FDA arrived at the same place from the paperwork side: the nomination package supplied a molecular formula that was wrong and a CAS number matching neither form of the substance. That is what an uncharacterised material looks like on paper.

The only safety information with any weight behind it belongs to the full-length protein, and even that is thin at whole-body doses. The one programme that has produced human immune-response and blood-clearance data for the protein given systemically is the Chinese recombinant product, whose Phase 1a in 54 healthy volunteers measured the highest tolerated dose alongside peak concentration, time to peak, total exposure, half-life, clearance rate and antibody formation.

[[embed:source:s41]]

Those numbers describe a 43-amino-acid recombinant protein dripped into a vein under a hospital protocol, and they are not published in the searchable literature. They do not describe the fragment, the route, or the setting in which TB-500 is actually used.

## Banned in sport at all times, and the wording names tendons

The 2026 Prohibited List, in force from 1 January 2026, lists under section S2.3 — Growth Factors and Growth Factor Modulators — "Thymosin-ß4 and its derivatives e.g. TB-500."

[[embed:source:s23]]

Four details decide what that means for you.

- **Prohibited at all times**, in competition and out of it. Using it in the off-season is still a violation.
- It is a **Non-Specified Substance** — the harsher sanction tier, with no starting presumption that the penalty should be reduced.
- The catch-all clause covers "other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching." The exact reason you would take it is the exact behaviour the clause prohibits, written out in the rule.
- "Other substances with similar chemical structure or similar biological effect(s)" are prohibited too, which sweeps in unnamed fragments and lookalikes.

Enforcement is real, and it has hit the pairing specifically. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for BPC-157 and TB-500. The United States Department of Defense has adopted WADA categories S0 through S5, which puts service members under the same restriction.

[[embed:source:s12]]

Sanctions do not require a positive test. They can be imposed on an admission, on possession, or on a purchase record. If you are in a college programme, a national federation, an Olympic pathway, most professional leagues, or the military, that exposure exists whether or not anybody ever tests you.

## The July 2026 vote started a process, it did not change the status

On 23–24 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, in favour of letting BPC-157, KPV and TB-500 be compounded — against FDA's own written recommendation that "a balancing of the criteria weighs against" listing them.

[[embed:source:s24]]

What that vote does and does not do:

- It does **not** make TB-500 an approved drug.
- FDA is **not bound** by the recommendation.
- It starts a formal rulemaking cycle that realistically runs eight to twelve months.
- As of this writing TB-500 is **not** on the 503A Bulks List and is not legally compoundable. No outsourcing facility has reported compounding it, and no pharmacy was found doing so.

"The FDA just approved it" is wrong twice: there is no approval, and the rulemaking has not finished.

## Thirty-one people wrote down what happened to them, and the split is not what the marketing says

Everything above this line is evidence. What follows is not, and it is counted anyway, because it is the only record of people using this for the reason you are reading about it.

Thirty-one first-person accounts, posted publicly on X between January and August 2026. Each one was located by search and then re-checked independently by pulling the post back and comparing the full text and the timestamp. Three candidates failed that check and are not counted. Nobody in this set was randomised, blinded, or controlled. Nobody tested the powder before injecting it, so the actual substance is unknown in every case. People who improved are far more likely to post than people who did not, so the set is selected before you even read it.

**The count: 17 said it helped. 8 said nothing happened. 6 had a reaction or got worse. Denominator 31.** Two of those 31 were treating a gut complaint rather than a musculoskeletal one. Drop those two and the split is 17 helped, 7 nothing, 5 worse, out of 29.

There is one number that matters more than the split, and it is at the bottom of this section.

Before the accounts themselves, the shape of them. The seventeen that helped cluster in shoulders
and elbows run for four to eight weeks; the eight that reported nothing and the six that reported a
reaction or a worsening are grouped under their own headings below, so you can read one group
without reading all thirty-one. If you came here about a specific injury, the section titled injury
by injury, what the record actually reaches is the one to read instead of these accounts: it sorts
every tissue by what evidence exists in it, and for four of the seven rows the honest entry is none.
No body-region tally is given for the thirty-one because the set is too small to divide without
producing percentages that look like measurements, which is the failure this page spends its first
section warning about.

Every account below is quoted in the person's own words, with the handle, the date and a link to the original post. All of it is anecdotal. None of it is evidence.

### Seventeen said it helped

The strongest reports come from shoulders and elbows, run for four to eight weeks.

> "Ran BPC 500mcg twice a day and 6mg of TB500 every 5th day for 6-8 weeks. Healed my torn rotator cuff" — @PayHereSukka, X, 30 July 2026. Anecdotal.

[[embed:source:w_7b0irg5j]]

> "Slight tear of my rotator cuff. Surgery was a 5 month rehab timeline, instead I took bpc-157 and tb-500. Was back to full rotation in my shoulder and benching good weight by a month and a half!" — @GrantWest14, X, 10 January 2026. Anecdotal.

[[embed:source:w_z5qnxkqk]]

> "I was dealing with a nagging golfers elbow for over a year. Would be tender the to the touch after hitting balls. Within a week of taking shots the pain started to disappear. Months later its compmetely healed." — @ryalljohnny1989, X, 3 August 2026. Anecdotal.

[[embed:source:w_bpr3c1ux]]

> "I took it alongside TB-500 and it fixed my tennis elbow and was back to lifting also within two week." — @Das_Bear_, X, 29 June 2026. Anecdotal.

[[embed:source:w_8aa4h36p]]

Three of the seventeen were treating exactly the disc problem that may have brought you here, and all three describe substantial relief inside a month.

> "I've been doing subcutaneous BPC TB+500 injections on both sides of the L5-S1 and a month in, the pain is dramatically less... the pain has been horrible for 6 years but this stuff really works. I don't wake up in awful pain anymore!" — @MithMuel, X, 30 June 2026. Anecdotal.

[[embed:source:w_srfrp1td]]

> "Blew up my back in 2017. L4/L5/S1 severe disc herniation. Doc diagnosed me with degenerative disc disease, told me to quit lifting... Found the Wolverine stack and within a month I was pain free." — @jasonsvoboda, X, 26 July 2026. Anecdotal.

[[embed:source:w_t1lhudd5]]

> "My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc... In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better. Now after the cycle, zero pain in biceps and shoulder. Disc still needs physio and rest, but already much better." — @MuroCrypto, X, 31 July 2026. Anecdotal.

[[embed:source:w_ionqqvc2]]

Read that last one closely, because it is the most careful account in the whole set. He separates his shoulder result from his disc result, says the disc "still needs physio and rest," and adds "Don't know if it works the same for everyone, I'm no expert." That is what an honest anecdote looks like.

Some report the effect arriving far faster than any tissue can rebuild — hours to days. That is a timescale for inflammation and pain signalling, not for collagen.

> "Wednesday I woke up in severe pain in my L Leg. It was so bad I couldn't bear any weight... Peptides started in the afternoon. Leg 75% better in the evening... Saturday: Woke up 100% better." — @L0V3lsKeY, X, 2 August 2026. Anecdotal.

[[embed:source:w_2m2r0oof]]

> "BPC-157 + TB-500 vastly accelerated my recovery timeline, eliminated my knee pain two days after i started, and brought the swelling in my jaw down within the week" — @howdymary, X, 9 March 2026. Anecdotal.

[[embed:source:w_7cn6wcbt]]

Two days is not tissue repair. Whatever changed there, it was not new collagen.

The remainder are knees, ankles, quads, and general joint pain.

> "4 weeks 1mg bpc and then 4 weeks 2mg in knee. No acl or meniscus...knee has never felt better since before the injury years ago...also did tb500 twice a week total 4mg" — @caezcrypto1, X, 30 July 2026. Anecdotal.

[[embed:source:w_4qf0wqtv]]

> "I'm 95% sure that BPC-157 and TB-500 helped me heal from several injuries including my left knee and right ankle. I really thought I was going to need surgery for both." — @JonahLupton, X, 26 July 2026. Anecdotal.

[[embed:source:w_albnpbru]]

> "I tore both quad tendons in separate years, the first recovery had taken almost a year. After the second surgery... I added BPC-157 and TB-500. By month five, I was sprinting and jumping again" — @pepfessions, X, 3 August 2026. Anecdotal.

[[embed:source:w_e9fjoshb]]

> "After a week of BPC-157 (8 injections, 500mcg subcutaneous abdominal), persistent ankle tendon pain from a snowboarding injury a year ago is barely noticeable... Yesterday I added TB-500 (1 injection, 2mg) as well" — @jordaaash, X, 30 March 2026. Anecdotal.

[[embed:source:w_dmeyan6q]]

> "Have done a BLAST OF TB 500 and BPC -157 and KPV! Have serious shoulder tear! Blasted all three for 2 weeks!... Took my shoulder from barely joking a cupping hand to back in gym!" — @tj_underwood, X, 31 July 2026. Anecdotal.

[[embed:source:w_1d35jifv]]

> "My 70 yr old dad tore rotator cuff and I had him do 1mg (BPC) injected daily in 2 doses for 4 months with 2-3x/weekly TB500 @ 2.5mg/dose. Within a few weeks, he was lifting his arm totally above his head again and all pain was gone." — @_REDwave_2024, X, 20 May 2026. Anecdotal, and second-hand — the son is reporting his father's result.

[[embed:source:w_8ed1wjyh]]

> "Promise you peptides are No Joke, I used the wolverine stack (BPC-157 and TB-500) to alleviate lifelong shoulder and joint pains" — @BenWolf1425771, X, 3 August 2026. Anecdotal, and the same post links to a supplier, so treat it as promotional.

[[embed:source:w_t3aoiz9r]]

Two of these seventeen carry their own warning on their face. One reports the benefit disappearing about six weeks after stopping — which is the opposite of what tissue repair does. Repaired tendon does not un-repair when you stop injecting.

> "All of the soreness, aches, and pains that disappeared while on BPC/TB500 returned after about 6 weeks for me. I start back on Monday" — @TheCaddieYardFL, X, 1 August 2026. Anecdotal.

[[embed:source:w_ses7fkwk]]

The other is @jordaaash above. He added TB-500 the day before he posted, after a week on BPC-157 alone, and the improvement he describes had already happened before the TB-500 went in. It is counted as a positive because the person counted it that way. It attributes nothing to TB-500.

### Eight said nothing happened

These are not softer versions of the positives. They are people who ran it for weeks at ordinary doses and got no change at all.

> "Did 3mg of BCP & 5mg of TB500 daily for two weeks into my elbow. It didn't do jack shit. This is my 3rd time trying peptides for various joint/tendon stuff and my 3rd time not noticing any improvement at all." — @prax1s_mm, X, 30 July 2026. Anecdotal.

[[embed:source:w_avr26qqh]]

> "Bpc and tb-500 did nothing for my elbow arthritis sadly. Used it for 6 weeks" — @replacementBux, X, 12 April 2026. Anecdotal.

[[embed:source:w_hyq2egsc]]

> "Age 62... I am very limited on what I can do at this point due to the severity of pain. I have been doing BPC 157 +TB 500 for 7 weeks, no improvement yet." — @ToddMil03223111, X, 9 July 2026. Anecdotal.

[[embed:source:w_89es50pi]]

> "I ran a heavy dose of klow into a heavy dose of bp-157 and tb500 for 2 months or more for my shoulder, did nothing, facing a shoulder replacement" — @moon25martin, X, 30 May 2026. Anecdotal.

[[embed:source:w_fqd0nz38]]

That last one is the harshest data point in the set: two months at heavy doses, no effect, still headed for a shoulder replacement.

Somebody treating the same lower-back problem as the three positive disc reports got nothing at all.

> "I'm trying it to see if it helps at all with inflammation for my lower back. L4/5 bulge and L5/S1 herniation. Bpc and Tb did nothing I could notice." — @HangryDBowman, X, 16 July 2026. Anecdotal.

[[embed:source:w_s75yt6kt]]

Three people saying a disc improved and one saying nothing changed, all treating an L5/S1 problem, none of them scanned before or after — that is a clean picture of exactly what uncontrolled reports can and cannot tell you.

Two more report the effect as too small to matter rather than absent.

> "I personally used bpc 157/ tb 500 combo for my shoulder issue. Barely moved the needle. 3/10." — @travfourr, X, 15 April 2026. Anecdotal.

[[embed:source:w_lk8z70he]]

> "I had some pain there and leading up to my bicep area. Didn't get much relief from bpc157/tb500." — @MittelstaedtTim, X, 11 June 2026. Anecdotal.

[[embed:source:w_fkvglkvn]]

One took an oral form for a gut complaint and got nothing, which is unsurprising given the peptide does not survive digestion.

> "Just finished a bottle of oral liposomal BPC157+TB500 and it seems it did nothing :/ (hoping it would help heal my gut)" — @Gronnet, X, 26 April 2026. Anecdotal.

[[embed:source:w_zj1lz4k4]]

### Six had a reaction or got worse

These are the reports vendor pages do not carry, and the most informative account in the whole set is the first one.

> "TB-500 made my shoulder left worse. I have bursitis and stopped TB and it's better. I was getting pain in left thumb and arm as well. I was pinning SubQ. I've used 3 different vendors who are legit. So I ruled out bad product. No issues with BPC-157." — @biotides, X, 7 July 2026. Anecdotal.

[[embed:source:w_q1dsmvn0]]

He had bursitis, the shoulder got worse on TB-500, it improved when he stopped, he had used three different suppliers so a bad batch is unlikely, and he had no problem with BPC-157. That is about as close as an uncontrolled self-report ever gets to isolating one variable.

> "i ran bpc 157 for few weeks felt decent then add tb 500 hand and skeletal felt worse i discontinued it it was the blend version 20mg" — @cryptotray79, X, 14 June 2026. Anecdotal.

[[embed:source:w_fgszb7lb]]

> "I ran TB-500 for a shoulder injury and got a head rush that lasted maybe 20 minutes. Injection site was red for a day." — @UndergroundBio, X, 3 August 2026. Anecdotal.

[[embed:source:w_wuu78tg1]]

Three describe immune-type reactions — hives, itching. That is the exact category FDA flagged in advance, on the grounds that clumped peptide and manufacturing contaminants provoke it.

> "Not my proudest moment, but after BPC-157 and TB-500 from the gray market, I got hives all over my body." — @stateofnomind, X, 10 March 2026. Anecdotal.

[[embed:source:w_dwju43tz]]

> "I took tb500 and bpc 157 mix for 3 days at 0.750 7.5 units on a 3mm needle i had some Hives show up on each side of love handles not the injection sites... Ive done research my self and stopped for now" — @GetterBankWest, X, 2 March 2026. Anecdotal.

[[embed:source:w_nad31utv]]

> "nothing moved the needle more re gut barrier symptoms than TB500. Until the development of an MCAS-like picture, it began to flair immune Sx: itching, hives from heat, etc." — @AmbrosesDrink, X, 4 August 2026. Anecdotal.

[[embed:source:w_llsxbr8a]]

### Two of the thirty-one used TB-500 without BPC-157, and both are in the last group

This is the number that matters. Twenty-nine of the thirty-one accounts ran TB-500 stacked with BPC-157, and several stacked a third and a fourth compound on top of that. Not one of those twenty-nine can attribute anything to TB-500. Every positive report in this set is a report about a combination.

The two accounts that isolate TB-500 are @biotides, whose bursitis shoulder got worse and recovered when he stopped, and @UndergroundBio, who got a head rush and a red injection site. Both sit in the "worse" column.

That is not evidence that TB-500 is harmful. Two reports settle nothing. It is a precise statement of how thin the isolated human experience with this compound actually is: out of 31 people who wrote down what happened, 2 took it on its own, and neither described a benefit.

### What these 31 reports can and cannot settle

They can settle that people are running this at milligram doses for weeks, mostly stacked, mostly for shoulders, elbows, knees and lower backs, and that a substantial fraction of them believe it worked.

They cannot settle whether it works. Nobody was blinded. Nobody imaged the injury before and after. Almost everybody changed something else in the same window — rest, physiotherapy, load reduction, a second compound, surgery. The conditions being treated improve on their own over the same timescale. And negative reports are systematically harder to find than positive ones, which means 17 out of 31 overstates the true positive rate by an unknown amount.

Hold this section against the evidence sections above and the shape is clear. The self-reported record is large, warm, and confounded. The controlled record for this exact molecule, in this exact tissue, is a single study in eight rats.
## Injury by injury, what the record actually reaches

| Your problem | Direct evidence in that tissue | Nearest real evidence | Where that leaves it |
|---|---|---|---|
| Tendon pain — Achilles, patellar, elbow | one 4-week rat study, 8 per arm, TB-500 into the belly cavity | Biçer 2026; Wu 2020 tendon cells in a dish | mechanism is plausible, one small animal result, nothing in people |
| Ligament sprain | one rat knee-ligament study, full protein, placed in the wound in glue | Xu 2013 | positive, but a different molecule at 1 µg delivered locally |
| Muscle strain or tear | none, only work on the body's own signal | Tokura 2011 | the pathway is real, adding more from outside is untested |
| Disc injury, disc-related pain | none | the scoping review lists spine and disc as sparse | no evidence at all in this tissue |
| Frozen shoulder | none | Ehrlich 2010 scar-cell suppression, rat sponge model | a scar-reduction argument only, and it belongs to the full protein |
| Plantar fasciitis | none | tendon data by analogy | no evidence, treated as tendon pain by assumption |
| Recovery after soft-tissue surgery | none in people | skin wound and heart animal work | untested |

Two of those rows carry an extra warning. The frozen-shoulder and disc arguments both rest on reducing scar, and the strongest scar-reduction mechanism in this literature runs through Ac-SDKP — the piece the sold fragment cannot make.

## Every human study ever registered on this molecule

Here is the whole clinical programme for the parent protein, with what actually happened to each trial. TB-500 appears in it once, as the fictional example.

| NCT | Indication | Sponsor | Phase | Enrolled | Status |
|---|---|---|---|---|---|
| NCT00382174 | pressure ulcers | RegeneRx | 2 | 72 | completed |
| NCT00832091 | leg ulcers from poor vein drainage | RegeneRx | 2 | 72 | completed |
| NCT00311766 | epidermolysis bullosa | RegeneRx | 2 | 30 | terminated |
| NCT00598871 | corneal wounds after diabetic eye surgery | ReGenTree | 2 | 12 | terminated |
| NCT00743769 | intravenous safety, healthy volunteers | RegeneRx | 1 | 0 | withdrawn |
| NCT01311518 | heart attack | RegeneRx | 2 | 0 | withdrawn |
| NCT01393132 | severe dry eye | Michigan Cornea Consultants | 2 | 9 | completed |
| NCT02597803 (ARISE-1) | dry eye | ReGenTree | 2/3 | 317 | completed |
| NCT02974907 (ARISE-2) | dry eye | ReGenTree | 3 | 601 | completed |
| NCT03937882 (ARISE-3) | dry eye | ReGenTree | 3 | 700 | completed |
| NCT02600429 (SEER-1) | nerve-damaged cornea | ReGenTree | 3 | 18 | terminated |
| NCT05555589 (SEER-2) | nerve-damaged cornea | ReGenTree | 3 | 70 planned | recruiting |
| NCT04555824 | healthy volunteers, Phase 1a | Beijing Northland | 1 | 54 | completed |
| NCT05485818 | heart attack | Beijing Northland | 2 | 62 | completed |
| NCT05984134 | heart attack | Beijing Northland | 2 | 90 | completed |
| NCT07586865 | heart attack | Beijing Northland | 2 | 189 planned | not yet recruiting |
| NCT07487363 | TB-500, heart biomarkers | "Hudson Biotech" | 1/2 | 80 planned | self-declared fictional example |

Four things fall out of that table.

**No musculoskeletal indication has ever been registered.** Not tendon, not ligament, not muscle, not fascia, not disc. Not by any sponsor, in twenty years, for either molecule. That absence is not a hole in the search. It is the state of the field.

**Both heart trials from the original sponsor were withdrawn before a single patient enrolled**, and the programme then moved to a different sponsor, a different country, and a recombinant full-length product.

[[embed:source:s36]]

**The published "Phase III" cornea result comes from a terminated trial.** SEER-1 stopped at 18 patients enrolled, and the ten-versus-eight comparison you read in the literature is that terminated trial's data. Its successor, SEER-2, is still recruiting toward 70.

[[embed:source:s39]]

[[embed:source:s42]]

**Three completed Phase 3 dry-eye trials covering 1,618 patients have produced no approval.** ARISE-1 finished in 2016, ARISE-2 in 2018, ARISE-3 in October 2021. That is the largest and most mature dataset this molecule has, in the indication where it performs best, and it has not turned into a medicine anybody can buy.

[[embed:source:s44]]

[[embed:source:s40]]

[[embed:source:s43]]

The skin programme closed the same way — two trials completed with safety as the main question, two stopped early.

[[embed:source:s37]]

[[embed:source:s38]]

## What is solid, what is not, and the gap underneath both

**Solid.** Thymosin beta-4 holds loose actin and controls how a cell builds its internal skeleton. Its seven-amino-acid actin-grabbing piece is the part that grows new blood vessels, working at around 50 nanomolar. The full protein closes rat skin wounds 42 to 61% faster, stops repair cells turning into the scar-pulling kind, works through integrin-linked kinase and Akt in injured heart muscle, pulls muscle precursor cells toward damage, and improves dry eye and nerve-damaged cornea in small controlled human trials.

**Not solid.** That any of that heals a human tendon, ligament, muscle, disc or fascia. That the fragment sold as TB-500 does what the full protein does. That milligram-per-week injections under the skin reach an injured structure at a concentration where the mechanism runs. That the compound is safe in a person over any length of time, because that study has never been run.

**The gap underneath both.** The evidence and the product are not the same substance. A regulator has written that down. The capped form has never been shown to do what the uncapped form does. And the one time anybody tested TB-500 itself in a dish, it did nothing. Every transfer of evidence from the 43-amino-acid protein to the seven-amino-acid fragment is an assumption, and it is the assumption the whole market stands on.

The practical consequence is narrow and specific. Tendon pain from overuse, an impingement, and a partial tear are three different problems with three different treatment plans, and no peptide tells them apart. Getting the diagnosis right changes what you should do this week far more than anything in this vial does. The scoping review that counted this entire literature lands in the same place, in its own words: the evidence "remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications."

*Not medical advice. TB-500 is sold for research use only, is not an approved drug, is not currently legal to compound, and is prohibited at all times in WADA-tested sport. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:bpc-157]]

[[embed:ara-290]]

[[embed:wolverine-stack]]

[[embed:wolverine-stack-ara-290]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:bpc-157-vs-nsaids]]


## Sources

1. The actin binding site on thymosin beta4 promotes angiogenesis — https://pubmed.ncbi.nlm.nih.gov/14500546/
2. Thymosin beta4 accelerates wound healing — https://pubmed.ncbi.nlm.nih.gov/10469335/
3. Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Pressure Ulcers — https://clinicaltrials.gov/study/NCT00382174
4. Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers — https://clinicaltrials.gov/study/NCT00832091
5. Thymosin beta-4 and venous ulcers: a European prospective, randomized study — https://pubmed.ncbi.nlm.nih.gov/17495250/
6. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial — https://pubmed.ncbi.nlm.nih.gov/26056426/
7. Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury — https://pmc.ncbi.nlm.nih.gov/articles/PMC3843122/
8. Thymosin beta4 is cardioprotective after myocardial infarction — https://pubmed.ncbi.nlm.nih.gov/17600280/
9. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review — https://doi.org/10.3390/app16126202
10. Thymosin beta4 enhances the healing of medial collateral ligament injury in rat — https://pubmed.ncbi.nlm.nih.gov/23523891/
11. TB-500 - Status, Risks, and Bans in Sport and Military — https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military
12. Thymosin beta4: potential to treat epidermolysis bullosa and other severe dermal injuries — https://pubmed.ncbi.nlm.nih.gov/31649007/
13. TB-500 - Status, Risks, and Bans (BSCG) — https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military
14. Thymosin beta4 improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Cornea 2015) — https://pubmed.ncbi.nlm.nih.gov/25826322/
15. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke — https://pubmed.ncbi.nlm.nih.gov/20627173/
16. Role of thymosin beta4 in tumor metastasis and angiogenesis (JNCI 2003) — https://pubmed.ncbi.nlm.nih.gov/14625258/
17. Thymosin beta4 has tumor suppressive effects in multiple myeloma — https://pubmed.ncbi.nlm.nih.gov/19833631/
18. FDA Briefing Document, Pharmacy Compounding Advisory Committee — TB-500-Related Bulk Drug Substances (TB-500 free base and TB-500 acetate) — https://www.fda.gov/media/193349/download
19. World Anti-Doping Code International Standard — Prohibited List 2026, section S2.3 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
20. FDA Panel Votes to Loosen Restrictions for Four Peptides — https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
21. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study — https://pubmed.ncbi.nlm.nih.gov/42542926/
22. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts — https://pubmed.ncbi.nlm.nih.gov/20880960/
23. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts — https://pubmed.ncbi.nlm.nih.gov/20536458/
24. The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis — https://pmc.ncbi.nlm.nih.gov/articles/PMC9655242/
25. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase — https://pubmed.ncbi.nlm.nih.gov/26962108/
26. Electrospun thymosin Beta-4 loaded PLGA/PLA nanofiber/microfiber hybrid yarns for tendon tissue engineering application — https://pubmed.ncbi.nlm.nih.gov/31753373/
27. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair — https://pubmed.ncbi.nlm.nih.gov/15565145/
28. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial — https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
29. Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NL005) — https://clinicaltrials.gov/study/NCT05485818
30. A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers — https://clinicaltrials.gov/study/NCT00743769
31. TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD — 'TBRIDGE-CV' [self-declared fictional example record] — https://clinicaltrials.gov/study/NCT07487363
32. A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction — https://clinicaltrials.gov/study/NCT01311518
33. A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa — https://clinicaltrials.gov/study/NCT00311766
34. A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds — https://clinicaltrials.gov/study/NCT00598871
35. Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy: SEER-1 — https://clinicaltrials.gov/study/NCT02600429
36. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-2 — https://clinicaltrials.gov/study/NCT02974907
37. A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers — https://clinicaltrials.gov/study/NCT04555824
38. Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 — https://clinicaltrials.gov/study/NCT05555589
39. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 — https://clinicaltrials.gov/study/NCT03937882
40. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 — https://clinicaltrials.gov/study/NCT02597803
41. Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye — https://clinicaltrials.gov/study/NCT01393132
42. X · @PayHereSukka · 2026-07-30 — https://x.com/PayHereSukka/status/2082956437056008230
43. X · @MuroCrypto · 2026-07-31 — https://x.com/MuroCrypto/status/2083184469956059529
44. X · @jasonsvoboda · 2026-07-26 — https://x.com/jasonsvoboda/status/2081426443024961838
45. X · @MithMuel · 2026-06-30 — https://x.com/MithMuel/status/2071802227342340531
46. X · @howdymary · 2026-03-09 — https://x.com/howdymary/status/2031137869285425498
47. X · @Das_Bear_ · 2026-06-29 — https://x.com/Das_Bear_/status/2071462119011492350
48. X · @ryalljohnny1989 · 2026-08-03 — https://x.com/ryalljohnny1989/status/2084312093067513939
49. X · @caezcrypto1 · 2026-07-30 — https://x.com/caezcrypto1/status/2082943665832374561
50. X · @L0V3lsKeY · 2026-08-02 — https://x.com/L0V3lsKeY/status/2083868515438666186
51. X · @tj_underwood · 2026-07-31 — https://x.com/tj_underwood/status/2083248032603107752
52. X · @jordaaash · 2026-03-30 — https://x.com/jordaaash/status/2038733749366755452
53. X · @pepfessions · 2026-08-03 — https://x.com/pepfessions/status/2084071774480736712
54. X · @JonahLupton · 2026-07-26 — https://x.com/JonahLupton/status/2081490976510468316
55. X · @GrantWest14 · 2026-01-10 — https://x.com/GrantWest14/status/2010124835264111079
56. X · @_REDwave_2024 · 2026-05-20 — https://x.com/_REDwave_2024/status/2057019155824652482
57. X · @BenWolf1425771 · 2026-08-03 — https://x.com/BenWolf1425771/status/2084389889303548201
58. X · @TheCaddieYardFL · 2026-08-01 — https://x.com/TheCaddieYardFL/status/2083641327833522639
59. X · @prax1s_mm · 2026-07-30 — https://x.com/prax1s_mm/status/2082901582627184835
60. X · @replacementBux · 2026-04-12 — https://x.com/replacementBux/status/2043445152849555478
61. X · @moon25martin · 2026-05-30 — https://x.com/moon25martin/status/2060514158739640718
62. X · @ToddMil03223111 · 2026-07-09 — https://x.com/ToddMil03223111/status/2075223118067433536
63. X · @HangryDBowman · 2026-07-16 — https://x.com/HangryDBowman/status/2077974266339803140
64. X · @travfourr · 2026-04-15 — https://x.com/travfourr/status/2044547711114895786
65. X · @MittelstaedtTim · 2026-06-11 — https://x.com/MittelstaedtTim/status/2064873594103222656
66. X · @Gronnet · 2026-04-26 — https://x.com/Gronnet/status/2048321787667103904
67. X · @biotides · 2026-07-07 — https://x.com/biotides/status/2074549220887941324
68. X · @cryptotray79 · 2026-06-14 — https://x.com/cryptotray79/status/2071013244072788255
69. X · @stateofnomind · 2026-03-10 — https://x.com/stateofnomind/status/2031391204232016324
70. X · @GetterBankWest · 2026-03-02 — https://x.com/GetterBankWest/status/2028322438984175693
71. X · @AmbrosesDrink · 2026-08-04 — https://x.com/AmbrosesDrink/status/2084497141234598355
72. X · @UndergroundBio · 2026-08-03 — https://x.com/UndergroundBio/status/2084421599072039066


---

# Retatrutide: the third receptor, and what the evidence now establishes

slug: retatrutide · https://miscsubjects.com/a/retatrutide · tags: peptide, retatrutide, glp-1, obesity, disc · updated 2026-08-05T02:14:48.127Z

Retatrutide is one molecule that switches on three different hormone receptors at once: GLP-1, GIP, and glucagon. Semaglutide hits one of those. Tirzepatide hits two. Retatrutide adds the third, and that third one is the interesting part, because glucagon is the hormone most people know as the one that raises blood sugar — the opposite of what a diabetes drug is supposed to do.

Understanding why adding it works is most of understanding this drug.

**Where the evidence stands, before anything else.** Retatrutide has been tested in people. Phase 2 randomised trials in obesity and in type 2 diabetes are published, and the first phase 3 trial — a double-blind randomised trial in type 2 diabetes — has now reported. The obesity phase 3 trials and the cardiovascular and kidney outcome trials are still running. It is not an approved medicine in any country, so nothing sold under this name is the material that was studied.

## Why putting glucagon into a weight-loss drug is not a mistake

Glucagon does raise blood sugar. It also does something else: it increases energy expenditure. It tells the liver to break down stored fat and it raises the rate at which the body burns energy at rest.

So a molecule that activates the glucagon receptor on its own would burn more energy and worsen blood sugar. A molecule that activates GLP-1 and GIP lowers blood sugar strongly and reduces appetite. Put all three on one peptide and the GLP-1 and GIP arms more than cover the blood sugar cost of the glucagon arm, and you keep the extra energy expenditure.

The result is a drug that attacks weight from both sides at once — appetite down and energy out up — rather than appetite alone. Every other drug in this class works mainly on the intake side.

The elegance of that design has been demonstrated in an unusual way. Researchers testing the components in mice engineered to have no working GLP-1 receptor at all found that retatrutide still normalised body weight in those animals.

[[embed:source:s11]]

That is a mechanistic result rather than a clinical one, and it matters because it isolates the contribution of the other two arms. The weight effect is not simply a stronger version of what GLP-1 drugs do.

## What it actually does to weight, in numbers

The comparison that puts it in context is a network analysis of the drugs acting on the glucagon receptor, which ranks them against placebo on weight.

[[embed:source:s12]]

Retatrutide produced the greatest weight reduction of the class — a mean difference of 13.44 kg against placebo, ahead of survodutide at 10.74 kg, with cotadutide's effect small and not statistically significant.

The same analysis found retatrutide had the largest effect on HbA1c, the three-month average blood sugar measure — and it was the only one of the four whose effect on HbA1c reached statistical significance.

In the type 2 diabetes programme the blood sugar numbers are striking on their own terms: HbA1c improved by 2.2%, and 82% of participants reached 6.5% or below — a threshold at which many people would no longer meet the diagnostic criteria for diabetes.

[[embed:source:s13]]

The same summary reports improvements across blood pressure, lipids, waist circumference, and an 82% reduction in liver fat.

## The body composition question, answered directly

The standard objection to very effective weight-loss drugs is that a large fraction of what is lost is muscle rather than fat. It is a serious objection, particularly in older people, and the more weight a drug takes off the more it matters.

A substudy measured body composition directly rather than inferring it.

[[embed:source:s14]]

Fat mass fell 26.1% on the 8 mg dose and 23.2% on 12 mg, against 2.6% on placebo. And on the question people actually want answered:

[[embed:source:s15]]

The proportion of the loss that was lean mass was similar to other obesity treatments. Retatrutide takes off more total weight, and it does not appear to take off a disproportionate share of muscle in doing so.

Two honest caveats. The study was funded by the manufacturer, which is normal at this stage and worth stating. And 85% of the participants were White, which limits how confidently the result generalises.

## The liver finding, and why it is arguably the most important one

An 82% reduction in liver fat is a large number in a field where liver fat has been hard to move. Fatty liver disease has almost no approved drug treatment; a 2026 review notes that only two agents are specifically approved for it, and places retatrutide among the pipeline drugs showing marked reductions in liver fat and early signals of benefit in the more advanced inflammatory form.

[[embed:source:s16]]

Another 2026 review of the same area places it alongside the other multi-receptor drugs and is careful about the limits.

[[embed:source:s17]]

Early clinical data indicating potent effects. Evidence on whether it changes scarring in the liver remains limited. That distinction — reducing fat in the liver versus changing the disease that fat drives — is the one that will decide whether this becomes a liver drug or a weight drug with a liver side effect.

## What it feels like to take, from the people who took it

A substudy asked participants in the diabetes trial about hunger and eating rather than only weighing them.

[[embed:source:s18]]

People on the higher doses reported being less likely to feel hungry or to overeat, and — the more interesting finding — the people who lost the most weight were the same people who reported the largest changes in hunger and overeating.

That correlation is worth holding onto for a practical reason. If your appetite has not changed on a drug in this class, the weight is less likely to follow, and that is information available within weeks rather than months.

## What "three receptors on one molecule" actually required

It is worth understanding why this took until now, because it explains why the class looks the way it does and what the constraints are.

GLP-1, GIP and glucagon are structurally related hormones — close enough that a single engineered peptide can be made to fit all three receptors, and far enough apart that fitting all three well is difficult. The design problem is not simply binding all three. It is binding them in the right *ratio*.

Too much glucagon activity relative to the other two and blood sugar rises. Too little and the extra energy expenditure that justifies including it disappears. Too much GLP-1 activity relative to the rest and the gastrointestinal effects become intolerable before the target dose is reached. The molecule has to be balanced, and the balance is a property of the peptide sequence and its fatty-acid modification, not something a prescriber can adjust.

That has a practical consequence people miss. With a single-receptor drug, dose is the only variable and more is more. With a three-receptor drug, the ratio between the three effects is fixed at the point of manufacture, and only the total is dose-dependent. It also means a peptide with the wrong sequence is not a weaker version of the drug — it is a different drug with a different balance, and its blood sugar effect could point the other way.

A 2026 review of the wider field places these engineered multi-agonists in context: they work by mimicking the several-hormone response the body produces after bariatric surgery, rather than by amplifying one signal.

[[embed:source:s23]]

That framing explains the size of the effects better than "a stronger GLP-1 drug" does. The comparison to surgery is not only about how much weight comes off; it is about which mechanism is being copied.

## Who this class does not suit, and the practical constraints

Some of what follows is class knowledge from the approved drugs rather than retatrutide-specific evidence, and it is labelled as such because the distinction matters.

**Anyone with a history of medullary thyroid carcinoma or the endocrine syndrome associated with it** is excluded from GLP-1 drugs on the basis of rodent findings. That exclusion is applied to the class.

**Gastroparesis and significant gastrointestinal disease** sit badly with drugs whose main mechanism includes slowing stomach emptying.

**Pregnancy** is a contraindication across the class, and the appetite mechanism means people using these drugs while trying to conceive need a conversation about timing rather than an assumption.

**Anyone on insulin or a sulfonylurea** faces a real interaction: as the drug improves blood sugar, existing medication that lowers it further can cause hypoglycaemia. This is managed by adjusting the other drugs, which requires somebody monitoring.

The last point is the one that connects back to the glucagon arm. Retatrutide's blood sugar effect is the *net* of three receptor effects, two lowering and one raising. The trials established that net in specific populations on specific background medications. That is not a constant of nature; it is a measured result in a defined group.

## The side effects, and the class risk worth naming

Gastrointestinal symptoms are the commonest problem — nausea, vomiting, diarrhoea, constipation — and they are the reason the dose is escalated slowly rather than started at target. In the phase 2 programme they were the main adverse events reported, with no major safety concerns identified.

[[embed:source:s19]]

"No major safety concerns in phase 2" is a real statement and a limited one. Phase 2 trials enrol hundreds of people for months. Rare harms and long-term harms are what phase 3 and post-marketing surveillance are for, and only the first of those has begun to report.

One class-level risk deserves naming because it is asked about constantly. A meta-analysis of GLP-1 receptor agonists found a slightly increased risk of pancreatitis, and no significant association with pancreatic cancer overall.

[[embed:source:s20]]

Note that this is a finding about the established GLP-1 drugs, not about retatrutide specifically. Applying it here is a reasonable inference from a shared mechanism, not a measurement.

There is also a mechanistic reason to watch blood sugar more carefully with this drug than with its predecessors. The glucagon arm raises blood sugar. In the trials the other two arms more than compensate. In someone whose situation differs from the trial population — different medications, different insulin reserve — that balance is an assumption rather than a measurement.

## Where it is in development, stated plainly

**Retatrutide is not an approved medicine anywhere.** That is the fact that governs everything below, and it is true despite the programme having moved past phase 2.

The first phase 3 result has published. TRANSCEND-T2D-1 was a double-blind randomised phase 3 trial in people with type 2 diabetes whose blood sugar was not controlled by diet and exercise alone, with change in HbA1c at week 40 as its primary endpoint.

[[embed:source:s1]]

Retention was high — 91% of participants completed the treatment period on the study drug and 94% completed the study, which for a drug whose main side effects are gastrointestinal is itself a tolerability finding.

[[embed:source:s24]]

The rest of the programme is still running: the obesity phase 3 trials, and the cardiovascular and kidney outcome trials.

[[embed:source:s21]]

That last part — cardiovascular and renal outcome trials — is not a formality. For drugs in this class, outcome trials are how the field learns whether the metabolic improvements translate into fewer heart attacks and less kidney failure, and the answer has not always followed the surrogate measures.

Phase 2 results of this size attract language that outruns the evidence. One 2026 perspective describes the weight reductions as comparable to bariatric surgery and calls the drug a watershed.

[[embed:source:s22]]

That may prove right. It was also written from phase 2 data, and the distance between "unprecedented in phase 2" and "approved and durable in practice" is where a great many promising drugs have stopped. The first phase 3 result is now in, in diabetes; the weight-loss phase 3 results and the outcome trials are not.

## What this means for anything sold under this name

This is the part that matters most to anyone reading this page with a purchase in mind.

Because retatrutide is not approved, nothing sold under that name is a licensed medicine. There is no pharmacy supply chain, no regulator checking identity or purity, and no manufacturer standing behind what is in the vial. The dosing that produced the results above came from a controlled programme with slow escalation and monitoring — and dose escalation exists in these trials precisely because starting at target dose causes the gastrointestinal effects that make people stop.

The honest position: the trial results are real, they are large, and they were produced under conditions that have almost nothing in common with obtaining an unapproved peptide and self-administering it. The operator of this site has a commercial interest in compounds of this kind, which is exactly why that sentence appears here rather than at the bottom in small type.

## Ten people, and what the evidence supports about them

Ten people with obesity take retatrutide at the higher doses in a trial setting. On the pooled evidence, they lose substantially more weight than they would on any other drug in this class, and the proportion of that loss which is muscle is no worse than with the alternatives. Most of them experience gastrointestinal side effects at some point, particularly while the dose is being raised. Those who report the biggest change in hunger are the same ones who lose the most weight. Their liver fat falls substantially. Their blood pressure, lipids and waist measurement improve. Whether any of that translates into fewer cardiovascular events over years is being tested now and is not yet known for any of them.

## What the trials do not tell you

Four gaps are worth naming precisely, because they are the questions people ask and the literature does not yet answer.

**What happens when you stop.** No published retatrutide data addresses this. For the approved drugs in the class, stopping is followed by substantial weight regain, which is what you would expect from a drug whose mechanism is suppressing appetite while it is present. There is no reason to assume this molecule behaves differently, and no evidence that it does. Anyone planning to take it should plan for what follows.

**Whether the effects last.** The phase 2 results run to 48 weeks. Weight loss curves in this class typically flatten as the body adjusts, and where that plateau sits for retatrutide over two or three years is unknown.

**Whether the metabolic gains become clinical ones.** The published phase 3 trial measured HbA1c, not heart attacks. Lower blood sugar, lower blood pressure, better lipids and less liver fat are surrogates. They are strongly associated with fewer heart attacks and less kidney failure, and drugs that improve surrogates have sometimes failed to improve outcomes. That is precisely what the running outcome trials exist to settle.

**Who it works badly for.** With 85% White participants in the body composition substudy and a trial population selected by trial criteria, the honest answer about how this performs across different populations is that it has not been measured properly yet.

Those four are not criticisms of the drug. They are the difference between a phase 2 result and a medicine.

## Where this sits against the others

Against semaglutide and tirzepatide, retatrutide's case is the third receptor and the energy-expenditure arm it brings. Against bariatric surgery, the comparison people keep reaching for, the honest version is that phase 2 weight reductions are in a comparable range while durability, complication profile and decade-scale outcomes are not comparable at all, because one of them has decades of follow-up and the other has none.

The most defensible summary available today: the largest weight effect measured in its class, the largest blood sugar effect in its class, a substantial liver fat effect, an ordinary side-effect profile for the class, no unexpected safety signal so far, one published phase 3 trial in type 2 diabetes with high completion rates, and no approval anywhere.

## The seven things this evidence supports

1. **The third receptor is the whole story.** Glucagon adds energy expenditure to appetite suppression, and the other two arms cover its effect on blood sugar.
2. **The weight effect is the largest in its class, and it is measured against placebo.** 13.44 kg mean difference, ahead of every comparator in the network analysis.
3. **The muscle question has been answered directly, not argued.** Fat mass down 26.1% at 8 mg, with the lean mass proportion similar to other treatments in the class.
4. **The liver result may matter more than the weight result.** An 82% reduction in liver fat, in a disease with almost no approved treatment — and no evidence yet on scarring.
5. **If your appetite does not change, watch closely.** The people with the largest changes in hunger were the ones who lost the most weight.
6. **It is not an approved drug.** One phase 3 trial has reported, in diabetes. The obesity phase 3 trials and the cardiovascular and kidney outcome trials have not.
7. **Nothing sold under this name is the drug that was studied.** The results came from a monitored programme with controlled escalation and verified material. That is not what an unapproved peptide purchase is.


## Sources

1. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial — https://pubmed.ncbi.nlm.nih.gov/42250575/
2. Efficacy and safety of retatrutide for the treatment of obesity — https://pubmed.ncbi.nlm.nih.gov/40728138/
3. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/39817343/
4. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/40291085/
5. Retatrutide-A Game Changer in Obesity Pharmacotherapy — https://pubmed.ncbi.nlm.nih.gov/40563436/
6. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
7. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) — https://clinicaltrials.gov/study/NCT05882045
8. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials — https://pubmed.ncbi.nlm.nih.gov/41090431/
9. A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes — https://clinicaltrials.gov/study/NCT05936151
10. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8) — https://clinicaltrials.gov/study/NCT07232719
11. GIPR:GCGR co-agonism restores normal weight in obese rodents — https://pubmed.ncbi.nlm.nih.gov/41997446/
12. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials — https://pubmed.ncbi.nlm.nih.gov/41787737/
13. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
14. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
15. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
16. Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes — https://pubmed.ncbi.nlm.nih.gov/41831086/
17. Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression — https://pubmed.ncbi.nlm.nih.gov/42195239/
18. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study — https://pubmed.ncbi.nlm.nih.gov/40916752/
19. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
20. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials — https://pubmed.ncbi.nlm.nih.gov/40988099/
21. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
22. The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities — https://pubmed.ncbi.nlm.nih.gov/41545327/
23. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders — https://pubmed.ncbi.nlm.nih.gov/41297910/
24. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial — https://pubmed.ncbi.nlm.nih.gov/42250575/


---

# The Wolverine stack plus ARA-290 for a degenerating disc and sciatica: the evidence at every link

slug: wolverine-stack-ara-290 · https://miscsubjects.com/a/wolverine-stack-ara-290 · category: peptides · tags: peptide, bpc-157, tb-500, ara-290, disc, sciatica, stack, wolverine · updated 2026-08-04T22:08:42.768Z

A worn spinal disc with a burning leg is not one problem. It is a breakdown running in three separate places at once, and the reason people add ARA-290 to the two-compound Wolverine stack is that the third place — the nerve fibres themselves — is the one the first two compounds do not touch.

The evidence state, before the argument. No study in any species has ever given all three compounds together, so the number of people or animals that have taken this stack under measurement is nought. One at a time the three are nothing like each other. ARA-290 has six human studies and 132 people who received the active compound; three of the six missed their main endpoint, the positive results cluster in one disease, sarcoidosis, and not one of the six enrolled a person with a back problem. BPC-157 has five published human studies covering about 130 people, none of them a finished controlled trial in a torn or worn tissue. The seven-amino-acid fragment sold as TB-500 has no human study at all and no established human dose. Two entries were filed on ClinicalTrials.gov in February 2026 by one sponsor, Hudson Biotech: NCT07437547, a 120-person randomised, double-blind, placebo-controlled hamstring trial marked recruiting, and NCT07487363, which names TB-500 and whose own public summary states that it is a fictional example of a registry record. Neither has reported anything. The animal record behind the disc argument is rats, mice and rabbits, and the one experiment that ever combined two of the three found the pair beat neither compound on its own. What has never been measured in a person: any of the three against a squeezed nerve root or a worn disc, and all three together in anything alive.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

This page sets out what is breaking down, what makes it break down faster, what each of the three compounds is proposed to build back, and how strong the evidence is at every single link. The grades differ enormously between links, and the strongest evidence in the whole stack sits on the compound most people leave out.

## Three things break down in a worn disc, and they break down in order

**The disc dries out.** The soft centre of a spinal disc is mostly water, held there by a large sugar-and-protein molecule called aggrecan that acts like a sponge. At birth that centre is about 90% water. By 60 it is closer to 70%, because the aggrecan gets chopped up and washed out. Less water means less pressure inside, and a disc that cannot hold pressure cannot spread load.

**The outer ring tears.** As the centre flattens, load transfers to the tough fibrous ring around it. That ring is not built to take the load directly, so it splits — small cracks first, then tears that run through to the outside. That is how a worn disc becomes a bulging or herniated one.

**The chemistry turns hostile, and nerves grow in.** Disc cells under load start pumping out two inflammatory signals, TNF-alpha and IL-1beta. Those signals do three things at once. They raise the enzymes that chew up the disc's own scaffolding while lowering the proteins that block those enzymes, so breakdown outruns building. They irritate any nerve root nearby. And they coax pain nerve fibres to grow into a disc that normally has none in its centre at all.

That third step is why worn and painful are different conditions. Plenty of badly degenerated discs never hurt. What makes a worn disc a painful one is chemistry, not the wear.

[[embed:degenerative-disc-disease]]

## The reason the disc cannot fix any of it

The spinal disc is the largest structure in the body with no blood supply of its own. Nothing feeds it directly. Nutrients seep in slowly through the bony end plates above and below, and those plates stiffen and calcify with age, so the supply gets worse exactly as the demand rises.

Every tissue that heals well heals because blood brings oxygen, raw material and repair cells. The disc gets almost none of that. This single fact governs everything that follows: it is why the breakdown mostly runs one way, why swallowed supplements struggle to reach the tissue, and why any serious attempt at rebuilding has to solve the blood supply before anything else can matter.

It is also why BPC-157 — a compound whose main proposed action is growing new blood vessels into damaged tissue — is the one people reach for, and why that reach has never been tested in a disc.

## What speeds the breakdown up, and which of those you control

Most of what drives disc breakdown is fixed: age, the genes you have, injuries you already had. Two are not fixed, and both have better evidence behind them than any compound on this page.

**Body weight.** A Mendelian randomisation analysis — the study design built specifically to separate cause from correlation, by using inherited genetic variation as the exposure — found that higher body mass index raises the odds of disc breakdown, of low back pain, and of sciatica. That is causal-grade evidence, which is a higher grade than anything supporting any of the three compounds here.

**Smoking.** Nicotine narrows the small vessels feeding a tissue that is already starved of blood, and it is directly toxic to disc cells, cutting their repair activity. For a structure whose central problem is nutrition, that is the worst possible input.

The widely repeated line that one pound of body weight equals four pounds on the spine is not a measured law. The genuine four-to-five-fold load spikes recorded inside living discs come from bending and lifting — the leverage of the trunk — not from a body-weight multiplier.

## Three compounds, three different parts of the problem, graded link by link

This is the argument for the three-compound stack, stated as a table so each link can be attacked separately. The grades run A to F and are defined immediately below the table.

| What is breaking down | The compound aimed at it | What that compound is proposed to do, in plain words | Strongest evidence for that link | Grade | What would prove this link wrong |
|---|---|---|---|---|---|
| No blood supply reaching the damaged tissue | BPC-157 | Grow new blood vessels into the injury by switching on the VEGF growth signal and the nitric-oxide system that widens vessels, so oxygen and raw material arrive | Rat Achilles tendon torn off the bone came back attached and mechanically stronger; cut ligament, crushed muscle and severed muscle-tendon join all healed faster than control | D | Counting vessels at the injury site in a controlled animal study and finding no difference against control |
| Repair cells not reaching or not organising | TB-500 | Bind actin, the filament a cell builds and takes apart to change shape, so repair cells can crawl into the wound and lay ordered collagen instead of scar | Rat Achilles repair, 32 animals, 8 per arm, four weeks: higher load to failure than control, p < 0.05; best tissue score, p = 0.016; most ordered collagen under stain | D | Measuring how many repair cells arrive at the wound and finding no increase |
| The nerve fibres themselves damaged and dying back | ARA-290 | Bind a receptor that only appears on tissue that is already injured, switching on a repair programme that regrows small nerve fibres, without raising red cell counts the way its parent hormone does | Randomised, placebo-controlled human trials. Corneal nerve fibre area rose 697 µm² above placebo at 4 mg a day for 28 days, p = 0.012, in 64 people with nerve fibre loss from sarcoidosis; nerve fibre density rose 2.6 fibres/mm² in the abnormal subgroup of a diabetic neuropathy trial, p = 0.02 | B | A randomised trial in a compressed nerve root showing no separation from placebo — which is the trial nobody has run |
| The nerve root chemically irritated by TNF-alpha | BPC-157 and TB-500, weakly | Calm the inflammatory signalling around the root | Rodent anti-inflammatory models only. The strongest available test of this target in humans — blocking TNF-alpha with a monoclonal antibody at the nerve root — produced a null result against steroid | E | Already largely answered against, see below |
| The displaced fragment physically pressing on the nerve | Nothing | No compound in this stack is claimed to move tissue | Not applicable | Not a claim | Any vendor asserting a peptide puts a disc back is making a claim with no mechanism behind it |
| All three compounds together | — | The three steps at once | Nothing. No study in any species has given all three | F | Untested in every sense |

## The grades explained, so the table can be argued with

- **A** — randomised, placebo-controlled human trial in the actual condition on this page. Nothing on this page holds an A.
- **B** — randomised, placebo-controlled human trial in a different condition, with the target tissue measured directly. ARA-290 holds a B, on nerve.
- **C** — controlled animal experiment in the target tissue.
- **D** — controlled animal experiment in a related tissue. BPC-157 and TB-500 both hold a D: their results are in tendon, ligament, muscle and nerve, never in a disc.
- **E** — cells in a dish, or a mechanism argued from a related pathway.
- **F** — no experiment of any kind.

Read the grade column and one thing jumps out. The compound with the strongest evidence is the one usually treated as the optional add-on, and the two compounds the stack is named after are the two graded D. If evidence quality drove what people bought, the ordering would be reversed.

## The nerve is the only link with randomised human evidence behind it

ARA-290, generic name cibinetide, is an eleven-amino-acid piece of erythropoietin — the hormone that tells bone marrow to make red blood cells. It was built by cutting out the section of that hormone responsible for tissue repair while leaving out the section responsible for red cells.

That split works because the two jobs run through two different receptors. Red cell production runs through the classical receptor. Tissue repair runs through a different pairing, which appears on tissue only after it has been damaged and is absent from healthy tissue. So the compound has, by design, almost nothing to bind to in an uninjured body, and it does not thicken the blood the way erythropoietin does.

The pharmacology has one oddity worth understanding, because it looks like a contradiction. A 4 mg injection under the skin peaks at about 3 ng/mL in the blood and is gone in roughly twenty minutes. Yet it is dosed once a day and the effects last for days. The reason is that binding the receptor starts a repair programme inside the cell, and the programme keeps running long after the compound has cleared. Short life in the blood, durable effect in the tissue.

[[embed:ara-290]]

## ARA-290's trials were real, and not one of them enrolled a back

Six human studies exist. One hundred and thirty-two people have received active compound across all of them. Three of the six missed their main endpoint. Here is every one.

| Study | Registration | People | Who was enrolled | Dose | Length | Result |
|---|---|---|---|---|---|---|
| Culver 2017, Phase 2b | NCT02039687 | 64, 16 per arm | Nerve fibre loss from sarcoidosis, with nerve pain | 1, 4 or 8 mg under the skin, daily | 28 days | Hit at one dose only. Corneal nerve fibre area above placebo: 109 µm² at 1 mg (not significant), 697 µm² at 4 mg (p = 0.012), 431 µm² at 8 mg (not significant). Pain in the moderate-to-severe group, p = 0.157, not significant |
| Brines 2015 | NTR3858 | 49 enrolled, 48 analysed | Type 2 diabetes with painful nerve damage in the feet | 4 mg under the skin, daily, self-injected | 28 days, followed 56 | Hit. HbA1c fell 0.16% at day 28 against 0.01% for placebo, p = 0.002. Pain score improved significantly. Nerve fibre density rose 2.6 ± 1.0 fibres/mm² in the 18 people whose baseline was genuinely abnormal, p = 0.02 |
| Dahan 2013 | Single centre, Leiden | 38 | Sarcoidosis with confirmed small nerve fibre loss | 4 mg under the skin, daily | 28 days | Split. Corneal nerve fibre density rose significantly. Skin nerve fibre density rose 0.38 ± 0.48 fibres/mm, 7.2% of baseline, not significant. Symptoms, temperature sensing and walking distance all improved |
| Heij 2012 pilot | No registration number | 22, 12 active | Sarcoidosis with nerve symptoms | 2 mg into a vein, three times a week | 4 weeks | Hit. Symptom score fell 11.5 ± 3.04 against 2.9 ± 3.34 for placebo, p < 0.05. Pain inventory and fatigue improved equally in both arms, so no separation there |
| Cerit 2015 | NCT02070783 | 36 healthy volunteers | Healthy adults, mood-processing model | 2 mg, single dose | One week | Missed. Some change in emotional processing, no effect on mood |
| Diabetic macular oedema | NCT06626971 | — | Swelling at the back of the eye in diabetes | — | — | Terminated |

[[embed:source:s1]]

[[embed:source:s2]]

Three things follow, and all three matter to somebody reading this with a leg that burns.

**The positive results cluster in one disease.** Three of the four hits are in sarcoidosis, where the nerve damage is driven by the immune system attacking the small fibres. That is a different cause from a nerve root squeezed and chemically irritated by a disc.

**The dose that worked is 4 mg a day and the dose above it did not work.** In the Phase 2b, 4 mg separated from placebo and 8 mg did not. A compound whose effect rises then falls as the dose climbs cannot be dosed by guesswork, and the doses people actually take — 250 to 1,000 mcg a day — sit four to sixteen times below the only dose that has ever worked.

**Nobody has run it against a compressed nerve root.** Not in a person, not in an animal. The entire nerve argument for a disc is a read-across from a different disease with a different cause, and read-across is exactly the step that fails most often in drug development.

[[embed:source:s3]]

## The chemical-irritation link is the weakest one, and it has been tested hard

The strongest case for BPC-157 and TB-500 in a disc is usually made on inflammation rather than structure: the argument that they calm the TNF-alpha driven chemistry making the nerve root hurt. That target has been tested in humans, properly, with a far more potent tool than a peptide.

Etanercept is a drug that blocks TNF-alpha directly. Put at the nerve root against epidural steroid in subacute lumbar nerve pain, it lost — steroid beat saline by 1.26 points on leg pain, which did not reach significance, and etanercept did worse than steroid on function by a margin that did. One other trial of 49 patients found separation only at the lowest of three doses, 0.5 mg, with the 2.5 mg and 12.5 mg arms not separating, at a loose significance threshold.

[[embed:source:s24]]

[[embed:source:s4]]

So the most potent, most targeted available block of TNF-alpha at a nerve root produced a null in the best-controlled trial and an upside-down dose response in the one positive trial. Two peptides with weaker, broader, unmeasured effects on the same pathway are proposed to succeed where that failed. That is the ceiling on the inflammation argument, and it is low.

[[embed:what-are-peptides-herniated-disc]]

## Two of the three have been tested together once, and the pair beat neither alone

In July 2026 a Turkish orthopaedic group published the only experiment that has ever put BPC-157 and TB-500 in the same animals and compared the pair against each one alone. Biçer and colleagues, Joint Diseases and Related Surgery, PMID 42542926.

Thirty-two rats. Achilles tendon cut across and surgically repaired. Four weeks of daily injection into the belly cavity, in four groups of eight: nothing, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both. Outcomes were breaking strength on a testing machine plus two scored measures of tissue quality read blind under a microscope.

What it found: TB-500 alone raised breaking strength against control (p < 0.05) and improved both tissue scores (p = 0.016 and p = 0.017), with the most ordered collagen fibres of any group. BPC-157 alone was numerically better than control without reaching significance. And the combination, in the authors' words, "did not confer additional benefits compared to either agent alone."

Their own explanation is that the two probably feed into shared machinery further downstream, so pushing from two directions does not push harder.

[[embed:source:s5]]

That is the single most important negative result for anyone building a stack, and it deserves to be read straight rather than explained away.

## Four ways that result could be wrong for a disc

Each of these names an experiment, not a caveat.

**Wrong tissue.** A stitched rat Achilles has some blood supply. A disc has essentially none, and the whole argument for BPC-157 is about growing vessels where there are none. A combination could be redundant in a tissue that already gets blood and not redundant in one that gets none. The experiment: the same four-arm design in a disc breakdown model.

**One dose of each.** Ten µg/kg of one and 60 µg/kg of the other, and nothing else tried. ARA-290's own human trials show why that matters — 4 mg worked and 8 mg did not, in the same trial. A single pair of doses tests one point, not the surface. The experiment: three dose levels of each, nine combination arms.

**A ceiling in the measurement.** TB-500 alone already hit significance on strength and on both tissue scores. If a stitched tendon at four weeks heals about as well as that model permits, there is no headroom for a combination to show anything, and the null means the ruler ran out. The experiment: repeat with a harder injury — a bigger gap, a delayed repair, an older animal — so the control arm heals badly.

**Four weeks.** Both dosing and measurement stopped at four weeks. Collagen keeps reorganising for months, and the ordered-fibre finding is precisely the kind of result that can diverge later. The experiment: the same design read at twelve and twenty-four weeks.

## All three together has never been tested in anything

No study in any species, at any dose, by any route, has given BPC-157, TB-500 and ARA-290 together. There is no animal experiment, no case series, no registry entry. The three-compound version of this stack rests entirely on the argument that the three act on different things and therefore should not get in each other's way.

That argument has one piece of evidence against it already, and the evidence is on this page: the only time two of the three were tested together, adding the second one bought nothing.

[[embed:wolverine-stack]]

## One February 2026 registry entry could move the evidence base, and its companion declares itself fictional

Two entries naming these compounds were filed on ClinicalTrials.gov in February 2026, both by the same sponsor, Hudson Biotech. A registry entry is a filing by the sponsor; nobody at the registry checks it, and neither entry has posted a result.

| Trial | Compound | People | Design | What it measures | Started |
|---|---|---|---|---|---|
| NCT07437547 | BPC-157 | 120 planned | Phase 2, randomised, double-blind, placebo-controlled. Grade II hamstring strain confirmed on MRI. Under the skin, once daily for 14 days | Days to unrestricted return to sport at 8 weeks; change in injury volume on MRI at day 14, read by radiologists blind to the group | 2 February 2026 |
| NCT07487363 | TB-500 | 80 planned | Phase 1/2, randomised, double-blind, placebo-controlled, stepped dose escalation, in adults with stable atherosclerotic heart disease | Side events at 12 weeks, serious events at 28 days, plus how the body absorbs and clears it | 5 February 2026 |

[[embed:source:s20]]

Take the second row first, because it decides how much weight the first can carry. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." It is a template, not a trial. The same sponsor filed eight entries of this shape between 2 and 15 February 2026 — covering BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II, tesamorelin, tirzepatide and retatrutide, one study site each.

The first row is the one that would matter. NCT07437547 has an imaging endpoint read by people who do not know who got what, which would make it the first study capable of saying whether BPC-157 changes the size of a real injury in a real person. Its listed site is Peking University Shenzhen Hospital. It is a hamstring, not a disc, and 14 days, not twelve weeks, so it will not answer the question on this page. It would answer whether the compound does anything measurable in a human body at all, which is the question underneath it — and it answers nothing until it reports.

Three separate orthopaedic and sports medicine reviews published in 2026 — in Sports Medicine, in the American Journal of Sports Medicine, and in the Journal of the American Academy of Orthopaedic Surgeons — audited this same literature independently and landed in the same place: real animal record, absent human record, unregulated products.

[[embed:source:s21]]

[[embed:source:s22]]

## The number any protocol has to beat is the disc's own recovery rate

This is the number most vendor pages leave out and it changes every decision on this page.

A 2024 meta-analysis pooled 31 studies and 2,233 people with a lumbar disc herniation treated without surgery. The overall rate at which the herniation shrank on its own was 70.39%. Broken out by type: 87.77% for a fragment that has broken free, 66.91% for an extrusion, 37.53% for a protrusion, 13.33% for a simple bulge. Counter to intuition, the bigger and more displaced the herniation, the more likely the body removes it.

[[embed:source:s23]]

That is the base rate. Seven in ten resolve with nothing done. Anybody who runs a twelve-week protocol during that window and improves has, on the numbers, a 70% chance of having improved anyway. One person cannot separate those two outcomes, and no amount of conviction about the result changes that.

[[embed:herniated-disc]]

## Seven people with a back problem wrote down what happened

Self-reports are counted here the same way they are counted anywhere on this site: the person had to state an outcome for themselves, commentary and dosing posts with no result attached were excluded, and negative reports are given the same space as positive ones.

Filtering the self-report record to people describing a back, disc or sciatic problem specifically gives seven usable reports.

| Outcome | Count |
|---|---|
| Said it helped | 4 |
| Said nothing changed | 2 |
| Said something got worse | 1 |
| **Total** | **7** |

**Helped — X, @MuroCrypto, 31 July 2026, anecdotal.** "My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc. Flared up hard in March, could barely sit or stand without pain. Went on for 3 months with zero improvement. In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better."
[[embed:source:s6]]

**Helped — Reddit, u/kunukxathletix, r/Sciatica, 7 March 2026, anecdotal.** "I tried ever and eventually decided to try injectable BPC 157 and within a few weeks pain started to ease, well this could be random so I continued use after about 6-7 weeks sciatic pain was almost all the way gone."
[[embed:source:s7]]

**Helped — X, @drmarlonperalta, 4 June 2026, anecdotal.** "I've suffered for 10+ years with lower back pain from a herniated disc... A 6-week cycle removed this distraction permanently."
[[embed:source:s8]]

**Helped, with the writer's own warning attached — X, @AJA_Cortes, 26 May 2024, anecdotal.** "Decided to try to taking oral BPC157 at 2000mcg daily. Also got two deep tissue massages, and a chiro adjustment. 7 days later, pain free. Did the BPC157 help? Maybe, maybe not. Im always open to possibility of placebo."
[[embed:source:s9]]

**Nothing changed — Reddit, u/ImNotSchema, r/backpain, 19 August 2025, anecdotal, ran both compounds.** "I also experimented with TB500 and BPC-157 peptides, but saw no improvement. The one thing that actually helped was Prednisone."
[[embed:source:s10]]

**Nothing changed — Reddit, u/Dizzy-Breakfast-9405, r/backpain, 25 April 2024, anecdotal.** "I even tried peptides (BPC-157) for a month, no results."
[[embed:source:s11]]

**Worse — Reddit, u/Miserable_Fan1984, r/backpain, 16 September 2024, anecdotal, herniated disc, ran both compounds.** "I started taking bpc 157 and tb 500 and 500mcg a day to help with healing but I have started to feel worse and have pain going down my leg again."
[[embed:source:s12]]

Seven is too few to mean anything statistically, and four in seven reporting improvement is what a 70% spontaneous shrink rate would produce with no compound involved at all. What the seven do establish is that the negative and the worse outcomes exist, are specific, and are written by people who wanted the opposite result.

The wider self-report set across all injuries — 40 reports, 21 helped, 15 nothing, 4 worse — is counted in full on the two-compound page.

[[embed:wolverine-stack]]

## What people report on ARA-290, which is a much thinner record

Four ARA-290 self-reports were found, and only one of them states an outcome.

[[embed:source:s13]]

The other three: one person two doses into a run for small fibre nerve damage with six to eight weeks left and no result yet, one post quoting the Phase 2b trial numbers rather than personal experience, and one skeptic asking the sharpest question in the whole set — whether repair signalling does anything while the nerve is still being squeezed.

[[embed:source:s14]]

That question has no published answer. Nobody has tested repair signalling against an ongoing mechanical squeeze.

Not one report was found, on any platform, of a person running all three compounds together. The three-compound stack has no human record at all — not a trial, not a case, not a forum post.

## Reconstituting three vials, one arithmetic at a time

All three ship as dry powder in a sealed glass vial. All three are mixed with bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is what makes it safe to put a needle into the same vial more than once. All three are measured on a U-100 insulin syringe, where 100 marks equal 1 mL, so one mark is 0.01 mL.

Two lines of arithmetic cover all three:

- Concentration in mcg per mL = total mcg in the vial ÷ mL of water added.
- Mcg per mark = concentration ÷ 100.

**BPC-157, 10 mg vial, 2 mL of water.** 10 mg = 10,000 mcg. 10,000 ÷ 2 = 5,000 mcg/mL. 5,000 ÷ 100 = 50 mcg per mark. A 500 mcg dose = 500 ÷ 50 = 10 marks = 0.10 mL.

**TB-500, 10 mg vial, 2 mL of water.** Identical arithmetic: 50 mcg per mark. 500 mcg = 10 marks. 2.5 mg = 2,500 ÷ 50 = 50 marks = 0.50 mL.

**ARA-290, 10 mg vial, 1.25 mL of water.** 10,000 ÷ 1.25 = 8,000 mcg/mL. 8,000 ÷ 100 = 80 mcg per mark. The 4 mg trial dose = 4,000 ÷ 80 = 50 marks = 0.50 mL, which is exactly the volume injected in the diabetes trial. Add 2 mL instead and you get 5,000 mcg/mL, 50 mcg per mark, and 4 mg becomes 80 marks.

| Compound | Vial | Water | Concentration | Mcg per mark | 250 mcg | 500 mcg | 1 mg | 4 mg |
|---|---|---|---|---|---|---|---|---|
| BPC-157 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| BPC-157 | 20 mg | 4.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| TB-500 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |
| ARA-290 | 10 mg | 1.25 mL | 8,000 mcg/mL | 80 | 3.1 marks | 6.25 marks | 12.5 marks | 50 marks |
| ARA-290 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks |

Below about five marks the graduations on a U-100 barrel are too close together to read, which is why the dilute ARA-290 fill is the right one if the dose is under a milligram.

Handling notes that apply to all three. Bring the vial to room temperature first. Run the water slowly down the inside wall rather than squirting it onto the powder. Swirl until clear, never shake — shaking tears peptide molecules apart at the air-water boundary and makes them clump, and clumping is the specific mechanism FDA named when it flagged the risk that the immune system reacts to these products. Once mixed, a vial keeps about four weeks in a fridge at 2–8 °C, which is the preservative's specification rather than a stability measurement on these peptides. Never freeze a mixed vial.

## A full day of all three, in marks and millilitres

| Pattern | BPC-157 | TB-500 | ARA-290 | Total marks | Total volume | Injections |
|---|---|---|---|---|---|---|
| Reachable doses | 500 mcg = 10 marks | 500 mcg = 10 marks | 1 mg = 20 marks | 40 | 0.40 mL | 3 |
| ARA at the dose that was actually trialled | 500 mcg = 10 marks | 500 mcg = 10 marks | 4 mg = 80 marks | 100 | 1.00 mL | 3 |
| BPC daily, TB twice weekly, ARA at the trial dose | 500 mcg = 10 marks | 2.5 mg = 50 marks, twice weekly | 4 mg = 80 marks | 90 most days, 140 twice a week | 0.90–1.40 mL | 2, or 3 twice weekly |

All figures assume 5,000 mcg/mL for BPC-157 and TB-500 and 5,000 mcg/mL for ARA-290. Do not mix any two of them in one syringe — different concentrations, different volumes, different schedules, and combining them makes every later adjustment a guess.

Note the second row. Running ARA-290 at the only dose ever shown to work in a person means the third injection is four times the volume of the other two put together.

## Twelve weeks of all three, priced to the dollar

Prices are from named research-chemical vendors, read on 4 August 2026. Nationwide Peptides publishes a range across vial sizes rather than a price per size, so the endpoints are what can be quoted exactly.

- BPC-157: $42.00 smallest listed size (5 mg), $63.00 largest (20 mg).
- TB-500: $38.00 smallest listed size (5 mg), $61.00 largest (10 mg).
- ARA-290: $43.00 at Nationwide Peptides; Luxe Peptides lists 10 mg at $50.00 and 16 mg at $70.00. The arithmetic below uses $50 per 10 mg.

[[embed:source:s15]]

[[embed:source:s16]]

Twelve weeks is 84 days. Every line shown:

**BPC-157 at 500 mcg a day.** 84 × 500 mcg = 42,000 mcg = 42 mg. Buying 20 mg vials: 3 vials (60 mg) × $63 = **$189**. Per day: $189 ÷ 84 = **$2.25**. A 20 mg vial at 500 mcg a day is 40 doses, but a mixed vial only keeps about 28 days, so 12 doses per vial get thrown away — that waste is already in the price.

**TB-500 at 500 mcg a day.** 42 mg. 5 × 10 mg vials × $61 = **$305**. Per day: **$3.63**. Each vial is 20 doses, which fits the four-week window with nothing wasted.

**ARA-290 at 1 mg a day.** 84 mg. 9 × 10 mg vials × $50 = **$450**. Per day: **$5.36**. Each vial is 10 doses, well inside the window.

**ARA-290 at the 4 mg trial dose.** 84 × 4 mg = 336 mg. 34 × 10 mg vials × $50 = **$1,700**. Per day: **$20.24**. Each vial lasts two and a half days.

**Consumables.** Bacteriostatic water, insulin syringes, alcohol swabs: about $40 for a three-compound twelve-week run at retail.

| What is run | Twelve-week materials | Per day |
|---|---|---|
| BPC-157 alone, 500 mcg/day | $189 + $40 = **$229** | $2.73 |
| TB-500 alone, 500 mcg/day | $305 + $40 = **$345** | $4.11 |
| ARA-290 alone, 1 mg/day | $450 + $40 = **$490** | $5.83 |
| ARA-290 alone, at the 4 mg trial dose | $1,700 + $40 = **$1,740** | $20.71 |
| All three, reachable doses | $189 + $305 + $450 + $40 = **$984** | $11.71 |
| All three, ARA-290 at the trial dose | $189 + $305 + $1,700 + $40 = **$2,234** | $26.60 |

The last two rows contain the honest problem with this stack. The compound holding the only randomised human evidence costs more than the other two combined at the dose that was tested, and costs about the same as them at a dose nobody has tested. Most people who buy all three resolve that by running ARA-290 at a quarter to a sixteenth of the trial dose, which means running the strongest-evidenced compound at a strength for which there is no evidence at all.

None of these prices buys a verified product. There is no pharmacy channel for any of the three. A batch-specific purity test and a mass-spectrometry identity report from an independent lab is the only thing standing between a buyer and a vial of something else, and an eleven-amino-acid peptide with a ring-closed front end, which is what ARA-290 is, is not an easy molecule to synthesise correctly.

## Twelve weeks with a worn L5-S1 and a leg that burns

One case, walked all the way through, with money, hours, measurements, decision points and failure conditions written down before anything starts.

**Week 0 — what exists, and what gets measured.** L5-S1 disc dried out and lost height on MRI, a small protrusion touching the S1 nerve root, burning down the back of the left calf into the outer foot. Leg pain 7/10, back pain 4/10. No weakness, no bowel or bladder change, no numbness in the saddle area — those three would be an emergency and would end this plan immediately. MRI already done: $400–$1,800 cash, $250–$400 typical Medicare allowable, 1 hour.

Five baseline measures written down, because a result nobody measured is a result nobody has:
1. Leg pain, 0–10, worst in the last 24 hours.
2. Oswestry Disability Index, a standard back questionnaire, scored out of 100.
3. Straight-leg-raise angle at which the leg pain starts, measured against a wall.
4. Nights woken by pain, per week.
5. Distance walked before the leg forces a stop.

**Weeks 1–12 — the part with human trials behind it.** Load management and progressive exercise, twice weekly for six weeks then weekly. 18 visits at $75–$150 = **$1,350–$2,700**, about 18 clinic hours plus 20 hours of home work. This is the only line on the page supported by randomised human trials in this exact condition, and it also happens to be the biggest line in money and hours. Everything else is added on top of it, never instead.

**Weeks 1–12 — the compounds, if they are run.** BPC-157 500 mcg a day, TB-500 500 mcg a day, ARA-290 1 mg a day, all under the skin of the abdomen, three separate injections. Materials **$984**. Time: about 6 minutes a day for three injections, so 8.4 hours over twelve weeks, plus roughly 35 minutes reconstituting seventeen vials.

**Week 4 — first decision point.** Stopping rule set in advance: if nights woken has not fallen and the straight-leg-raise angle has not gained at least 10 degrees, ARA-290 stops. The reason it is ARA-290 that gets tested first is that it is the most expensive line and the one with the most specific promise — it either does something to nerve symptoms or it does not, and nerve symptoms are the fastest-moving measure on the list. Money saved by stopping there: **$300**.

**Week 6 — second decision point.** If leg pain has not moved at all, the whole compound protocol stops and the money goes to the exercise programme, which continues either way. Money saved: about **$450**.

**Week 8 — the escalation gate.** If leg pain is still 6/10 or above and disability is still above 40, this is where an epidural steroid injection sits in standard practice: $800–$5,000 cash, $161 Medicare allowable, 3 hours including travel and recovery. The pooled evidence gives it about 6 points on a 0–100 leg pain scale short term, which is below the 10-to-30-point range most people would call a meaningful change.

**Week 12 — the state at the end.** Running total: $1,350–$2,700 physical therapy, $984 materials, $400–$1,800 MRI, $0–$5,000 if an injection was used. Total **$2,734 to $10,484**. Patient time: roughly 47 hours. Base-rate expectation, from the 2,233-patient pooled data, is substantial improvement in leg pain for most people over twelve weeks with no compounds at all.

**What would count as failure, written before the start.**
- No movement on nights woken or straight-leg-raise angle at week 4.
- No movement on leg pain at week 6.
- Any new problem: swelling, worse pain in an untreated area, any change in vision.
- New weakness, new numbness in the saddle area, or any bowel or bladder change at any point — stop everything and get seen the same day.
- Relief that arrives inside a week and disappears within two weeks of stopping. That pattern points at irritation settling rather than tissue rebuilt, and it means the compounds bought a symptom holiday, not a repair.

**The week 12 decision.** Disabling leg pain past twelve weeks, with imaging that matches the symptoms, is where surgery stops being premature. Microdiscectomy runs $15,000–$50,000 list, measured at $14,137 above non-surgical care over two years in trial data, and it buys faster relief rather than a better one-year outcome — the recovery rate at a year is the same either way.

## Where United States law puts all three, which is not the same place

None of the three is an approved medicine in the United States. None is banned outright. But their positions differ, and the difference is worth knowing before buying.

**BPC-157 and TB-500** both appear on FDA's public list of bulk drug substances "nominated but withdrawn" — put forward for use in compounded medicines, placed in the agency's category 2 for possible significant safety risks, then pulled by whoever nominated them. FDA's stated concerns are, in its own words, that products containing BPC-157 "may pose risk for immunogenicity for certain routes of administration", and that for the thymosin beta-4 fragment "FDA has not identified any human exposure data" and "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans."

**ARA-290 appears nowhere on those lists.** It was never nominated for compounding at all. That is not a cleaner status — it is a thinner one. It means no regulator has published a safety assessment of it as a compounding ingredient, favourable or otherwise. It did receive orphan drug designation in both the United States and Europe, and then its developer stopped, so there is no late-stage programme and no pharmaceutical supply of it anywhere.

What follows in plain terms:

- No pharmacy can lawfully compound any of the three. None is on the 503A list traditional compounding pharmacies work from, nor the 503B list outsourcing facilities work from.
- On 23–24 July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6, one abstention, in favour of allowing BPC-157 and TB-500 to be compounded, against FDA's own written recommendation. That vote is advice. It binds nothing, approves nothing, and the rulemaking it starts realistically runs eight to twelve months.
- "Research use only" printed on a vial is a shipping label. It is not a legal category and it makes nothing safe or lawful to inject.

[[embed:source:s17]]

[[embed:source:s18]]

## One of the three ends a tested athlete's season

Anyone competing under anti-doping rules — collegiate, professional, masters, a national federation, an Olympic pathway — and anyone serving in the United States military needs this before anything else on the page.

- **TB-500 is named on the WADA 2026 Prohibited List**, under S2.3, growth factors: "Thymosin-ß4 and its derivatives e.g. TB-500." Prohibited at all times, in and out of competition, in the harsher non-specified tier. The catch-all in that same clause covers substances affecting "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity" — the exact reason to take it is written into the ban.
- **BPC-157 is named** under S0, non-approved substances, also prohibited at all times.
- **ARA-290 is not named**, but S0 covers any substance with no current approval by any government health authority for human use, and ARA-290 has none. Treat it as covered.
- Strict liability applies. Intent does not matter and neither does who recommended it. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for BPC-157 and TB-500.
- A sanction does not require a positive test. An admission, a possession finding, or a purchase record is enough.
- The Department of Defense lists BPC-157 on its prohibited supplement ingredients list and states that it is not a dietary ingredient, it is an unapproved drug.

[[embed:source:s19]]

There is no off-season window. Off-season use is a violation.

## What would prove each link wrong

The value of a stack argued as separate links is that each link can be broken separately. Here is what would break each one, with the current state of the evidence beside it.

| Link | Current state | The result that would break it |
|---|---|---|
| Blood supply reaching the disc, BPC-157 | Grade D. Repeated positive results in tendon, ligament, muscle, nerve and spinal cord in rats, mostly from one research group. Nothing in a disc, ever | A controlled animal study in a disc, counting vessels and measuring disc height, showing no difference against control |
| Repair cells crawling in, TB-500 | Grade D. One controlled rat tendon study with 8 per arm. The ligament and skin results used the full 43-amino-acid protein, not the 7-amino-acid fragment that is sold | The rat tendon study repeated at a larger size with no strength difference; or a direct comparison of the fragment against the full protein showing the fragment does nothing |
| Nerve fibres regrowing, ARA-290 | Grade B. Randomised human trials with a measured structural endpoint, in a different disease, never in a compressed root | A randomised trial in a compressed nerve root showing no separation from placebo |
| Chemical irritation calmed, BPC-157 and TB-500 | Grade E, and already damaged. Direct TNF-alpha blockade at the nerve root produced a null against steroid in the best-controlled trial | Nothing further needed — the burden here sits with anyone claiming the peptides beat what etanercept could not |
| The three acting on different things | Grade F. Never tested. The only test of two of them together found the pair beat neither alone | A three-arm animal study — each compound alone, all three together — showing the three-way combination matches the best single agent |
| Anything beating the disc's own recovery | Grade F. 70.39% of herniations shrink on their own | Any protocol that has not been measured against a control group in this condition cannot claim to beat 70% |

Five links. One at grade B, two at D, one at E, two at F. Not one at grade A, because no randomised trial of any of these compounds has ever enrolled a person with a disc problem.

That is the honest state of it. The mechanism argument is coherent, the three compounds genuinely act on different things, and the amount of measurement behind that coherence ranges from real human trials on one link to literally nothing on another.

[[embed:bpc-157]]

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:wolverine-stack]]


## Sources

1. Culver DA et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Phase 2b, NCT02039687. PMID 28475703 — https://pubmed.ncbi.nlm.nih.gov/28475703/
2. Brines M et al. ARA 290 in type 2 diabetes with painful neuropathy — randomised double-blind placebo-controlled trial, NTR3858, full text with pharmacokinetics and adverse events — https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
3. ClinicalTrials.gov NCT02039687 — Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis. Completed — https://clinicaltrials.gov/study/NCT02039687
4. Cohen SP et al. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. Ann Intern Med 2012. PMID 22508732 — https://pubmed.ncbi.nlm.nih.gov/22508732/
5. Biçer O, Adanir O, Güleryüz Y, Balci EC. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 23 July 2026. PMID 42542926 — https://pubmed.ncbi.nlm.nih.gov/42542926/
6. X — @MuroCrypto, 31 July 2026 — anecdotal, positive, herniated lumbar disc, ran both compounds — https://x.com/MuroCrypto/status/2083184469956059529
7. Reddit r/Sciatica — u/kunukxathletix, 7 March 2026 — anecdotal, positive, sciatic pain — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
8. X — @drmarlonperalta, 4 June 2026 — anecdotal, positive, ten years of low back pain from a herniated disc — https://x.com/drmarlonperalta/status/2062565899714925044
9. X — @AJA_Cortes, 26 May 2024 — anecdotal, positive, L5-S1 flare, writer flags placebo himself — https://x.com/AJA_Cortes/status/1794522474702336108
10. Reddit r/backpain — u/ImNotSchema, 19 August 2025 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
11. Reddit r/backpain — u/Dizzy-Breakfast-9405, 25 April 2024 — anecdotal, no effect after a month — https://www.reddit.com/r/backpain/comments/1ccysh4/chronic_onesided_thoracic_pain/
12. Reddit r/backpain — u/Miserable_Fan1984, 16 September 2024 — anecdotal, got worse, herniated disc, ran both compounds — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
13. X — @NewsDeskOne, 17 July 2026 — anecdotal, positive, ARA-290 for nerve symptoms in the feet — https://x.com/NewsDeskOne/status/2077929820760019113
14. X — @vedichi_, 16 July 2026 — anecdotal, skeptical, names the read-across problem directly — https://x.com/vedichi_/status/2077787145238913472
15. Nationwide Peptides — ARA-290 (cibinetide), BPC-157 and TB-500 research-chemical listings, prices read 4 August 2026 — https://www.nationwidepeptides.com/products/ara-290-cibinetide-peptide/
16. Luxe Peptides — ARA-290 peptide listing, prices read 4 August 2026 — https://luxepeptides.is/ara-290/
17. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, current as of 22 April 2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
18. FDA — 23-24 July 2026 meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
19. World Anti-Doping Code International Standard — Prohibited List 2026, effective 1 January 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
20. NCT07437547 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Hudson Biotech. Recruiting, started 2 February 2026 — https://clinicaltrials.gov/study/NCT07437547
21. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 12 April 2026. PMID 41966639 — https://pubmed.ncbi.nlm.nih.gov/41966639/
22. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev, 1 January 2026. PMID 41490200 — https://pubmed.ncbi.nlm.nih.gov/41490200/
23. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis. Clin Spine Surg, 2024. PMID 37559207 — https://pubmed.ncbi.nlm.nih.gov/37559207/
24. Randomized, double-blind, placebo-controlled trial of transforaminal epidural etanercept for symptomatic lumbar disc herniation. PMID 24165696 — https://pubmed.ncbi.nlm.nih.gov/24165696/


---

# Degenerative Disc Disease

slug: degenerative-disc-disease · https://miscsubjects.com/a/degenerative-disc-disease · tags: condition, degenerative-disc-disease, spine, disc · updated 2026-08-04T20:50:29.410Z

Your radiology report says degenerative disc disease. Here is the number that should have been printed next to it, and almost never is.

Researchers pooled 33 imaging studies covering 3,110 people who had **no back pain at all**. Radiologists read their scans without knowing they were pain-free. Disc degeneration was present in 37% of the 20-year-olds, 68% of the 50-year-olds, and 96% of the 80-year-olds. Disc bulges: 30% at age 20, rising to 84% at age 80. A tear in the outer ring of the disc: 19% at 20, 29% at 80.

[[embed:source:s19]]

Find your own age in that list. Whatever fraction of pain-free people your age carry the same finding, that is the fraction of people walking around today with your scan and no symptoms. At 50, roughly two out of three pain-free people have disc degeneration on imaging. The finding did not put them in pain and it is not, by itself, what put you in pain.

This page is built around one question, because it is the only question that matters when you are holding a report like that: **what is breaking down, and what moves the balance the other way.** Everything below is arranged as that chain — what degrades, what speeds the degrading, what rebuilds, what speeds the rebuilding — with the strength of the evidence stated at every single link.

## The name is wrong and the wrongness is doing damage

"Degenerative disc disease" is not a disease. It is a description of what a disc looks like when it has aged. It has no diagnostic threshold, no defined progression, and no expected endpoint of disability. Radiologists apply the phrase to a scan; it travels to you as a verdict.

The phrase does real harm on arrival. A 19-year-old on r/backpain asked whether she would "just be miserable for the rest of my life" after two bulging discs and this label.

[[embed:source:s15]]

Nothing in the imaging data supports that reading. Discs dry out with age the way skin loses elasticity with age. Some of those discs hurt. Most do not.

## What each phrase on your report actually describes

Report language is precise and unhelpful. Here is the translation, once, so you can match this page to the paper in your hand.

- **The disc has dried out** (the word on a report is *desiccation*, which means exactly that — the drying out of the disc, which shows up dark instead of bright on the scan). The centre of the disc has lost water.
- **Disc height loss.** The dried disc is flatter, so the two bones it separates sit closer together.
- **Disc bulge.** The disc's edge extends past the rim of the bone all the way around, symmetrically. Present in 30% of pain-free 20-year-olds.
- **Protrusion / extrusion / herniation.** Material has pushed out through the outer ring at one spot. That is a different problem with a different natural history, covered separately.
- **A tear in the outer ring** (*annular fissure*). A crack in the tough fibrous wall.
- **Facet arthropathy.** Wear in the two small joints at the back of the same spinal level, which take more load once the disc flattens.
- **Modic changes.** Swelling or fatty change in the bone immediately above and below the disc. Type 1 is the swollen, active kind and it matters more than the rest — see below.
- **A pinched nerve root** (*radiculopathy*). A nerve leaving the spine is being compressed or chemically irritated, which sends pain down a leg or arm.

## The disc has almost no blood supply, and that single fact governs everything after it

The disc between two vertebrae is the largest structure in your body with no blood vessels running through it. Nutrients arrive by seeping slowly through the bony plates above and below.

[[embed:source:s2]]

Researchers injected a tracer into volunteers and tracked how long it took to reach the middle of a disc: about five minutes to reach the vertebral body, two hours to reach the bony plate, and **six hours to reach the centre of the disc**. In discs that had already degenerated, that delivery was measurably worse.

[[embed:source:s26]]

Every tissue that heals well heals because blood arrives fast, bringing oxygen, building blocks and repair cells. Your disc gets a six-hour trickle. That is why:

- degeneration tends to move one direction over decades,
- an oral supplement has a poor route in,
- anything that further narrows those tiny vessels — nicotine is the clearest example — hits this tissue harder than any other,
- and every serious attempt at rebuilding a disc has to solve the delivery problem before it solves anything else.

## The breakdown starts as water loss and ends as a mechanical cascade

The soft centre of the disc (*nucleus pulposus*) is mostly water, held there by a large molecule called aggrecan. Water under pressure is what makes a disc a working shock absorber. Aggrecan gets cut up and lost with age, water content falls from roughly 90% in infancy toward 70% by age 60, and the cushion stops pressurising properly.

[[embed:source:s1]]

Then the cascade runs, in this order:

1. **Water out, height down.** A flatter disc no longer spreads load evenly.
2. **Load transfers outward.** Pressure that the watery centre used to carry is dumped onto the tough outer ring (*annulus fibrosus*) and onto the two small joints at the back.
3. **The outer ring cracks.** Tears form. That is how slow degeneration becomes a sudden herniation in some people.
4. **The disc's own cells start producing inflammatory signals** — chiefly TNF-alpha and IL-1beta.
5. **Those signals raise the enzymes that cut up the scaffold between cells** (the *extracellular matrix*; the enzymes are the MMPs) **while lowering the proteins that hold those enzymes back** (the TIMPs). The disc now dismantles itself faster than it rebuilds.

[[embed:source:s6]]

6. **Nerve fibres and small blood vessels grow into a disc that should have neither.** A healthy disc's interior has no nerve supply. A degenerated one recruits some. That is one route by which a structural change becomes a felt pain.

[[embed:source:s4]]

This is not a story assembled backwards from correlations. Inject TNF-alpha into a healthy rat disc and you produce both pain behaviour and degeneration; block TNF-alpha at the moment of injury and you prevent both, out to long-term follow-up.

[[embed:source:s5]]

So the mechanism has a direction and a lever. Breakdown outrunning rebuilding is the whole condition. Every intervention on this page is judged by one test: does it slow the breaking down, or speed the building back?

## Wear is not pain — here is exactly what separates the two

You already know most pain-free people your age have these findings. The next question is which findings actually track with pain. A meta-analysis compared 1,193 pain-free adults against 1,904 adults with back pain, all aged 50 or under, and gave the odds for each imaging feature.

[[embed:source:s20]]

**Findings that were more common in people with pain:**

| Finding | Odds it appears in a person with pain vs without |
|---|---|
| Disc bulge | 7.5× |
| Spondylolysis (a stress crack in the bone arch) | 5.1× |
| Disc extrusion | 4.4× |
| Modic type 1 change (active bone swelling next to the disc) | 4.0× |
| Disc protrusion | 2.7× |
| Disc degeneration itself | 2.2× |

**Findings that showed no significant association with pain:**

| Finding | Result |
|---|---|
| Modic changes of any type lumped together | no significant difference |
| Tear in the outer ring | no significant difference |
| High-intensity zone | no significant difference |
| Spondylolisthesis (one bone slipped forward on another) | no significant difference |
| Central canal narrowing | no significant difference |

Two things fall out of that table. First, "disc degeneration" carries the *weakest* pain association of everything in the significant column — 2.2×, in a finding that 96% of pain-free 80-year-olds have. Second, the bone next to the disc matters more than the literature used to admit: when studies restrict themselves to one clearly defined patient group instead of lumping everyone together, active type 1 bone swelling tracks with chronic back pain and disability, and burning the small nerve that supplies that bone reduces both.

[[embed:source:s27]]

An older landmark study makes the same point in blunter terms. In 98 people with no back pain, 52% had a disc bulge, 27% had a protrusion, and only 36% had entirely normal discs at every level. The authors' conclusion was that finding a bulge or protrusion on the scan of someone with back pain "may frequently be coincidental."

[[embed:source:s21]]

The practical consequence: your scan cannot tell you why you hurt. It can rule out the dangerous things and it can raise or lower a probability. Pain that changes with position, load and time of day, in a pattern that matches one level, is doing more diagnostic work than the report is.

## Six inputs measurably speed the breaking down

Age and genetics are fixed. These are not.

**1. Bending and lifting, not body weight arithmetic.** Pressure sensors placed inside living human discs found that standing loads a disc at roughly 0.5 MPa, and lifting around 20 kg with a rounded back drives it past 2.3 MPa — more than four times standing pressure. Sitting slumped exceeds sitting upright.

[[embed:source:s8]]

The widely repeated line that one pound of body weight equals four pounds on the spine is not a measured law and no study establishes that multiplier. The measured spikes come from the lever arm of your own torso when you bend forward, which is why lifting technique moves a bigger number than the scale does on any single day.

[[embed:source:s9]]

**2. Body weight, on a causal-grade design.** Mendelian randomisation uses inherited genetic variants as a natural experiment, which isolates cause from correlation better than any observational study can. It found higher BMI causally raises the odds of disc degeneration, back pain, and sciatica — roughly a third higher odds of sciatica per one standard-deviation rise in BMI.

[[embed:source:s7]]

**3. Smoking, which attacks the exact weakness this tissue has.** Nicotine narrows the small vessels feeding a disc that already receives the slowest nutrient delivery in the body, and is directly toxic to the disc's own cells, reducing their rebuilding activity.

[[embed:source:s17]]

**4. Poor sleep, prospectively measured.** In 761 people with chronic back pain followed for six months, those reporting sleep problems at the start had 1.5× the odds of not recovering and 2.7× the odds of higher pain. Those who *developed* sleep problems during follow-up: 2.2× and 3.0×. Those whose sleep problems resolved had roughly **half** the odds of non-recovery (0.50) and half the odds of high pain (0.49). Sleep is not downstream of the pain here — it moved with the outcome in both directions.

[[embed:source:s24]]

**5. Not moving.** Bed rest and immobility get their own section below, because the evidence on the other side is the strongest thing on this page.

**6. Long-term blanket anti-inflammatory use, with a specific and limited case against it.** Anti-inflammatory painkillers block COX-2, and COX-2 is part of the repair phase, not only the pain phase. In animal tendon and bone models the healing is measurably weaker; in humans the outcome data is genuinely unsettled and the honest verdict is argued out in full on a separate page. What is not unsettled is the stomach, kidney and heart cost of taking them for months.

[[embed:bpc-157-vs-nsaids]]

## What the disc can rebuild by itself, and what it cannot

Be exact here, because this is where most writing on the subject either despairs or lies.

**What can improve without any intervention:** pain, function, inflammation, muscle support, load tolerance, sleep, and the nerve sensitisation that amplifies all of it. These are the things people actually feel, and every one of them is movable.

**What does not spontaneously regrow:** the water content and height of a disc that has already lost them. No exercise programme, injection or compound has been shown to restore disc height and hydration in a human being.

The gap between those two lists is the single most useful thing to understand about this diagnosis. **Your target is the pain and the function, and those are separable from the structure.** People whose discs never change get better all the time.

## Movement is the only lever with a clinically important effect size

Cochrane pooled **249 randomised trials** of exercise for chronic low back pain. Against no treatment, usual care, or placebo, exercise reduced pain by 15.2 points on a 0–100 scale (95% CI −18.3 to −12.2), moderate-certainty evidence, and the authors' pre-set threshold for a clinically important difference was 15 points. It clears the bar. Function improved by 6.8 points, which does not clear the function bar. Against other conservative treatments, exercise beat education alone by 12.2 points and beat non-exercise physiotherapy by 10.4, and tied with manual therapy.

[[embed:source:s22]]

Nothing else on this page produces a 15-point pain reduction with 249 trials behind it. Note also what the same review found about which exercise: no single type won. The comparison that mattered was exercising versus not.

For preventing the *next* episode, there is now a trial of the cheapest possible intervention. WalkBack randomised 701 adults who had just recovered from an episode of back pain to either a progressive individualised walking programme with six physiotherapist sessions, or nothing. Median time to the next activity-limiting episode: **208 days in the walking group versus 112 days in the control group**, hazard ratio 0.72 (95% CI 0.60–0.85, p=0.0002). Cost per quality-adjusted life-year gained: AU$7,802.

[[embed:source:s23]]

Walking nearly doubled the time to the next flare. That is a real number from a real randomised trial, and it is available to you without equipment, a prescription, or a payment.

## Sleep, nicotine and weight each move a measured number

**Stopping smoking.** In 5,333 patients tracked through spinal care, current smokers reported worse pain on every scale than people who had never smoked. Patients who quit during their course of care improved significantly more than those who kept smoking on worst pain, current pain, and average weekly pain. The group that continued smoking showed **no clinically important improvement in reported pain at all** across the whole episode of care.

[[embed:source:s25]]

That is the strongest single-behaviour signal in this entire article. Not a risk-factor association — a measured difference in how much better people got.

**Fixing sleep.** The 0.50 and 0.49 odds ratios above are the resolving-sleep-problems group. Halved odds of non-recovery is not a wellness aside.

**Losing weight.** Here the honest answer is weaker than you would expect from the causal genetic evidence. A systematic review of 11 weight-loss studies in people with back pain (689 participants, only one randomised trial, seven of them bariatric surgery) found very low-quality evidence of improvement, and low-quality evidence that a lifestyle intervention was no better than a waiting list.

[[embed:source:s28]]

So: the genetics say excess weight causes the problem, and the intervention trials have not yet shown that losing it fixes the problem. Both statements are true at once. Weight loss is worth doing on the causal evidence; do not expect the pain to track the scale week by week.

## Injections and biologics: what has been tried, and what came back

**Platelet-rich plasma.** A double-blind randomised trial against corticosteroid for disc-origin back pain found no significant difference between the groups.

[[embed:source:s11n]]

**Stem cells, the optimistic read.** Pooled human data across studies of mesenchymal stem cell injection into the disc report reduced disc-origin pain and disability.

[[embed:source:s12]]

**Stem cells, the controlled read.** The DREAM study was double-blind and sham-controlled — the design that removes the effect of having a needle put in your back by someone who believes it will work. Bone-marrow stem cells showed no significant advantage over sham at six months.

[[embed:source:s18]]

**Animal work.** Stem cells and growth factors restore disc height and water content in animals fairly reliably. The translation to humans is where it stops.

[[embed:source:s10]]

The count that matters: **zero injections have restored disc height or water content in a human being in a controlled trial.** That is one row, and it is an honest row. It is not the whole picture, because the whole picture includes the 15.2-point exercise effect and the halved non-recovery odds from sleep, both of which are larger and better evidenced than anything in a syringe.

## Where the peptides sit in this chain, stated exactly

The disc's core failure is a tissue with almost no blood supply that cannot deliver repair cells to itself. Three compounds are studied against exactly that failure, and each has a precise evidence position.

**BPC-157** drives new blood vessel growth and connective-tissue repair in animals — torn rat Achilles tendons regain mechanical strength, severed nerves regrow faster. It has never been tested against a disc in any species, and there is no completed randomised human trial in any injury.

[[embed:bpc-157]]

**TB-500** (the synthetic fragment of thymosin beta-4) has animal data for cell migration and new vessel growth in poorly supplied tissue, and the same total absence of disc data.

[[embed:tb-500]]

**ARA-290** is the one with human trials, and they are for nerve pain rather than disc structure: it targets the inflammatory receptor pathway that TNF-alpha runs through, and randomised human trials in small-fibre nerve damage reported improvements in nerve fibre density and pain scores.

[[embed:ara-290]]

The reasoning chain is coherent and it is still a chain of inference, not a result: the disc fails at blood supply, these compounds act on blood supply in other tissues, therefore they might act on the disc. Nobody has run that last step. Anyone who tells you otherwise is selling something. The mechanism-by-mechanism version, including where the inference breaks, is here:

[[embed:what-are-peptides-herniated-disc]]

## Ten people with this diagnosis, counted

Published trials tell you what happens on average. They do not tell you what people with this label say is happening to them. So here is every first-person account gathered for this page, counted, with the negatives given the same room as the positives.

**Denominator: 10 accounts** — 7 from X, 3 from Reddit threads already filed on this page. **Outcome: 1 resolved, 7 still in pain at the time of posting, 2 outcome not stated.**

**Resolved — 1 of 10.** He was told the L5-S1 finding meant a lifelong struggle and probable surgery. He dropped the nerve medication after ten days, took four sessions with a sports physiotherapist, added strength work he had never done before, and was back playing competitive squash inside a month.

[[embed:source:s29]]

**Still in pain at the time of posting — 7 of 10.**

Three years from diagnosis, and the day-to-day version of it:

[[embed:source:s30]]

Eleven years of prescribed medication for this diagnosis, and where that went. This is the most important negative account on the page:

[[embed:source:s31]]

Diagnosed at half her mother's age, years into pain medication already:

[[embed:source:s32]]

What a flare actually feels like, without the clinical vocabulary:

[[embed:source:s33]]

In pain since February, and building the exact intervention with 249 trials behind it, on his own:

[[embed:source:s34]]

And the account where the door is closed on treatment entirely:

[[embed:source:s35]]

From Reddit, diagnosed at 26:

[[embed:source:s14]]

**Outcome not stated — 2 of 10.** The 19-year-old asking whether she will be miserable for life (quoted at the top), and a Reddit account of a lumbar epidural steroid injection at L4-L5.

[[embed:source:s16]]

**Now read that count against the trial data, because they disagree, and the disagreement is informative.** Seven out of ten posting people are in pain. Ninety-six per cent of pain-free 80-year-olds have this finding. Both are true, because people who feel fine do not post about their discs and people whose pain resolved stop searching the term. Anecdote counts tell you what the loud end of the distribution looks like; they do not tell you the base rate. This one has a heavy selection bias toward suffering and should be read as such. What it does establish, honestly: at least one person told he faced a lifelong struggle and probable surgery was back playing competitive squash in a month, and the thing that got him there was loaded exercise.

## Every link in the chain, with the strength of the evidence for it

| Link in the chain | What the evidence is | Strength |
|---|---|---|
| Disc changes are near-universal with age and often painless | 33 studies, 3,110 pain-free people, age-banded | Strong |
| Disc degeneration alone is weakly associated with pain (2.2×) | Meta-analysis, 3,097 adults ≤50 | Strong |
| Active type 1 bone swelling next to the disc tracks with pain | Meta-analysis 4.0×; nerve-ablation trials in defined groups | Moderate |
| The disc is nourished by slow seepage, six hours to the centre | Tracer imaging in living volunteers, 150 discs | Strong |
| Water and aggrecan loss drive the mechanical cascade | Consistent across tissue and imaging studies | Strong |
| TNF-alpha causes both the pain and the degeneration | Controlled animal model, cause tested both directions | Strong in animals, inferred in humans |
| Exercise reduces chronic back pain by a clinically important margin | 249 randomised trials, −15.2 points | Strong |
| Walking delays the next episode | 1 randomised trial, 701 people, 208 vs 112 days | Moderate |
| Quitting smoking improves reported pain | 5,333 patients, prospective, matched comparison | Moderate |
| Fixing sleep halves the odds of non-recovery | 761 patients, prospective, 6 months | Moderate |
| Higher body weight causally worsens degeneration and sciatica | Mendelian randomisation | Strong for cause |
| Losing weight relieves back pain | 11 studies, 1 randomised, 689 people | Very weak |
| Platelet-rich plasma beats corticosteroid | Double-blind randomised trial | Negative result |
| Stem cells restore the disc in humans | Sham-controlled Phase 2b | Negative at 6 months |
| Stem cells restore disc height in animals | Multiple animal models | Strong in animals |
| BPC-157 or TB-500 helps a human disc | No trial in any species on a disc | Absent |
| ARA-290 improves nerve fibre density and nerve pain | Randomised human trials, small-fibre nerve damage | Moderate, different tissue |

## What actually changes the trajectory, in order of evidence strength

1. **Move, and keep moving.** Any structured exercise. The 249-trial effect does not depend on picking the right style.
2. **Walk, specifically, once the acute episode settles.** 208 days versus 112 to the next flare.
3. **Stop smoking if you smoke.** The continuing-smoker group showed no clinically important pain improvement over an entire course of care.
4. **Fix sleep before you fix anything else that is optional.** Halved odds of non-recovery.
5. **Change how you lift, not just how much you weigh.** Bending doubles-to-quadruples disc pressure; that is the measured lever.
6. **Treat the scan as information about probability, not about your future.** 96% of pain-free 80-year-olds share your finding.
7. **Use anti-inflammatories as short courses for flares, and know the specific cost of taking them for months.**
8. **If your pain shoots down a leg and started suddenly, you are probably reading the wrong page.** A herniation has a completely different natural history and a much better one.

[[embed:herniated-disc]]

Go to an emergency department immediately, not next week, for loss of bladder or bowel control, numbness in the groin or inner thighs, or leg weakness that is getting worse by the day. Those are the exception to everything above.

*This page explains mechanism and the state of the evidence. It is not a diagnosis or a treatment plan, and it is not medical advice. The compounds discussed are investigational and unproven for disc conditions. Discuss your own scan and your own symptoms with a clinician who can examine you.*


## Sources

1. Cervical Degenerative Disc Disease (StatPearls) — https://www.ncbi.nlm.nih.gov/books/NBK560772/
2. Discogenic Low Back Pain: Anatomy, Pathophysiology and Treatments of Intervertebral Disc Degeneration — https://pmc.ncbi.nlm.nih.gov/articles/PMC9820240/
3. Pathophysiology of Degenerative Disc Disease — https://www.asianspinejournal.org/journal/view.php?doi=10.4184%2Fasj.2009.3.1.39
4. Disc in Flames: Roles of TNF-alpha and IL-1beta in Intervertebral Disc Degeneration — https://pmc.ncbi.nlm.nih.gov/articles/PMC4751407/
5. Inhibiting TNF-alpha at time of induced disc injury limits long-term pain and degeneration in a rat model — https://pmc.ncbi.nlm.nih.gov/articles/PMC6022768/
6. Tumor necrosis factor-alpha: a key contributor to intervertebral disc degeneration — https://academic.oup.com/abbs/article/49/1/1/2548944
7. Association of Abdominal Obesity with Lumbar Disc Degeneration - An MRI Study — https://pmc.ncbi.nlm.nih.gov/articles/PMC3571955/
8. New in vivo measurements of pressures in the intervertebral disc in daily life (Wilke et al., 1999) — https://pubmed.ncbi.nlm.nih.gov/10222525/
9. Activities of Everyday Life with High Spinal Loads — https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0098510
10. Stem cell therapy for degenerative disc disease: Bridging the gap between preclinical promise and clinical potential — https://pmc.ncbi.nlm.nih.gov/articles/PMC10950333/
11. Effect of Platelet-Rich Plasma on Intervertebral Disc Degeneration: A Critical Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC7704139/
12. PRP Releasate vs Corticosteroid for Discogenic Low Back Pain: Double-Blind RCT — https://pmc.ncbi.nlm.nih.gov/articles/PMC8777786/
13. Mesenchymal stem cells can improve discogenic pain in patients with IVD degeneration: a systematic review and meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC10313064/
14. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disabled Myotendinous Junctions in Rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC8615275/
15. I was diagnosed with degenerative disc disease at 26 — https://www.reddit.com/r/backpain/comments/1mazvnp/i_was_diagnosed_with_degenerative_disc_disease_at/
16. degenerative disc disease at 19?? will i spend the rest of my life miserable?? — https://www.reddit.com/r/backpain/comments/jwozyf/degenerative_disc_disease_at_19_will_i_spend_the/
17. My experience with a lumbar epidural steroid injection — https://www.reddit.com/r/backpain/comments/18le0gj/my_experience_with_a_lumbar_epidural_steroid/
18. Effects of Tobacco Smoking on the Degeneration of the Intervertebral Disc — https://pmc.ncbi.nlm.nih.gov/articles/PMC4547737/
19. Intradiscal MSC Therapy for Low Back Pain: Phase IIB DREAM Study (double-blind, sham-controlled) — https://pubmed.ncbi.nlm.nih.gov/40462867/
20. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations (AJNR 2015, PMID 25430861) — https://pubmed.ncbi.nlm.nih.gov/25430861/
21. MRI Findings of Disc Degeneration are More Prevalent in Adults with Low Back Pain than in Asymptomatic Controls (AJNR 2015, PMID 26359154) — https://pubmed.ncbi.nlm.nih.gov/26359154/
22. Magnetic resonance imaging of the lumbar spine in people without back pain (NEJM 1994, PMID 8208267) — https://pubmed.ncbi.nlm.nih.gov/8208267/
23. Exercise therapy for chronic low back pain (Cochrane 2021, PMID 34580864) — https://pubmed.ncbi.nlm.nih.gov/34580864/
24. WalkBack: individualised progressive walking and education to prevent low back pain recurrence (Lancet 2024, PMID 38908392) — https://pubmed.ncbi.nlm.nih.gov/38908392/
25. Persistent and Developing Sleep Problems and Poor Outcome in Chronic Low Back Pain (Pain Pract 2018, PMID 28423222) — https://pubmed.ncbi.nlm.nih.gov/28423222/
26. Smoking Cessation Related to Improved Patient-Reported Pain Scores Following Spinal Care (JBJS 2012, PMID 23095839) — https://pubmed.ncbi.nlm.nih.gov/23095839/
27. ISSLS prize winner: A study of diffusion in human lumbar discs (Spine 2004, PMID 15564914) — https://pubmed.ncbi.nlm.nih.gov/15564914/
28. Modic changes as seen on MRI are associated with nonspecific chronic lower back pain and disability (J Orthop Surg Res 2023, PMID 37170132) — https://pubmed.ncbi.nlm.nih.gov/37170132/
29. The effectiveness of weight loss programs for low back pain: a systematic review (BMC Musculoskelet Disord 2022, PMID 35606809) — https://pubmed.ncbi.nlm.nih.gov/35606809/
30. Told L5-S1 would be a lifelong struggle; back on the squash court in a month (anecdotal) — https://x.com/sandipsabharwal/status/1863588573112615172
31. Compressed L4/L5 since 2023, still in daily pain (anecdotal) — https://x.com/thepottersart98/status/2083313695883657583
32. Eleven years of prescribed pain medication for degenerative disc disease, and what it became (anecdotal) — https://x.com/misteaz79/status/2084480977137799183
33. Diagnosed at half her mother's age, on pain medication for years (anecdotal) — https://x.com/sigma_eren/status/2083326223556419787
34. A bad day with degenerative disc disease, described plainly (anecdotal) — https://x.com/munkehsoup/status/2083319010343731272
35. Degenerative disc disease plus a herniation at L4-L5, building his own mobility routine (anecdotal) — https://x.com/FatherNerdGamer/status/2082996012554019305
36. Degenerative disc disease with no available pain treatment (anecdotal) — https://x.com/Drift0r/status/1997478666969010616


---

# Herniated disc: 70% resorb without surgery and 95% recover at one year

slug: herniated-disc · https://miscsubjects.com/a/herniated-disc · tags: condition, herniated-disc, sciatica, spine, disc · updated 2026-08-04T20:48:43.175Z

Start with the two numbers that should govern every decision you make about this in the next twelve months.

**Roughly seven out of ten herniated discs shrink and disappear on their own.** A meta-analysis pooled 31 studies covering 2,233 people treated without surgery: the disc material was reabsorbed in 70.39% of them overall. Broken down by how far the disc had pushed out — 87.77% for a fragment that had fully broken free, 66.91% for an extrusion, 37.53% for a protrusion, 13.33% for a bulge. Most of it happened inside the first six months.

[[embed:source:s26]]

**Roughly nineteen out of twenty people are recovered at one year, whichever route they take.** A randomised trial assigned 283 people with severe sciatica lasting 6 to 12 weeks to either early surgery or continued conservative care with surgery only if needed. Surgery relieved leg pain faster and produced faster perceived recovery. But at one year, the probability of perceived recovery was **95% in both groups**.

[[embed:source:s27]]

Hold those two numbers up against every claim anyone makes to you about a treatment for this — including every claim on this page. Seven in ten discs shrink on their own. Nineteen in twenty people are recovered at a year. Anything sold to you has to beat that baseline, or it has to be honest that it is buying you speed and comfort inside a recovery that was going to happen anyway.

## Before anything else: the symptoms that mean go now, not next week

These override everything below. Get to an emergency department immediately if you have:

- **Loss of bladder or bowel control**, or new difficulty starting or stopping urination
- **Numbness in the saddle area** — groin, buttocks, inner thighs, the parts that would contact a bicycle seat
- **Leg weakness that is getting worse day by day**, especially in both legs
- **Sudden loss of sexual sensation**

These can mean the nerve bundle at the base of the spine is being crushed. The window for preventing permanent damage is measured in hours, and the risk rises sharply past roughly 48 hours.

[[embed:source:s17]]

That is the whole exception list. If none of those apply, the rest of this page is about the ordinary case, and the ordinary case behaves far better than the diagnosis sounds.

## What actually happened inside your back

The disc between two bones of your spine is a fibre-wound ring with a pressurised, water-rich core. Under load, the core pushes outward and the ring contains it.

A herniation is the core (*nucleus pulposus*) pushing out through a crack in the ring (*annulus fibrosus*), almost always toward the back and to one side, because that is where the ring is thinnest and where a nerve root happens to be sitting.

[[embed:source:s1]]

The key word is **displaced**. Nothing was destroyed, nothing was severed, nothing was worn away. Living tissue moved from where it belongs to where it does not. That single distinction is why the 70% number exists — your body has a well-documented mechanism for removing tissue that is in the wrong place, and no mechanism at all for regrowing tissue that is gone.

Worth knowing before you read your report again: in people with **no back pain at all**, 29% of 20-year-olds and 43% of 80-year-olds have a disc protrusion on their scan. A true extrusion is rarer — in one study of 98 pain-free people, 27% had a protrusion and only 1% had an extrusion.

[[embed:source:s28]]

[[embed:source:s29]]

So a protrusion on your report may or may not be the thing hurting you. An extrusion that matches your symptom pattern almost certainly is.

## Your pain is four separate problems wearing one name

This is the most useful reframe on the page, because each of the four responds to different things, on different timescales, and only one of them is what the MRI is measuring.

**Layer 1 — Physical pressure.** Disc material is occupying space a nerve root needs. This is what the scan shows and what surgery removes.

**Layer 2 — Chemical irritation.** The material leaking out is not inert. It carries inflammatory signals that inflame the nerve directly, with no compression required.

**Layer 3 — Nerve fibre damage.** A nerve root that has been squeezed and chemically inflamed for weeks has damaged fibres. That is what produces the numbness, the pins and needles, and the weakness — and it recovers on nerve-repair timescales, which are slower than everything else here.

**Layer 4 — The surrounding tissue.** The torn ring, the segment that now moves differently, the muscles that have been guarding for months, and the movement patterns you have built around the pain.

Now the honest part, up front: **no compound, supplement, injection or peptide has been shown to reduce Layer 1.** The only two things that reduce physical pressure on the nerve are your own body reabsorbing the fragment over months, and a surgeon removing it. Anyone offering you a substance that shrinks a herniation is claiming something no study in any species supports. Everything else on this page is aimed at Layers 2, 3 and 4 — which, as it happens, is where most of your pain is coming from.

## Why a small herniation can hurt more than a large one

Here is the fact that explains why the imaging so often fails to match how you feel. Sciatica is largely chemical.

The core material carries TNF-alpha, which by itself produces nerve pain and nerve damage in controlled animal work — the compression is not required for the pain.

[[embed:source:s7]]

And it is loaded with an inflammatory enzyme called phospholipase A2, measured in herniated human discs at **20 to 100,000 times the activity of any other source described in the literature**.

[[embed:source:s8]]

Read that magnitude again. Displaced disc material is, chemically, one of the most inflammatory substances your body can put next to a nerve.

Two consequences fall out of it directly:

1. **Pain size does not track herniation size.** A small tear that leaks a lot of chemically active material next to an irritable nerve can hurt more than a large fragment sitting in a roomy space.
2. **Your pain will usually ease long before your scan changes.** The chemical irritation settles in weeks. The fragment shrinks over months. People routinely feel fine while the imaging still looks alarming, which is one good reason not to re-scan a recovering back.

## The counterintuitive rule: the worse it looks, the better it clears

Intuition says the big extruded fragment is catastrophic and the small contained bulge is minor. The resorption data says the reverse, and the gradient is steep:

| What the report says | Chance it reabsorbs |
|---|---|
| Sequestration — a fragment fully broken free | 87.8% |
| Extrusion — pushed out past the ring | 66.9% |
| Protrusion — bulging but still contained | 37.5% |
| Bulge — the whole rim extends outward | 13.3% |

[[embed:source:s26]]

A separate systematic review of predictive factors reaches the same conclusion: extruded and sequestered fragments are significantly more likely to regress completely than contained ones.

[[embed:source:s3]]

The mechanism explains the gradient exactly. Read the next section and the table stops being surprising.

## The removal mechanism runs on inflammation and blood supply — which is why it works better the further out the fragment is

The inside of a healthy disc is one of the few places in your body the immune system never visits. It has no blood supply and no immune surveillance. When core material breaks out through the ring, it enters a completely different neighbourhood: one with blood vessels, oxygen, and white blood cells that have never encountered this tissue before and treat it as foreign.

What happens next is a cleanup operation. Immune cells called macrophages swarm the fragment and digest it. New blood vessels grow into the edge of the fragment to supply the operation.

[[embed:source:s5]]

That new vessel growth at the fragment's rim is described as the principal driver of resorption, and it runs on VEGF, the body's main vessel-growth signal.

[[embed:source:s6]]

Now the gradient makes sense. **The more completely the fragment has broken out of the disc, the more of its surface is exposed to the cleanup crew.** A sequestered fragment is fully surrounded and clears 87.8% of the time. A contained bulge is still sealed inside the ring, invisible to the immune system, and clears 13.3% of the time. Exposure is the variable.

This has a direct and uncomfortable implication for treatment, taken up two sections below.

## What genuinely speeds recovery, ranked by the evidence behind it

**1. Keep moving. Do not go to bed.** Staying active beats bed rest for acute low back pain and sciatica — bed rest slows recovery rather than protecting it.

[[embed:source:s18]]

**2. Structured exercise, once you can tolerate it.** Cochrane pooled 249 randomised trials of exercise for chronic low back pain: a 15.2-point reduction on a 0–100 pain scale against no treatment, usual care or placebo, which clears the review's own pre-set threshold for a clinically important difference. No single style of exercise won. Doing it is what mattered.

[[embed:source:s30]]

**3. If you have a directional preference, use it.** Some people find one specific direction of movement — usually leaning backwards — pulls the pain out of the leg and back toward the spine. That migration of pain toward the centre is a good sign, and in the subgroup that shows it, the McKenzie approach of repeated end-range movements outperformed other exercise.

[[embed:source:s19]]

**4. Walk, once the acute stage passes.** In 701 adults randomised after recovering from an episode of back pain, a progressive individualised walking programme pushed the median time to the next activity-limiting episode from 112 days to 208 days, hazard ratio 0.72.

[[embed:source:s31]]

**5. Stop smoking.** Nicotine narrows the small vessels feeding a disc that already has the slowest nutrient delivery of any tissue in your body, and is directly toxic to disc cells. In 5,333 patients tracked through spinal care, the group who kept smoking showed no clinically important improvement in pain across an entire course of care.

[[embed:source:s24]]

**6. Reduce the load, on causal-grade evidence.** Mendelian randomisation — the design that uses inherited genetic variation as a natural experiment to separate cause from correlation — found higher BMI causally raises the odds of disc degeneration, back pain and sciatica, at roughly a third higher odds of sciatica per standard-deviation increase in BMI.

[[embed:source:s23]]

## What to skip, and what it costs you to try it anyway

**Bed rest.** Actively worse than staying active. Every day in bed is a day of losing the muscle support that gets you through this.

[[embed:source:s18]]

**Spinal traction.** The Cochrane review of 32 trials found little or no impact on pain, function or return to work, including specifically in people with sciatica. Machines, tables, inversion, and hanging all sit here.

[[embed:source:s20]]

**Repeat scanning a back that is improving.** Your pain resolves on a timescale of weeks; the fragment shrinks over months. A follow-up scan during that window shows you an unchanged herniation while you are actually getting better, and the psychological cost of that image is real.

**Any product claiming to dissolve a herniation.** See Layer 1 above. Nothing has done this in any species in a controlled study.

## Injections buy time, and they may cost you something to do it

Epidural steroid injections produce real short- and medium-term reduction in sciatica pain, with no significant long-term benefit and no change to the underlying natural history.

[[embed:source:s21]]

Understand them for what they are: a bridge across a stretch of pain bad enough to stop you moving, sleeping or working. If the pain is preventing the movement that is the best-evidenced thing you can do, an injection that restores movement is buying something worth having.

Now the tension, stated plainly rather than buried. **Your resorption engine is an inflammatory process.** Suppressing inflammation is the mechanism of both steroids and anti-inflammatory painkillers. In preclinical work corticosteroids inhibited resorption, and a clinical series that deliberately avoided anti-inflammatory drugs reported resorption in every patient.

[[embed:source:s25]]

That is not a reason to refuse a single injection in a crisis. It is a reason to be specific about the difference between a short course and a policy. Weeks of blanket anti-inflammatory suppression as a standing strategy is working against the process clearing your disc. The full argument, with the stomach, kidney and heart numbers attached to it, is here:

[[embed:bpc-157-vs-nsaids]]

## Surgery is faster, not better, at one year — with two things it does not do

The largest randomised evidence is the SPORT trial. Over eight years, both surgical and non-operative patients improved substantially. Surgery delivered faster and greater early relief. It was not a requirement for recovery in most people.

[[embed:source:s9]]

The Dutch trial quoted at the top of this page puts the same finding in one sentence: faster relief with early surgery, identical 95% recovery probability at one year.

[[embed:source:s27]]

Two things surgery does not do:

- **It does not regenerate the disc.** Removing displaced material leaves you with a disc that has less material in it and a tear in the ring.
- **It is not permanent-proof.** Reoperation reached about 15% by eight years in SPORT, roughly 85% of those for a re-herniation at the same level.

[[embed:source:s22]]

Surgery is the right answer for the emergency list at the top, for weakness that is worsening, and for pain that has failed 6 to 12 weeks of genuine conservative care with imaging that matches the symptoms. It is a decision about how long you are willing to hurt, not a decision about whether you will recover.

## Twelve people with a herniated disc, counted

Trials give you averages. Here is what people say happened to them, counted, with the outcomes that did not go well given the same room as the ones that did.

**Denominator: 12 first-person accounts** — 9 from X, 3 from a Reddit thread already filed on this page. **Outcome: 8 resolved or near-resolved, 1 improved but not resolved, 2 still in pain at the time of posting, 1 outcome not stated.** All non-surgical unless stated.

**Resolved — 8 of 12.**

Three years pain-free from a fifteen-minute routine done twice a week:

[[embed:source:s32]]

Eleven months of the worst pain of his life, then near-total resolution on a self-built programme:

[[embed:source:s33]]

Eight months to heal, described without any triumphalism:

[[embed:source:s34]]

A cane at 22, five years of daily pain, told surgery was the only option, and now pain-free:

[[embed:source:s35]]

The long version — years of experimenting, and what finally worked was loaded strength training:

[[embed:source:s36]]

And from Reddit, three accounts on the same thread, including one with a measured reduction on repeat imaging:

[[embed:source:s12]]

[[embed:source:s13]]

[[embed:source:s14]]

**Improved but not resolved — 1 of 12.** Functional in three months, explicitly not back to 100%, and honest about it:

[[embed:source:s37]]

**Still in pain at the time of posting — 2 of 12.**

Third herniation at the same level, thoracic, told surgery is not really an option:

[[embed:source:s38]]

Three weeks in and at the end of her rope — which is exactly what week three of this feels like:

[[embed:source:s39]]

**Outcome not stated — 1 of 12.** Newly diagnosed, told to expect one to three months.

[[embed:source:s40]]

**How much weight to put on that count.** Eight in twelve resolved sits close to the 70% resorption rate and the 95% one-year recovery figure, which is reassuring but partly coincidence: these accounts are heavily selected. People write recovery threads because "did anyone's disc reabsorb?" is a question people search; people in month two of agony often post nothing at all. Note also what the resolved accounts have in common — every one of them describes movement, exercise or physiotherapy, and not one describes a substance. Note the honest one too: @ViktorBunin explicitly says he is not at 100% three months in, which is a more accurate picture of month three than most recovery posts give you.

## Every link, with the strength of the evidence behind it

| Link | Evidence | Strength |
|---|---|---|
| About 70% of herniations reabsorb without surgery | Meta-analysis, 31 studies, 2,233 patients | Strong |
| The more the fragment has broken out, the better it clears | Same meta-analysis, gradient 87.8% → 13.3% | Strong |
| 95% recovered at one year regardless of surgery | Randomised trial, 283 patients | Strong |
| Surgery relieves leg pain faster | Randomised trial + SPORT, 8-year follow-up | Strong |
| Resorption is driven by immune clearance and new blood vessel growth | Mechanistic human and animal studies | Strong |
| Sciatica pain is substantially chemical, not only mechanical | Controlled animal model; enzyme measured 20–100,000× in human discs | Strong |
| Anti-inflammatory suppression can impede resorption | Preclinical inhibition plus one clinical series | Moderate |
| Staying active beats bed rest | Cochrane review | Strong |
| Exercise reduces pain by a clinically important margin | 249 randomised trials, −15.2 points | Strong |
| McKenzie helps the directional-preference subgroup | Randomised trial in responders | Moderate |
| Walking delays the next episode | Randomised trial, 701 people | Moderate |
| Traction helps | Cochrane, 32 trials | Negative |
| Bed rest helps | Cochrane | Negative |
| Epidural steroid gives short-term relief | Meta-analysis | Moderate, temporary |
| Epidural steroid changes the long-term course | Meta-analysis | No effect |
| Higher body weight causally raises sciatica odds | Mendelian randomisation | Strong for cause |
| Smoking accelerates disc degeneration; quitters improve more | Mechanistic plus 5,333-patient cohort | Moderate |
| Any compound reduces physical pressure on the nerve | No study, any species | Absent |
| BPC-157 or TB-500 helps a human disc | No trial, any species, on a disc | Absent |
| ARA-290 improves nerve fibre density and nerve pain | Randomised human trials, small-fibre nerve damage | Moderate, different condition |

## Where the compounds could plausibly act, and where they cannot

Map them onto the four layers and the picture becomes precise instead of promotional.

**Layer 1, physical pressure: nothing.** Time or a surgeon. No exceptions.

**Layer 2, chemical irritation: this is where the mechanistic case sits.** The inflammatory receptor pathway that TNF-alpha runs through is the target of ARA-290, and that compound has actual randomised human trials — for nerve damage rather than for a disc.

[[embed:ara-290]]

**Layer 3, nerve fibre damage.** A severed rat sciatic nerve regrew faster with BPC-157, which is the closest thing to a relevant animal result that exists. It is a rat, it is a cut nerve rather than a compressed one, and no human has been studied.

[[embed:bpc-157]]

**Layer 4, surrounding tissue.** Animal tendon, ligament and muscle repair is where both BPC-157 and TB-500 have the most consistent data — mechanically stronger healed tissue, faster cell migration into poorly supplied tissue.

[[embed:tb-500]]

There is one more thing worth holding onto. Your resorption engine runs on new blood vessel growth, and new blood vessel growth is precisely what these compounds are studied for driving. That could be read as encouraging. It could equally be read as a caution, since nobody has ever tested whether pushing that pathway helps clearance or does something unwanted next to an inflamed nerve. Neither reading is a result. The full mechanism-by-mechanism version, including where each inference breaks, is here:

[[embed:what-are-peptides-herniated-disc]]

And the slower wear process that sets up many herniations in the first place is a separate page with a very different set of numbers:

[[embed:degenerative-disc-disease]]

## What to actually do, this week

1. **Check yourself against the emergency list at the top.** If any of it applies, stop reading and go.
2. **Get out of bed and move within your tolerance.** Not through sharp pain, but not still either.
3. **Find out whether you have a directional preference.** If one direction repeatedly pulls the pain out of your leg and toward your spine, that is a lead worth following with someone who can watch you do it.
4. **Use pain relief to enable movement, in short courses, not as a standing policy.**
5. **Do not book a repeat scan because you still hurt at week six.** Your pain and your imaging are on different clocks.
6. **Count from the start of the episode, not from the day of the scan.** Most of the resorption in that 70% happened inside six months.
7. **Set the surgical decision on a rule, before the bad week arrives:** worsening weakness, or 6 to 12 weeks of genuine conservative effort with pain you cannot live inside, and imaging that matches your symptoms.

*This page explains mechanism and the state of the evidence. It is not a diagnosis, a treatment plan, or medical advice. Red-flag symptoms — bladder or bowel changes, saddle numbness, worsening weakness — are emergencies. The compounds referenced are investigational and unproven for disc conditions.*


## Sources

1. Lumbar Disc Herniation (StatPearls) — https://www.ncbi.nlm.nih.gov/books/NBK560878/
2. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-Analysis — https://pubmed.ncbi.nlm.nih.gov/28072796/
3. Systematic review and meta-analysis of predictive factors for spontaneous regression in lumbar disc herniation — https://pubmed.ncbi.nlm.nih.gov/37486886/
4. Prediction and Mechanisms of Spontaneous Resorption in Lumbar Disc Herniation: Narrative Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC11165499/
5. Characteristics and mechanisms of resorption in lumbar disc herniation — https://pmc.ncbi.nlm.nih.gov/articles/PMC9396855/
6. VEGF-induced angiogenesis in herniated disc resorption — https://pubmed.ncbi.nlm.nih.gov/12038611/
7. TNF-alpha in the nucleus pulposus mediates radicular pain in mice — https://pubmed.ncbi.nlm.nih.gov/18670336/
8. High levels of inflammatory phospholipase A2 activity in lumbar disc herniations — https://pubmed.ncbi.nlm.nih.gov/2218714/
9. Surgical vs Nonoperative Treatment for Lumbar Disk Herniation: SPORT Randomized Trial — https://jamanetwork.com/journals/jama/fullarticle/204281
10. Obesity as a Risk Factor for Sciatica: A Meta-Analysis — https://academic.oup.com/aje/article/179/8/929/108237
11. Obesity increases the odds of intervertebral disc herniation and spinal stenosis; an MRI study of 1634 low back pain patients — https://pubmed.ncbi.nlm.nih.gov/38363366/
12. r/Sciatica - herniated disc reabsorption (Alternative-Tomato18) — https://www.reddit.com/r/Sciatica/comments/d3p8jc/has_anyone_had_their_herniated_disc_be/
13. r/Sciatica - herniated disc reabsorption (ame880) — https://www.reddit.com/r/Sciatica/comments/d3p8jc/has_anyone_had_their_herniated_disc_be/
14. r/Sciatica - herniated disc reabsorption (mydiscgotsuckedbacki) — https://www.reddit.com/r/Sciatica/comments/d3p8jc/has_anyone_had_their_herniated_disc_be/
15. The probability of spontaneous regression of lumbar herniated disc: a systematic review — https://pubmed.ncbi.nlm.nih.gov/25009200/
16. Cauda Equina and Conus Medullaris Syndromes (StatPearls) — https://www.ncbi.nlm.nih.gov/books/NBK537200/
17. The natural history of lumbar disc herniation and radiculopathy — https://pubmed.ncbi.nlm.nih.gov/12027305/
18. Bed rest for acute low-back pain and sciatica (Cochrane) — https://pmc.ncbi.nlm.nih.gov/articles/PMC10762886/
19. RCT: McKenzie Method vs Motor Control Exercises in chronic LBP with a directional preference — https://pubmed.ncbi.nlm.nih.gov/27594441/
20. Traction for low-back pain with or without sciatica (Cochrane) — https://pubmed.ncbi.nlm.nih.gov/23959683/
21. Efficacy of epidural steroid injection for sciatica secondary to lumbar disc herniation: meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC11150834/
22. Surgical vs Non-Operative Treatment for Lumbar Disc Herniation: 8-Year SPORT results — https://pmc.ncbi.nlm.nih.gov/articles/PMC3921966/
23. Causal Associations of Obesity With Disc Degeneration, Low Back Pain, and Sciatica: Mendelian Randomization — https://pmc.ncbi.nlm.nih.gov/articles/PMC8692291/
24. Effects of Tobacco Smoking on the Degeneration of the Intervertebral Disc — https://pmc.ncbi.nlm.nih.gov/articles/PMC4547737/
25. Lumbar Disc Herniation Resorption: When and How Does It Occur? — https://pmc.ncbi.nlm.nih.gov/articles/PMC12890389/
26. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis (Clin Spine Surg 2024, PMID 37559207) — https://pubmed.ncbi.nlm.nih.gov/37559207/
27. Surgery versus prolonged conservative treatment for sciatica (NEJM 2007, PMID 17538084) — https://pubmed.ncbi.nlm.nih.gov/17538084/
28. Imaging features of spinal degeneration in asymptomatic populations (AJNR 2015, PMID 25430861) — https://pubmed.ncbi.nlm.nih.gov/25430861/
29. Magnetic resonance imaging of the lumbar spine in people without back pain (NEJM 1994, PMID 8208267) — https://pubmed.ncbi.nlm.nih.gov/8208267/
30. WalkBack: walking and education to prevent low back pain recurrence (Lancet 2024, PMID 38908392) — https://pubmed.ncbi.nlm.nih.gov/38908392/
31. Exercise therapy for chronic low back pain (Cochrane 2021, PMID 34580864) — https://pubmed.ncbi.nlm.nih.gov/34580864/
32. Eight months to fully heal a herniated disc (anecdotal) — https://x.com/SignatiusC/status/2082516526762975377
33. A cane at 22, five years of daily pain, told surgery was the only option, now pain free (anecdotal) — https://x.com/DrRichHuntsman/status/1542510810290827265
34. Years of experimenting, and what finally worked was loaded strength training (anecdotal) — https://x.com/GregPorto/status/1866589329851658629
35. Functional at three months from an L5/S1 herniation, explicitly not at 100% (anecdotal) — https://x.com/ViktorBunin/status/1940473782587552191
36. Third herniation at the same thoracic level, surgery not on the table (anecdotal) — https://x.com/MindlessMuttAD/status/2083679586928255256
37. Week three of a herniated disc, described from inside it (anecdotal) — https://x.com/windupskadi/status/2084644612291842310
38. Newly diagnosed, told one to three months (anecdotal) — https://x.com/Raiyuden_YT/status/1516102705655300103
39. Sciatica from a herniated disc, 95% pain free for three years on a 15-minute routine (anecdotal) — https://x.com/grassfedagent/status/2084101100106338387
40. Eleven months of severe sciatica, then near-total resolution on a self-built programme (anecdotal) — https://x.com/sisto_official/status/1795576275873972340


---

# BPC-157 vs NSAIDs: Repair or Suppress?

slug: bpc-157-vs-nsaids · https://miscsubjects.com/a/bpc-157-vs-nsaids · tags: bpc-157, nsaids, tendon, regeneration, disc · updated 2026-08-04T20:45:47.628Z

Say the asymmetry out loud before anything else, because most pages comparing these two hide it.

**Ibuprofen has been tested in people, at scale, and it works.** A Cochrane overview pulled together 39 systematic reviews covering roughly 460 randomised trials and about 50,000 participants, all measuring one thing: how many people get at least half their pain taken away. Ibuprofen 400 mg came out at a number-needed-to-treat of 2.5 — treat five people, two get at least 50% pain relief who would not have got it from a dummy pill. Fast-acting ibuprofen 200 mg: 2.1. Ibuprofen 200 mg with paracetamol 500 mg: 1.6, one of the best numbers in the entire table.

[[embed:source:s23]]

**BPC-157 has never completed a randomised controlled trial in a human being for any injury.** Not for tendon, not for muscle, not for a disc, not for a joint. The evidence is rats, a small number of early-phase human safety studies on other conditions, and a large volume of self-reported experience.

[[embed:bpc-157]]

That is the honest starting position and it does not favour the peptide. If your only question is "will this reduce my pain in the next four hours," the answer is the drug with 50,000 participants behind it, and no amount of mechanism argument changes that.

Now the two things that make this a real question rather than a rout.

## For back pain specifically, the drug's own trials are unimpressive

The 50,000-participant number comes from post-surgical pain. Back pain is a different question and it has its own trials, and they are far less flattering.

**Acute low back pain.** Cochrane pooled 32 trials, 5,356 participants. Against placebo, anti-inflammatories reduced pain by **7.29 points on a 0–100 scale** (95% CI −10.98 to −3.61), moderate-quality evidence. Disability improved by 2.02 points on a 0–24 scale, high-quality evidence. The reviewers' own summary of that magnitude: "small and probably not clinically relevant." No difference between COX-2-selective and older ones. Almost half the studies were industry-funded.

[[embed:source:s21]]

**Chronic low back pain.** Cochrane, 13 trials. Against placebo, **3.30 points on the same 0–100 scale** (95% CI −5.33 to −1.27), low-quality evidence. Disability, 0.85 points on a 0–24 scale. And this line, which deserves to be read twice: when the reviewers restricted the analysis to trials at low risk of bias, the difference between the drug and placebo got *smaller*.

[[embed:source:s22]]

Set those numbers beside the one intervention with a genuinely large effect for the same condition: structured exercise, pooled across 249 randomised trials, produced a **15.2-point** pain reduction, which cleared the reviewers' pre-set threshold for a clinically important difference.

[[embed:source:s24]]

So the honest ranking for a back, on human trial evidence, is: exercise 15.2 points, anti-inflammatories 7.3 points for acute and 3.3 for chronic, BPC-157 untested. The drug beats the peptide because the peptide has nothing. It loses badly to walking and lifting.

## What each one actually does to the tissue

An anti-inflammatory blocks an enzyme called COX-2. COX-2 makes prostaglandins. Prostaglandins are what make an injury swell, throb and hurt. Block the enzyme, lose the prostaglandins, lose the pain. That is the whole drug.

The complication is that prostaglandins are not only a pain signal. They are also the opening instruction of tissue repair — the message that recruits repair cells to a damaged site and starts the rebuilding. One molecule, two jobs. The drug cannot separate them.

BPC-157 runs the opposite way. It is a short chain of fifteen amino acids based on a sequence found in human stomach juice, and in animals it raises VEGF, the signal that grows new blood vessels into damaged tissue, and drives connective-tissue cells to migrate into and repair an injury. It has no pain-blocking action of its own worth speaking of.

One suppresses the signal. The other is studied for accelerating what the signal is calling for. That is the actual axis of this comparison, and neither side of it is automatically the right answer — it depends entirely on what you are trying to buy.

## The case against months of anti-inflammatories is specific, numbered, and not about healing

Most arguments against these drugs are vague and moralising. The real case is none of those things. It is four separate, measured harms, three of which are not in serious dispute.

### The stomach

The largest analysis of individual patient data — 280 trials against placebo covering 124,513 participants, plus 474 head-to-head trials covering 229,296 — put numbers on it by drug. Upper gastrointestinal complications, meaning a perforation, obstruction or bleed:

| Drug | Increase in upper gut complications vs placebo |
|---|---|
| Naproxen | 4.22× |
| Ibuprofen | 3.97× |
| Diclofenac | 1.89× |
| COX-2-selective drugs (coxibs) | 1.81× |

[[embed:source:s18]]

Note what that table does to the popular story. Naproxen, the one usually recommended as the heart-safe choice, has the *worst* gut number in the set. There is no drug in that column that is free.

The head-to-head randomised trial confirms the direction. PRECISION randomised 24,081 patients with arthritis and raised heart risk to celecoxib, ibuprofen or naproxen for a mean of 20 months. Gastrointestinal events were significantly lower with celecoxib than with either naproxen (p=0.01) or ibuprofen (p=0.002).

[[embed:source:s19]]

### The heart

From the same 124,513-participant analysis:

| Drug | Major vascular events | Major coronary events |
|---|---|---|
| Coxibs | 1.37× | 1.76× |
| Diclofenac | 1.41× | 1.70× |
| Ibuprofen | 1.44× (not significant) | 2.22× |
| Naproxen | 0.93× (no increase) | — |

**Heart failure risk was roughly doubled by all of them.** In absolute terms: for every 1,000 people taking a coxib or diclofenac for a year, three extra major vascular events, one of them fatal.

[[embed:source:s18]]

That is the honest trade-off between the two tables. Naproxen is the kindest to your heart and the harshest on your stomach. Celecoxib is the reverse. There is no free option, and PRECISION found celecoxib was not worse than the other two on heart outcomes at moderate doses, which softened but did not erase the coxib concern.

[[embed:source:s19]]

### The kidneys

Forty studies covering 1,757,118 participants. Long-term use raised the odds of developing or worsening chronic kidney disease: pooled odds ratio 1.24, pooled hazard ratio 1.50. In people who already had kidney disease, the hazard ratio was 1.67.

[[embed:source:s20]]

In PRECISION, kidney events were significantly lower with celecoxib than with ibuprofen (p=0.004).

[[embed:source:s19]]

### The report pile at the regulator, and exactly what it is not

FDA's public adverse event system holds reports sent in voluntarily by patients, doctors and manufacturers. Queried on 4 August 2026, it holds **283,544 reports naming ibuprofen** and **165,063 naming naproxen**.

Say what those numbers are before reading them. They are counts of reports, not counts of people harmed. There is no denominator anywhere in the system — nobody knows how many people took either drug and reported nothing, and that missing number is the one an incidence rate would need. A report is not a finding that the drug caused the event. The same event can arrive more than once. Reporting rises when a drug is in the news. Nothing in this table is a rate, and it cannot be turned into one.

| Reported event | Reports naming ibuprofen | Reports naming naproxen |
|---|---|---|
| Acute kidney injury | 7,141 | 3,145 |
| Kidney failure | 4,216 | 2,562 |
| Bleeding in the gut | 2,689 | 1,486 |
| Heart attack | 1,781 | 1,770 |
| Stomach ulcer | 1,394 | 867 |
| Black stool from a gut bleed | 1,208 | 478 |
| Heart failure | 634 | 305 |
| Bleeding from the stomach lining | 622 | 489 |
| Ulcer in the first part of the small intestine | 614 | 359 |

[[embed:source:s42]]

Two things are worth taking from it. The kidney rows sit above the gut rows for both drugs, which is the opposite of the ordering most people carry in their heads, and it lines up with the direction of the 1,757,118-participant kidney analysis rather than contradicting it. And the single most reported term for both drugs is not a harm at all: **"drug ineffective" — 27,383 times for ibuprofen and 22,584 for naproxen.** Set that beside the Cochrane back-pain numbers at the top of this page and it is the same finding arriving from the other end of the evidence pyramid.

The controlled trials above give you rates. This gives you the shape of what lands when something goes wrong. Use it for the second and never for the first.

### Tendon and soft-tissue healing — the one that is genuinely contested

This is the argument most often made and least often made carefully. Here is what the evidence supports and where it stops.

**In animals it is consistent and specific.** In a rotator cuff repair model, both an older anti-inflammatory (indomethacin) and a COX-2-selective one (celecoxib) produced significantly weaker tendon-to-bone healing than untreated controls, out to eight weeks.

[[embed:source:s1]]

**The timing pattern is the strongest part of the case.** Give ibuprofen during the early repair window and tendon healing is measurably worse; give the same drug later and the effect fades. That is exactly the pattern you would predict if the drug is interrupting the initial repair instruction rather than merely masking pain.

[[embed:source:s3]]

**Bone shows it too.** Pooled animal data show these drugs measurably reduce the mechanical strength of healing fractures.

[[embed:source:s6]]

**The mechanism is not a coincidence.** Knock out COX-2 in mice and fractures heal badly. Restore the downstream prostaglandin signal and the healing is rescued. The enzyme the drug exists to block is the same enzyme repair runs on.

[[embed:source:s8]]

**It reaches human repair cells.** In a human study, infusing an anti-inflammatory locally during exercise abolished the normal rise in muscle satellite cells — the stem cells that rebuild muscle after loading.

[[embed:source:s7]]

**And now the counter-evidence, which is real.** A meta-analysis of human fracture outcomes that adjusted for confounders found **no significant increase in fracture non-union** among people taking these drugs.

[[embed:source:s5]]

**There is even a species-level reason it might not translate.** Human skeletal stem cells were directly compared with rodent ones and turned out to be substantially less dependent on COX-2 for their function.

[[embed:source:s4]]

So the fair verdict, stated as a rate rather than a mood: **animal healing impairment is consistently reproduced; human cellular repair signals are measurably blunted; human clinical healing outcomes show no proven harm.** Anyone claiming these drugs are proven to wreck human healing is overstating. Anyone claiming the concern is invented is ignoring the timing data and the knockout mice.

## Why this argument gets sharper when the injury is a disc

A herniated disc is the one case where the healing question is not theoretical, because the mechanism that removes a herniation *is* an inflammatory mechanism.

Displaced disc material meets blood supply and immune cells for the first time. Immune cells digest it, new blood vessels grow in to supply the operation, and about 70% of herniations reabsorb on their own within roughly six months.

[[embed:herniated-disc]]

Suppress that inflammation continuously and you are working against the clearance. This is not purely inference: corticosteroids inhibited resorption in preclinical work, and a clinical series that deliberately withheld anti-inflammatory drugs reported resorption in every patient.

[[embed:source:s17]]

That evidence is a case series, not a randomised trial, and it should be weighted as such. But it points the same direction as the tendon timing data, and it is the reason "a few days for a flare" and "eight months of daily tablets" are different decisions rather than different doses of the same decision.

The slower wear process behind many of these discs is a separate question with its own numbers, and it changes what a long course of anything is being asked to do:

[[embed:degenerative-disc-disease]]

## What BPC-157 actually has, listed without inflation

**In animals, the tendon results are the strongest thing it has.** A transected rat Achilles tendon treated with BPC-157 came back with greater load-to-failure and better collagen organisation than controls.

[[embed:source:s10]]

**The cellular behaviour matches.** Tendon cells showed better outgrowth, survival and migration — the three behaviours that define active repair rather than scarring over.

[[embed:source:s11]]

**And the mechanism is the mirror image of the drug's.** BPC-157 raises VEGF and drives new blood vessel growth into healing muscle and tendon — the same vascular pathway that COX-2 blockade suppresses.

[[embed:source:s12]]

**It protects against the drug's own gut damage, in rats.** Given alongside diclofenac, BPC-157 counteracted the gastrointestinal, liver and brain lesions the drug caused.

[[embed:source:s13]]

**The same protection held when adjuvant arthritis and drug-induced gut lesions were put on the animal together.**

[[embed:source:s14]]

**What none of that is:** a human result. Every item above is a rodent. There is no completed randomised controlled trial of BPC-157 in a human injury, no dose established for a human tendon, and no study of any kind against a human disc.

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:what-are-peptides-herniated-disc]]

## Seven people on long-term anti-inflammatories, counted

**Seven first-person accounts from X, counted.** **Four of the seven reported a harm. One was warned off by a doctor before anything went wrong. One reported no problems over more than ten years. One is worried and getting tested, with no result back yet.**

Read this panel knowing exactly what is wrong with it: people post about the ulcer that sent them to hospital, not about the uneventful decade. The harm fraction here is not the population rate — the population rate is in the tables above, and it is a 4× relative increase on a small absolute base, not four in seven. This panel tells you what the harm looks like when it lands, not how often it lands.

**Reported a harm — 4 of 7.**

Kidney filtration flagged on bloodwork after years of six tablets a day:

[[embed:source:s25]]

A stomach bleed that lasted a year, and twelve years of avoiding the whole drug class afterwards:

[[embed:source:s26]]

Five tablets a day for five years for back pain, and a stomach that can no longer tolerate the drug at all:

[[embed:source:s27]]

An ulcer, black stool, and an emergency room:

[[embed:source:s28]]

**Warned off, no harm reported yet — 1 of 7.** Nearly two years of naproxen with a stomach-protecting drug alongside it, then a new doctor capping it at six months:

[[embed:source:s29]]

**No problems — 1 of 7.** Over ten years of use, including long continuous stretches, and no reported issue:

[[embed:source:s30]]

**Worried, no result yet — 1 of 7.** Years of heavy use, now getting kidney and liver function tested:

[[embed:source:s31]]

## Ten people on BPC-157, counted

**Ten first-person accounts from X**, all self-reported, none verified, none from a trial. **Six said it helped. One said it helped and raised the possibility of placebo himself. Two said it did not work. One reported no outcome either way. Nobody reported a serious harm, and the only physical complaint in the set was at an injection site.**

Two of the six positive accounts carry either a supplier link or a follow-me pitch attached to the post. That is not proof they are false, but it is a selection problem you should hold in mind while reading them.

**Said it helped — 6 of 10.**

A dried-out lower disc plus a year-old biceps tendon problem, six weeks of BPC-157 and TB-500 — tendon and shoulder resolved, disc improved but explicitly still needing physiotherapy:

[[embed:source:s32]]

Elbow tendon pain of months' standing, injected locally at the site:

[[embed:source:s33]]

A two-and-a-half-year knee injury the poster says nothing else had fixed:

[[embed:source:s34]]

Shoulder and joint pain on the BPC-157 plus TB-500 combination — note this post also links a supplier:

[[embed:source:s35]]

A rotator cuff for which surgery had been recommended, two eight-week cycles, surgery avoided — note this post ends in a follow-me pitch:

[[embed:source:s36]]

Two months, rotator cuff quiet during training, and heartburn gone as a side effect:

[[embed:source:s37]]

**Helped, but he flagged placebo himself — 1 of 10.** This is the most intellectually honest account in the set, and it is worth more than the enthusiastic ones:

[[embed:source:s38]]

**Said it did not work — 2 of 10.**

Ten years of on-and-off use and a flat verdict, including new tendon pain appearing while on it:

[[embed:source:s39]]

Eight weeks for a shoulder, judged not a success — with an interesting detail: stomach problems he had stopped noticing came back two weeks after stopping, which is the one place his account supports the gut-protective animal data even while rejecting the injury claim:

[[embed:source:s40]]

**No outcome reported — 1 of 10.** An injection-site problem from using too large a needle.

[[embed:source:s41]]

**What ten accounts can and cannot establish.** They cannot establish that it works — there is no control group, no blinding, no independent measurement, and a heavy bias toward people who bought the thing and want it to have worked. What they do establish, honestly: the reported experience is not uniformly positive, two of ten users describe no benefit at all, one of the enthusiasts volunteered placebo as an explanation unprompted, and nobody in this set reported a serious adverse event. Hold that against the 50,000-participant table at the top of this page and the size of the gap is the point.

## What is legal, which is a separate question from what works

**BPC-157 is not an approved drug anywhere.** Its regulatory position has moved recently, so the specific dates matter more than the summary. FDA placed it in Category 2 of the 503A bulk substances list in September 2023, barring pharmacy compounding. It was off all three categories by the 14 May 2026 revision after the nominations were withdrawn. In July 2026 FDA's own briefing document recommended against adding it; on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend adding it anyway, against FDA staff. It is not on the 503B outsourcing-facility list either.

**It is prohibited in sport at all times.** WADA's 2026 Prohibited List names BPC-157 explicitly under S0, non-approved substances — in and out of competition, not only on competition day. The US Department of Defense lists it on its Prohibited Dietary Supplement Ingredients List and states plainly that it is not a dietary ingredient but an unapproved drug, at any route.

**What it is sold as:** research chemical, research use only. That is a shipping label, not a legal category granting you permission to use it.

[[embed:bpc-157]]

**Ibuprofen and naproxen are over-the-counter medicines** with approved labels, approved dose ceilings, and pharmacist advice attached. That difference is not a footnote — it is the reason one of them has 50,000 participants of evidence behind it and the other does not.

## The decision table

| Your situation | What the evidence supports | What the evidence does not support | Legal position |
|---|---|---|---|
| Acute pain in the first few days, any injury | A short course of an anti-inflammatory. NNT 2.5 for ibuprofen 400 mg on at least 50% pain relief | That it speeds your healing, or that avoiding it makes you heal better | Over the counter |
| Acute back pain specifically | The same short course, with realistic expectations — 7.3 points on a 0–100 scale, which the reviewers called probably not clinically relevant | That it will do much. Movement outperforms it by roughly double | Over the counter |
| Chronic back pain, months in | Exercise. 15.2 points across 249 trials, against 3.3 points for the drug | Daily long-term anti-inflammatories as the plan. The effect shrinks in the least-biased trials and the harm accumulates | Over the counter, but this is the use with the harm tables attached |
| A herniated disc actively reabsorbing | Short courses to enable movement | Continuous suppression for months. Steroids inhibited resorption in preclinical work; one series avoiding these drugs saw resorption in every patient | Over the counter |
| You already have stomach disease or a bleed history | Avoiding the older drugs. Coxibs 1.81× vs ibuprofen 3.97× and naproxen 4.22× for upper gut complications | That any of them is gut-neutral | Prescription for coxibs in most places |
| You have heart disease or heart failure | Caution across the whole class. Heart failure risk roughly doubled by all of them; naproxen alone did not raise major vascular events | That the choice of drug removes the risk | Over the counter, which does not mean low-risk here |
| You have kidney disease | Avoiding long-term use. Hazard ratio 1.67 for progression in people who already have it | That short courses carry the same risk as chronic use | Over the counter |
| Tendon or soft-tissue injury where healing is the goal | Load management, progressive rehabilitation, and using pain relief sparingly in the first repair window | Either extreme. Animal harm is consistent; human non-union data shows none | Over the counter |
| You are considering BPC-157 for an injury | Nothing, in humans. Animal tendon repair is real and consistent; that is the entire honest case | Any human dose, any human timeline, any disc claim, any comparison of its effect size to the drug's | Not approved anywhere. Banned in sport at all times. Prohibited for US service members |
| You are a competing athlete | Whatever is on your sport's permitted list | Using BPC-157 under any framing, including "research use only" | WADA S0, strict liability, in and out of competition |

## The one-line version of each side

**For the drug:** it demonstrably relieves pain in humans at scale, it is legal, it is cheap, and the healing concern is unproven in human outcomes. Its costs are measured, drug-specific, and rise with duration rather than dose alone.

**For the peptide:** it has a coherent repair mechanism, consistent animal tendon results, and animal evidence that it protects the gut lining the drug damages. It has no human trial for any injury, no established dose, no legal approval, and a user-report base with two in ten reporting nothing at all.

Those two paragraphs are not equivalent and this page has not tried to make them equivalent. One is a medicine with a known effect size and a known bill. The other is an interesting hypothesis being taken by a lot of people ahead of its evidence.

*This page compares the state of the evidence. It is not medical advice and not a dosing recommendation. Do not stop a prescribed medicine on the basis of a web page. BPC-157 is sold for research use only, is not approved for human use in any jurisdiction, and is prohibited in sport at all times.*


## Sources

1. Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing — https://pubmed.ncbi.nlm.nih.gov/16210573/
2. NSAID therapy effects on healing of bone, tendon, and the enthesis — https://pmc.ncbi.nlm.nih.gov/articles/PMC3764618/
3. The detrimental effects of systemic Ibuprofen delivery on tendon healing are time-dependent — https://pubmed.ncbi.nlm.nih.gov/23982408/
4. Cross-species comparisons reveal resistance of human skeletal stem cells to inhibition by NSAIDs — https://pmc.ncbi.nlm.nih.gov/articles/PMC9454294/
5. Do NSAIDs affect bone healing rate, delay union, or cause non-union: an updated systematic review and meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC11420001/
6. NSAIDs and bone healing in animal models - a systematic review and meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC8268344/
7. Local NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric exercise — https://pubmed.ncbi.nlm.nih.gov/19713429/
8. Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4 — https://pubmed.ncbi.nlm.nih.gov/19628768/
9. Reduced COX-2 Expression in Aged Mice Is Associated With Impaired Fracture Healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC3276605/
10. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and stimulates tendocyte growth in vitro — https://pubmed.ncbi.nlm.nih.gov/14554208/
11. The promoting effect of BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
12. Modulatory effect of BPC 157 on angiogenesis in muscle and tendon healing — https://pubmed.ncbi.nlm.nih.gov/20388964/
13. BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced GI, liver, and encephalopathy lesions — https://pubmed.ncbi.nlm.nih.gov/21295044/
14. BPC 157 positively affects both NSAID-induced gastrointestinal lesions and adjuvant arthritis in rats — https://pubmed.ncbi.nlm.nih.gov/9403784/
15. NSAIDs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC12746519/
16. Management of Acute Pain From Non-Low Back Musculoskeletal Injuries: ACP/AAFP Clinical Guideline — https://pubmed.ncbi.nlm.nih.gov/32805126/
17. Lumbar Disc Herniation Resorption: When and How Does It Occur? — https://pmc.ncbi.nlm.nih.gov/articles/PMC12890389/
18. Vascular and upper gastrointestinal effects of NSAIDs: meta-analyses of individual participant data from randomised trials (Lancet 2013, PMID 23726390) — https://pubmed.ncbi.nlm.nih.gov/23726390/
19. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis — PRECISION (NEJM 2016, PMID 27959716) — https://pubmed.ncbi.nlm.nih.gov/27959716/
20. NSAIDs: what is the actual risk of chronic kidney disease? A systematic review and meta-analysis (Rom J Intern Med 2025, PMID 39412516) — https://pubmed.ncbi.nlm.nih.gov/39412516/
21. Non-steroidal anti-inflammatory drugs for acute low back pain (Cochrane 2020, PMID 32297973) — https://pubmed.ncbi.nlm.nih.gov/32297973/
22. Non-steroidal anti-inflammatory drugs for chronic low back pain (Cochrane 2016, PMID 26863524) — https://pubmed.ncbi.nlm.nih.gov/26863524/
23. Single dose oral analgesics for acute postoperative pain in adults — an overview of Cochrane reviews (Cochrane 2015, PMID 26414123) — https://pubmed.ncbi.nlm.nih.gov/26414123/
24. Exercise therapy for chronic low back pain (Cochrane 2021, PMID 34580864) — https://pubmed.ncbi.nlm.nih.gov/34580864/
25. Six ibuprofen a day for years, kidney filtration flagged on bloodwork (anecdotal) — https://x.com/rjust1421/status/2079732817420816700
26. A stomach bleed that lasted a year, then twelve years avoiding the whole drug class (anecdotal) — https://x.com/TheFengHunter/status/2065052345642205232
27. Five ibuprofen a day for five years for back pain, stomach no longer tolerates it (anecdotal) — https://x.com/jbf789/status/2060150691117605310
28. Ulcer, black stool, emergency room (anecdotal) — https://x.com/DadStrayer/status/2051426299843870966
29. Two years of naproxen for spinal pain, then a six-month cap (anecdotal) — https://x.com/BraisbyI/status/2076624300556112226
30. Over ten years of use, no reported problems (anecdotal) — https://x.com/meetjeo/status/2036117578112766127
31. Years of heavy use, kidney and liver tests pending (anecdotal) — https://x.com/BamaDarling/status/2080126143349346337
32. A dried-out lower disc plus a year-old biceps tendon problem, six weeks of BPC-157 and TB-500 (anecdotal) — https://x.com/MuroCrypto/status/2083184469956059529
33. Elbow tendon pain of months, 2 mg injected locally each day (anecdotal) — https://x.com/Compound_Cowboi/status/2083353093878448335
34. A two-and-a-half-year knee injury the poster says nothing else fixed (anecdotal) — https://x.com/raymondAjenkins/status/2084117597361189075
35. Lifelong shoulder and joint pain on the BPC-157 plus TB-500 combination — post links a supplier (anecdotal) — https://x.com/BenWolf1425771/status/2083968934064316770
36. Rotator cuff surgery recommended, two eight-week cycles, surgery avoided — post ends in a follow-me pitch (anecdotal) — https://x.com/michaelo_x/status/2072480753938751554
37. Two months, rotator cuff quiet during training, heartburn gone (anecdotal) — https://x.com/Shift_leader06/status/2071665450971181146
38. A disc flare that resolved in seven days, with placebo raised by the user himself (anecdotal) — https://x.com/AJA_Cortes/status/1794522474702336108
39. Ten years of on-and-off use and a flat negative verdict (anecdotal) — https://x.com/LtCrandog/status/2082758463407473109
40. Eight weeks for a shoulder, judged not a success — but stomach problems returned after stopping (anecdotal) — https://x.com/WayneLMarsh/status/2081368522601509373
41. An injection-site problem from using too large a needle (anecdotal) — https://x.com/FreezerBurnv2/status/2080030523506806963
42. openFDA adverse event reports naming ibuprofen and naproxen (FAERS, queried 2026-08-04) — https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:%22ibuprofen%22&count=patient.reaction.reactionmeddrapt.exact


---

# BPC-157: Body Protection Compound

slug: bpc-157 · https://miscsubjects.com/a/bpc-157 · tags: peptide, bpc-157, disc, tendon, gut · updated 2026-08-04T20:44:21.585Z

If you have a disc that is wearing out, you are deciding between things that slow the wearing and things that claim to rebuild. BPC-157 is sold as the second kind. BPC-157 is a short chain of 15 amino acids copied from a protein found in human stomach juice. Around 150 animal papers, mostly rats, report it speeding repair in tendon, ligament, muscle, nerve, bone and gut. Five studies have been run in people, covering about 130 people in total, and none of them was a finished controlled trial in a torn or worn-out tissue. It has never been approved as a medicine anywhere. It is banned in sport at all times. Nobody has ever tested it on a spinal disc, in a rat or in a person.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.
## The two clocks running in your back

A disc has two parts. The soft centre (the *nucleus pulposus*) is a water-holding gel that takes the load. Around it is a tough ring of layered fibres that keeps the gel where it belongs. Degeneration is the gel losing water and the ring cracking, in that order, over years.

Three things drive that.

The first is blood supply, or the near-absence of it. A disc is the largest structure in your body with no blood vessels running into it. Nutrients seep in through the bone plates above and below, and waste seeps out the same way. Those plates harden and clog with age. Once they do, the centre of the disc is a long way from any food supply, and cells in the middle start dying of the thing every tissue dies of when the plumbing fails.

The second is water. The gel holds water because of long sugar-protein molecules packed inside it. Cells make those molecules; dying cells stop making them. Less of them means less water, less water means a flatter disc, and a flatter disc loads its ring unevenly.

The third is the tearing itself. The ring is under shear every time you bend. When the centre stops cushioning, the ring takes load it was never built for, splits, and lets gel push out into the space where nerve roots run. That is a herniation, and the leg pain that follows is a squeezed nerve root (*radiculopathy*).

What makes it break down faster: smoking, which narrows the same small vessels feeding the bone plates; sustained loading without recovery; obesity; a genetic hand you did not choose, which explains more of the variation than most people expect; and — this is the one worth knowing before you read the rest of this page — steroid injections, which reliably reduce pain and reliably make the tissue heal worse.

Set against that, regeneration in a disc means one of three things: cells surviving longer, cells making more of the water-holding molecules again, or the ring physically closing. Every claim made for BPC-157 in a back is a claim about the first two, made by way of the blood supply. Nobody claims it closes a torn ring.

## Made in the stomach, and it survives the stomach

The name is literal: Body Protection Compound. The 15-piece chain is a fragment of a larger protein that sits in human stomach juice, and its one genuinely odd physical property is that it does not fall apart in that juice for more than 24 hours. Almost no peptide survives a stomach. That single property is the only reason a swallowed form is discussed at all, and it points at the gut as the compound's home ground.

Nearly the whole research record traces to one group in Zagreb, Croatia, led by Predrag Sikirić, running since 1993 and now past 150 papers.

That cuts both ways. It is a coherent, decades-deep programme applying one consistent dosing scheme across dozens of tissues, and it is also most of the world's evidence coming from a single group with a stake in the answer. It is the reason independent trials in people matter more here than they would for a compound many labs had poked at.

## What the different kinds of proof can and cannot tell you

Before the evidence, one table, said once, so the rest of the page does not have to keep apologising for itself.

| Kind of study | What it can settle | What it cannot settle |
|---|---|---|
| Cells in a dish | That the compound touches a specific switch inside a cell | Anything about a whole animal, a dose, or a person |
| Rats and dogs | That it changes a real injury in a living body, and by how much | Whether the same thing happens in a human, at what dose, or with what harm |
| Small safety studies in people | That a given dose did not visibly hurt a few dozen people over days | Whether it works, for anything |
| Chart reviews and phone follow-ups | What people remembered when asked | Whether the compound or the passage of time caused it |
| Randomised placebo trials | Whether it works | Nothing else needed — this is the one that settles it, and for a torn tissue none has finished |
| Forum and social posts | What exposure people are actually running, and what harms turn up at that exposure | Whether it works. Not weakly — not at all |


## Five studies in people, and the biggest one about an injury was a round of phone calls

FDA compiled the total published human experience for its July 2026 review. It is short enough to print in full.

| Study | How it was taken, and how much | People | Design | What happened |
|---|---|---|---|---|
| Healthy volunteers, rectal | up to 2 mg/kg daily × 8 days | 24 | Safety only | Nothing serious; headache and wind most common |
| Ulcerative colitis (Ruenzi 2005) | 80 mg rectal daily × 2 weeks | ~53 split into groups, ~26 treated | Randomised; published only as a conference abstract | Difference between groups 1.6 points, range −4.84 to 1.62 — the range crosses zero, so no effect was shown |
| Knee pain (Lee & Padgett 2021) | 2–4 mg into the joint, 1–2 injections | 17 found, 16 reached | Looked back at charts, then rang people up | 14 of 16 (87.5%) said they felt better; no dummy injection, no pain score, no scan |
| Interstitial cystitis | 10 mg into the bladder | 12 | No comparison group | Nothing serious reported |
| Healthy volunteers, into a vein | 10 mg then 20 mg | 2 | Safety pilot | No harm seen |

[[embed:source:w_9qu2rfyq]]

Two things fall out of that table and they are both worth sitting with.

The only randomised trial ever run on BPC-157 in a person was about an inflamed bowel, it exists only as a conference abstract, and the result range crosses zero — meaning the treated group and the untreated group cannot be told apart. And the only published report of BPC-157 doing anything for a musculoskeletal injury in a human is somebody reading old charts and then telephoning the people in them.

[[embed:source:w_nfh8rh08]]

Eleven of twelve people who got BPC-157 alone in that knee series said they improved a lot. There was no dummy injection, no random assignment, no standard pain questionnaire and no imaging. That is exactly the design that cannot separate a real drug effect from the well-known fact that sticking a needle into a sore knee makes people feel better for a while.

[[embed:source:s3]]

[[embed:source:s27]]

Two registered trials matter. A 2015 safety and absorption study in 42 healthy volunteers in Mexico gave single swallowed doses of 1 mg, 3 mg or 6 mg, then 3 mg every eight hours for two weeks. It never posted results, and the results submission was formally cancelled in 2016. Nobody knows what it found.

[[embed:source:w_rwwqkuud]]

The trial that could actually settle the tissue-repair question started recruiting in February 2026. It is randomised, double-blind, placebo-controlled, injected under the skin once a day for 14 days alongside a standard rehab programme, in 120 people aged 18–45 who have a grade II hamstring tear confirmed on a scan within 72 hours of doing it. The two things being measured are days until they can play sport again and the change in the size of the injury on the scan from day 0 to day 14. It is expected to finish in February 2027.

[[embed:source:s6]]

Until that reads out, there is nothing controlled in a human for any soft-tissue injury. Not weak data. None.

## Rats: what happened, in which tissue, at what dose

This is where nearly all the positive findings live. Read it as a picture of what the compound does in a living body when everything about the animal, the dose and the injury is controlled — and remember that the animals were young, healthy and injured on purpose, which is not your disc.

### A rat Achilles torn off the bone came back mechanically stronger

The join between tendon and bone is the hardest soft-tissue repair in the body and the one that most often fails. In rats whose Achilles tendon was surgically cut off the heel bone, BPC-157 raised the load the repair could take before failing, its stiffness and its springiness, all significantly above untreated animals. Under the microscope the collagen fibres were better lined up, there was more type I collagen — the strong, rope-like kind — and more blood vessels had grown in. Dose was 10 µg/kg, 10 ng/kg or 10 pg/kg into the belly cavity once a day, starting 30 minutes after surgery.

The same paper carries the finding most relevant to anyone who has already had a cortisone shot: the steroid 6α-methylprednisolone consistently made the healing worse, and BPC-157 substantially undid that damage.

[[embed:source:w_59xoi0m3]]

### Cut a ligament, crush a muscle, or sever the join between them — all three healed faster

The ligament model cut through the medial collateral ligament in rats and followed them 90 days. Treated animals came out ahead on four separate measures at once: how the leg worked, how strong the ligament was, how it looked to the eye, and how it looked under the microscope. Three different ways of giving it each worked — injection into the belly cavity at 10 µg/kg or 10 ng/kg daily, a cream at 1.0 µg per gram rubbed on, and plain drinking water at 0.16 µg/mL.

[[embed:source:w_ccsq5zep]]

The muscle model both cut through and crushed the rat calf muscle, and deliberately gave the animals a steroid to wreck the healing. The authors' finding is that BPC-157 completely reversed that steroid damage, given either by injection or as a cream, with the leg working normally again in treated animals.

[[embed:source:w_gttxaz57]]

The place where muscle turns into tendon — a classic site of grumbling strain that never settles — got its own study. In treated rats the injured leg's stiffening resolved completely, while untreated animals stayed disabled. The muscle wasting seen in untreated animals was prevented. By days 28 to 42 the new tissue ran in the right direction instead of being bridged by scar. Both the microgram and the nanogram doses worked.

[[embed:source:w_urj74cu2]]

The biggest recent study, from January 2025, pulled the quadriceps entirely off its bony anchors and then treated the rats only through their drinking water. The vastus muscles reattached as early as 21 days. Rectus femoris was back to normal anatomy at about 28 days. At three months the mature fibres ran parallel to the bone and sat right against it. Reattachment was tracked on ultrasound — the same imaging used on people.

[[embed:source:w_67ce14vu]]

The review that swept this whole literature screened 544 papers and kept 36. Thirty-five of the 36 were animal or lab work. Across muscle, tendon, ligament and bone the results point the same way: better function, better structure, better mechanical strength. The same authors put the counterweight in the same breath — harm is possible from unregulated manufacturing, contamination, and the fact that safety in people is unknown.

[[embed:source:w_bburqn2u]]

### A cut sciatic nerve regrew faster, which is the nearest thing to a nerve finding

Rats with a completely severed sciatic nerve got 10 µg/kg or 10 ng/kg into the belly cavity, into the stomach, locally at the repair site, or loaded straight into the tube bridging a removed segment. Self-mutilation of the dead-feeling limb — the standard sign that a rat's nerve pain is bad — did not happen in treated animals. Electrical testing showed stronger muscle signals. Weekly walking tests improved. Counting fibres under the microscope found more of them, thicker, with better insulation around them, at one to two months.

[[embed:source:w_032xvatb]]

Read what that is and is not. It is a nerve cut clean through and sewn back together. It is not a nerve being slowly squashed by a bulging disc or a tight tunnel in the wrist. No study of BPC-157 in a squashed or chronically compressed nerve has ever been published. The difference is not a technicality: a cut-and-repaired nerve has to regrow along a clear path, and a squashed nerve has to survive a mechanical problem that is still there. Different problems, different bottlenecks.

### Nobody has ever tested it on a disc

Two rat spinal-cord studies exist and both squash the cord itself, not a disc.

The 2019 study opened the spine at L2–L3 and compressed the tail end of the cord for 60 seconds, then gave a single injection into the belly cavity ten minutes later at 200 µg/kg or 2 µg/kg. Treated rats got progressively better tail movement, did not self-mutilate, and their spasticity had resolved by day 15, with less swelling and fewer dead motor nerve cells in the grey matter.

[[embed:source:s127]]

The 2022 follow-up is the more interesting one, because it waited before treating. After a one-minute squash by a 60–66 g weight that definitely paralysed the tail, one group got 2 µg/kg into the belly cavity at ten minutes. A second got a 10 ng/kg dose into the stomach on day 4. A third drank 10 µg/kg in water from day 4 to day 30. Recovery was described as fast and lasting out to a full year, with only patchy swelling, minimal bleeding and no loss of nerve insulation at day 30. Treatment started four days late still worked — which matters, because nobody turns up at a clinic ten minutes after their back goes.

[[embed:source:w_dmscp9sw]]

Neither of those is a disc. There is no published study of BPC-157 in a herniated or worn-out disc, in any species. And the doses used in the spinal work run up to a hundred times the doses used in the tendon work, so you cannot even carry a number across.

The argument people make for the disc goes like this: the disc has almost no blood supply, its healing is therefore limited by blood supply, and BPC-157's main proposed action is growing new blood vessels — so it should help. That argument is coherent. It also has no animal model behind it, let alone a human one. Nobody has put this compound in a degenerating disc and looked.

There is one more wrinkle worth stating, because it runs the other way. A worn disc is not supposed to have blood vessels in it. Part of what goes wrong in a painful disc is that vessels and pain nerves grow *into* the cracked ring, from the outside in, and that ingrowth is one of the better-supported explanations for why some worn discs hurt and others do not. A compound whose headline action is growing new vessels is being proposed for a tissue where new vessel growth is part of the pain. Nobody has tested which way that lands.

## How the compound is supposed to build tissue back

Strip the marketing and the proposed action is a short chain you can check link by link.

BPC-157 raises the signals that grow new blood vessels at an injury. New vessels bring oxygen and repair cells to tissue that had neither. Alongside that, it pushes collagen production and gets tissue-building cells to crawl into the gap.

The receptor step has been worked out in detail. In the cells that line blood vessels, BPC-157 makes the cell pull VEGFR2 — the main docking point for the body's chief vessel-growing signal — inside itself, and then switches on the VEGFR2–Akt–eNOS chain over time. Block the pulling-inside step with a chemical called dynasore and the whole effect disappears, which means the pulling-inside is required, not incidental. Vessel density went up both in a dish and in living animals, and blood flow came back faster in muscle that had been starved of it.

[[embed:source:w_fo79e9nk]]

The crawling step has its own named mechanism. In tissue-building cells taken from rat tendon, BPC-157 dose-dependently added phosphate groups to two proteins, FAK and paxillin, which are the machinery a cell uses to grip a surface and haul itself along. The total amount of those two proteins did not change; only the switched-on fraction rose. The same study found the cells were not making more of themselves, so the effect is cells moving and surviving, not cells multiplying in number.

[[embed:source:w_ud0jx8hb]]

A third mechanism sits underneath both. Tendon cells given BPC-157 at 0.5 µg/mL grew about seven times more growth hormone receptors by day three, measured both as the instruction and as the finished protein. The cell does not get more growth hormone. It gets better at hearing the growth hormone already going past.

[[embed:source:w_y4s15wvm]]

Nitric oxide — the gas that makes vessels widen — is pushed up in some situations and down in others, always paired with mopping up damaging free radicals. The Zagreb group reads that two-way behaviour as the whole point of the molecule: it pushes tissue toward normal rather than in one fixed direction. FDA reads the same observation as the reason no dose-response curve has ever been drawn for it. Both readings fit the data.

[[embed:source:s38]]

Now map that chain onto your disc, honestly. Link one, new vessels: real, shown in cells and in rats, never in a disc. Link two, vessels feeding a starved tissue: real in muscle, never shown in a disc, and a disc is starved through hardened bone plates rather than through missing vessels, which is a different blockage. Link three, cells making the water-holding molecules again: never studied for this compound, in any tissue. The chain has a hole in the middle of it exactly where your problem is.

## The painkiller you are probably already taking runs the opposite way to expected

Most people who arrive with back pain are already on an anti-inflammatory, and most compounds interact badly with those. This one was studied as an antidote to them.

Diclofenac at 12.5 mg/kg into the belly cavity once daily for three days produced severe stomach, gut and liver damage in rats, raised bilirubin, AST and ALT, made the liver heavier, and caused prolonged drowsiness that progressed to liver-driven brain failure with brain swelling and damaged nerve cells. BPC-157 blocked that entire cascade at both the microgram and the nanogram dose, given either by injection or in drinking water.

[[embed:source:w_odtbasyy]]

Read carefully, that is a gut-and-liver protection finding, not proof that combining the two heals a tendon better. What it does mean is that the medicine most likely to already be in the room is not, in rats, a documented problem.

The steroid interaction is the more useful one for a back. Two separate studies show BPC-157 undoing the damage a corticosteroid does to healing tendon and muscle. If you have had a cortisone injection into a joint or around a nerve root, the animal data says that shot measurably impaired the repair you went in for, and that this compound reversed that impairment in rats. That is the single most relevant animal finding on this page for a person with a degenerating spine, because so many people arrive having already had the shot.

## It is gone from your blood in about fifteen minutes

The only published measurements of what the body does to this compound come from rats and beagles.

Average time to clear half of it: 15.2 minutes. In dogs given it into a vein, 5.27 minutes. Peak level in the blood arrived three minutes after an injection into muscle. How much reaches the blood after an injection into muscle (bioavailability) was 14–19% in rats and 45–51% in dogs — wildly different between two species, and far from all of it. It leaves in urine and bile. Levels in kidney, liver, stomach wall, thymus and spleen went well above the level in blood.

[[embed:source:w_n7ahbrni]]

A compound cleared that fast cannot be working by keeping a steady level in your blood. Whatever it does, it does fast and locally, then sets off a slower tissue process that outlasts the exposure by weeks. Two practical things follow. First, that is the argument for splitting a daily dose rather than taking it all at once. Second, a once-a-week schedule has nothing behind it.

No measurement of any of this has ever been made in a person. Every number in this section is a rat or a dog, carried across species by assumption.

## Turning powder into a dose is arithmetic, not judgement

BPC-157 arrives as a freeze-dried white powder in a sealed glass vial, usually 5 mg or 10 mg. You add liquid to it. The liquid is bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is the thing that lets you put a needle into the same vial repeatedly over weeks. Plain sterile water dissolves the powder fine but has no preservative, so that vial is a one-time proposition.

The measuring device is a U-100 insulin syringe. U-100 means 100 units in a millilitre, so one unit on the barrel is 0.01 mL. Every conversion you will ever need comes from two lines:

- Micrograms per mL = total micrograms in the vial ÷ mL of water you added.
- Micrograms per syringe unit = that number ÷ 100.

Worked through: a 10 mg vial holds 10,000 mcg. You add 2 mL of bacteriostatic water. 10,000 ÷ 2 = 5,000 mcg per mL. 5,000 ÷ 100 = 50 mcg in one unit. A 250 mcg dose is therefore 250 ÷ 50 = 5 units on the barrel.

| Vial | Water added | Strength | Mcg per unit | Units for 250 mcg | Units for 500 mcg | Doses in the vial at 250 mcg |
|---|---|---|---|---|---|---|
| 5 mg (5,000 mcg) | 2.0 mL | 2,500 mcg/mL | 25 | 10 | 20 | 20 |
| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 20 |
| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 5 | 10 | 40 |
| 10 mg (10,000 mcg) | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 | 15 | 40 |
| 10 mg (10,000 mcg) | 5.0 mL | 2,000 mcg/mL | 20 | 12.5 | 25 | 40 |

Adding more water does not add or remove peptide. The vial holds what it holds. More water only changes how many syringe units carry a given dose. More water gives you bigger, easier-to-read unit counts and a slightly bigger squirt going in. Less water gives you a smaller sting and finer lines to misread. Below about 5 units per dose, the error in reading a U-100 barrel starts to swamp the dose itself — which is the practical argument for putting 3 mL rather than 2 mL into a 10 mg vial.

Ruining the peptide by accident is easy. Let the vial come to room temperature first. Run the water slowly down the inside wall of the glass rather than blasting it onto the powder. Swirl until it dissolves. Never shake it — shaking tears at the surface where liquid meets air, which unfolds peptide chains and makes them clump together, and clumping is the exact thing FDA named as the trigger for the immune system reacting to it (immunogenicity).

## The clock starts the moment you add water

| State | Temperature | How long it actually lasts |
|---|---|---|
| Sealed, still a powder | 2–8 °C, out of the light | Months to years, to the maker's date; −20 °C for long holding |
| Mixed with bacteriostatic water | 2–8 °C | About four weeks — that limit is set by the preservative, not the peptide |
| Mixed, left on the counter | 20–25 °C | Hours to days; treat it as ruined |
| Mixed, then frozen | −20 °C | Do not. Freezing and thawing clumps the peptide |

Do the arithmetic against your own plan before you buy. A 10 mg vial at 250 mcg a day is 40 doses. Four weeks is 28 doses. You will throw away roughly a third of the vial, or you must buy a smaller one, or take more per day. There is no fourth option — refreezing it is the one thing that definitely damages it.

## Where the needle goes was never settled, because nobody asked the animals

Two placements compete and the animal work cannot referee between them, because rats were dosed into the belly cavity, into the stomach or rubbed on the skin, almost never at a specific human-style injection site.

- **Under the skin, near the sore part.** What most people do. The argument is a higher concentration where the repair is needed, which fits a 15-minute clearance and fits tissue levels running above blood levels.
- **Under the skin of the belly, anywhere.** Standard for gut, nerve and organ targets, and easier to do to yourself. The argument is that a compound reaching kidney, liver and stomach wall above blood level obviously travels, so the entry point may not matter.

The evidence tilts slightly toward the entry point not mattering. Several of the strongest structural results in the entire literature — the cut ligament, the muscle-tendon junction, the quadriceps reattachment, the sciatic nerve, the spinal cord — were produced in rats that simply drank the compound and still repaired a specific injury a long way from their gut. Nothing anywhere in the record shows a local injection beating a systemic one head to head.

Here are the doses that exist, all of them either from rats or scaled up from rats:

| Where the number comes from | The dose | How long |
|---|---|---|
| The standard rat tier | 10 µg/kg, 10 ng/kg or 10 pg/kg once a day | For as long as the study ran |
| The rat drinking-water equivalent | 0.16 µg/mL in water, about 12 mL per rat per day | For as long as the study ran |
| Scaling 10 µg/kg straight up to a 70 kg adult | about 0.7 mg per day | Not an established human dose. Just arithmetic |
| Given to humans into a joint, published | 2–4 mg per injection, 1–2 injections | One course |
| Given to humans by mouth, published (2015 Phase 1) | 1, 3 or 6 mg once; then 3 mg every 8 hours | Two weeks |

There is no validated human dose, no validated cycle length, no taper and no ceiling. USADA states it without softening: nobody knows whether a safe dose exists, or whether there is any way to use this compound safely for a named condition.

[[embed:source:w_af5ht9pr]]

Now notice what the table shows, because it is the single most overlooked fact about this compound. Every dose ever given to a human in a published study is measured in **milligrams**. Scaling the standard rat dose up to an adult lands at roughly 0.7 mg. The regimens circulating on forums and printed on vendor sites are measured in **micrograms** — a thousandth of a milligram — and land around 250 to 500 mcg. That is roughly a hundredth of anything ever formally given to a person. Nothing in the literature supports the microgram regimens. Nothing in the literature refutes them either. The dose question is not contested; it is simply open, and everyone taking it is guessing.

## The tablet and the vial are not the same product

Swallowed BPC-157 exists as capsules or tablets, commonly 500 mcg each, and the stomach-survival finding is what makes that format arguable at all. But surviving your stomach acid and getting into your bloodstream are two separate questions, and only the first has ever been shown in a person.

| | Tablet you swallow | Vial you mix and inject under the skin |
|---|---|---|
| What is actually proven about this route | Survives human stomach juice past 24 hours | In rats, 14–19% of an injection into muscle reaches the blood; in dogs, 45–51% |
| Animal evidence using this route | Substantial — the ligament, muscle-tendon junction, quadriceps reattachment, nerve and spinal cord studies all worked with the compound given by mouth or in water | Extensive, but nearly all of it into the belly cavity rather than under the skin |
| What has been given to humans this way | 1–6 mg by mouth in the 2015 Phase 1; 80 mg per enema in the colitis trial | 2–4 mg into a joint; 10–20 mg into a vein |
| Best-supported target | The gut, and any whole-body target where the rat drinking-water arm worked | Musculoskeletal — by convention, not by any head-to-head comparison |
| How much gets into a human's blood | Never measured | Never measured |
| What it costs you in practice | No needles, no mixing, no four-week clock | Needles, arithmetic, a fridge, and a four-week clock |

The evidence is friendlier to the swallowed route than the injection convention implies. Several of the strongest structural repair results in the whole corpus — ligament, muscle-tendon junction, muscle reattached to bone, delayed spinal cord recovery — came from rats drinking it in water. What nobody has is a measurement of how much of a swallowed dose gets into a human's blood, so choosing between the two forms rests on rat route data and on convenience, not on anything measured in a person.

## How long anything would take, if it worked

Timelines here are set by tissue biology, not by the compound. Collagen remodels at the speed collagen remodels. Nerves regrow at about a millimetre a day. Nothing changes that.

| Model | Time to the reported result |
|---|---|
| Squashed spinal cord, spasticity gone | 15 days |
| Quadriceps reattached to bone, vastus muscles | 21 days |
| Quadriceps reattached to bone, rectus femoris | ~28 days |
| Muscle-tendon junction, tissue running the right way | 28–42 days |
| Cut sciatic nerve, function and microscope findings | 1–2 months |
| Cut medial collateral ligament, full follow-up | 90 days |
| Hamstring tear Phase 2, injury size on scan | 14 days (the primary measure; reads out 2027) |

No human timeline has been established, because no controlled human trial has finished.

The one inference that is honest: these are collagen and nerve timescales — four to twelve weeks. Anything promising a result inside a fortnight is describing pain relief, not repair. That distinction has a consequence you can act on. Pain relief arrives before tissue has been rebuilt. If you feel better at day 10 and go back to loading your spine on that signal, you are loading a structure that has not changed.

## FDA's own toxicology is more specific than the safety talk around it

The Zagreb group's stated position is that BPC-157 is very safe, with no side effects in trials and a lethal dose never reached in toxicology work. FDA read the same body of work and described it differently.

In 28-day repeat-dose studies injecting into muscle, rats showed shortened clotting time and dogs showed lengthened clotting time on the same test — an unexplained effect on clotting that runs in opposite directions in two species. Blood ALT, glucose and triglycerides went up. No cancer-causing study of BPC-157 in either of its two chemical forms has ever been done. It did not damage DNA, and no birth-defect signal appeared when it was injected through gestation days 6–15.

FDA raised four objections. They are independent of each other, which means answering one leaves the other three standing.

| The objection | What it actually means |
|---|---|
| Not enough clinical safety information to describe the safety profile | The human safety file is too small to draw a picture from — not "reassuring so far", but too small to say anything |
| Real risk that the immune system reacts to it, made worse by clumping and by peptide impurities | Part of the risk comes from how it is made and handled, not from the molecule alone |
| No dose-response relationship established | The flat pattern where micrograms, nanograms and picograms all work reads to FDA as a weakness, not a feature |
| No molecular target identified | Despite the VEGFR2 and FAK work, no confirmed receptor has been pinned down |

[[embed:source:w_9qu2rfyq]]

## The cancer question has a real answer and a real hole in it

The worry is mechanically sensible. A tumour cannot grow past a millimetre or two without recruiting new blood vessels. A compound whose headline action is growing new blood vessels could, in principle, supply them. An independent 2025 review states the worry and lands on the practical version of it: a cancer nobody has found yet.

[[embed:source:w_uhm2s5ar]]

The Zagreb group published a formal rebuttal in the same journal. Their case is that BPC-157 strongly *blocked* vessel growth into the cornea, that it has shown anti-tumour activity both in living animals and in a dish, and that its nitric oxide effect is always paired with mopping up free radicals — that it pushes vessel growth toward the normal, self-limiting kind rather than driving it indiscriminately.

[[embed:source:s131]]

Where that leaves you: no published rodent study shows BPC-157 speeding up tumour growth. No cancer-causing study exists. There is zero human cancer safety data. An active or suspected cancer is the one situation the mechanism itself argues against, and the missing study means the argument cannot be closed either way. If you have had a cancer, this is the question to take to your oncologist rather than to a forum.

## FDA said no, and its own advisory committee said yes by two votes

The regulatory position moved twice during 2026, and most summaries you will find online are stale.

| Date | What happened |
|---|---|
| Sept 2023 | FDA puts BPC-157 in Category 2 of the 503A bulk-substances list — significant safety risk, which bars compounding pharmacies from making it |
| 14 May 2026 | The revised interim list carries only six substances in Category 2. BPC-157 is in none of Categories 1, 2 or 3 — the nominations were withdrawn |
| July 2026 | FDA's own briefing document recommends against adding BPC-157 to the 503A list |
| 23 July 2026 | The Pharmacy Compounding Advisory Committee votes 8–6, with one abstention, to recommend adding it — against FDA's own staff |

If a page you are reading still says BPC-157 is FDA Category 2, it has not been updated since 14 May 2026.

[[embed:source:w_ghpbaz64]]

One detail in the meeting agenda changes what that vote means. The only condition FDA evaluated was ulcerative colitis. Tendonitis was among the uses put forward, and FDA declined to evaluate it because there was not enough information. A favourable vote about a bowel condition is not a favourable vote about tendon or disc repair, and it is being quoted as though it were.

[[embed:source:w_38qd7eam]]

The committee itself was not persuaded of much. One panelist who voted yes described the thing being voted on as a black box. One who voted no pointed out that roughly 30% of people given a dummy treatment report improvement — sometimes even on objective measures — which is the entire difficulty with the uncontrolled reports the nomination rested on.

[[embed:source:w_oje4lc91]]

Reporting on the meeting noted that a majority of the panelists voting yes had ties to the peptide industry.

[[embed:source:w_lkfuwkh8]]

The vote creates no authority. It is advisory, FDA is not bound by it, and a formal rulemaking cycle realistically runs eight to twelve months.

[[embed:source:s129]]

## There are two legal ways to compound a peptide and BPC-157 is on neither list

503A covers traditional compounding pharmacies. 503B covers registered outsourcing facilities, and it is a separate list with a separate standard: an outsourcing facility may not compound with a bulk substance unless that substance is on the 503B list, or the finished medicine is on FDA's drug shortage list at the time. BPC-157 is not on the 503B list, and the July 2026 vote concerned 503A only.

[[embed:source:w_iff2eacs]]

That same page sets out what FDA expects of any lawfully compounded substance: a valid certificate of analysis, manufacture by an establishment registered under section 510 of the FD&C Act, and compliance with any applicable USP or National Formulary monograph. Grey-market BPC-157 meets none of the three.

## If you compete in anything, this is a strict-liability problem

BPC-157 is named explicitly on the WADA 2026 Prohibited List under S0, Non-Approved Substances, banned at all times — not just on competition day. S0 covers any substance with no current approval by any government health authority for human use anywhere, which is exactly what BPC-157 is.

[[embed:source:w_u19qrezt]]

Strict liability means you are responsible for what is in your body regardless of intent and regardless of who recommended it. That applies at college, professional and masters level, in sports most people do not think of as drug-tested.

The Department of Defense goes further. Its Operation Supplement Safety programme lists BPC-157 on the Prohibited Dietary Supplement Ingredients List and states the position flatly: BPC-157 is not a dietary ingredient, it is an unapproved drug. That applies to service members however it is taken.

[[embed:source:w_h2eu8h3c]]

## "Research use only" is a shipping label, not a legal category

Nearly all BPC-157 sold to the public is labelled a research chemical, not for human consumption. That phrase creates no lawful route to a person. It is a disclaimer attached to a product with no legal standing as a medicine, a food or a supplement in the United States. USADA names the tell directly: sites that print "research only" while also printing human dosing instructions are describing what they expect to happen.

The purity problem is the concrete risk, and it is bigger than the legal one. Independent testing of grey-market peptide samples finds mislabelling, wrong dosing or contamination in roughly 30%, and the contaminant classes are specific: bacterial toxins, incomplete chains that are missing pieces, leftover solvents, heavy metals, live microbes and breakdown products. Incomplete chains and clumping are the same two failure modes FDA named as the things that make an immune reaction more likely — which means the supply-chain risk and the drug risk are the same risk wearing two hats.

[[embed:source:w_macsi7l3]]

> 30% contained incorrect amino acid sequences and two-thirds of samples fell below the 95% purity threshold.

[[embed:source:s130]]

A certificate reading "99% by HPLC" does not clear a batch, and understanding why is worth two minutes. HPLC confirms the target peptide is there and measures how much of the total it is. It says nothing about what the other 1% consists of. An incomplete chain or a fever-causing bacterial toxin sits inside that remainder and never shows up. What you want is HPLC *and* mass spectrometry, done per batch, by a laboratory that is not the seller. A vendor's own certificate is not third-party testing, and a certificate photographed from a different batch is not a certificate at all.

## Which problems the evidence actually reaches

Every positive animal model in this literature is an acute surgical injury — a tendon cut through, a ligament severed, a muscle crushed, a tendon torn off bone, a nerve cut. There is no rat model of a fifteen-year grumbling tendon, and no reason to assume a repair signal helps tissue whose problem is failed remodelling rather than an unfilled hole.

| Your problem | What the animal data actually covers | How strong |
|---|---|---|
| Fresh tendon tear or rupture | Achilles cut through and torn off bone: strength to failure, stiffness, type I collagen all improved | Strongest animal case |
| Tendon pulling off bone | Achilles detachment and quadriceps reattachment, confirmed on ultrasound at 21–28 days | Strong in animals, nothing in humans |
| Ligament sprain | Medial collateral ligament cut through, 90-day follow-up, four measures | Strong in animals, nothing in humans |
| Fresh muscle strain | Calf muscle cut and crushed; the one Phase 2 trial targets a grade II hamstring | Animals plus one trial reading out 2027 |
| Pain where muscle becomes tendon | Its own rat model; stiffening resolved, wasting prevented | Strong in animals, nothing in humans |
| Healing spoiled by a cortisone shot you already had | Two studies show the steroid damage to tendon and muscle healing reversed | Animals, directly relevant, nothing in humans |
| You are on daily anti-inflammatories | Diclofenac damage to gut, liver and brain fully blocked | Animals; a protection finding, not a repair finding |
| Nerve cut and surgically repaired | Sciatic nerve: electrical signals, walking, insulation all improved | Moderate in animals, nothing in humans |
| Long-standing overuse tendon pain | No model exists. Every positive study is a fresh injury | Weak — the mechanism does not obviously apply |
| Carpal tunnel or other trapped nerve | No compression model exists | Absent |
| Herniated lumbar disc, sciatica | No disc model exists. Nearest thing is a squashed rat spinal cord at a 100× dose | Absent |
| Degenerative disc disease itself | Nothing. Not one study, in any species | Absent |

Three rows carry the weight and they are not the three people expect.

The cortisone-reversal row is the most useful finding in the entire animal literature, because a large share of people with a bad back arrive having already had a steroid injection that measurably worsened the healing they came in for. If any part of this compound's animal record applies to you, that is the part with the clearest logic behind it.

The long-standing-tendon-pain row is weak exactly where demand is highest.

And the two disc rows are empty. The problem people ask about most is the one with no animal model at all — and, as the next section shows, it is also one of the problems that generates the loudest success stories.

## Fifty people said what happened to them, and here is the count

Everything above this heading is evidence. Everything below it is testimony, and the difference is not a matter of degree.

This page holds 50 first-person accounts posted publicly between 2015 and 2026 — 40 on Reddit across r/Peptides, r/steroids, r/backpain, r/Sciatica, r/climbharder, r/PEDs, r/Biohackers, r/moreplatesmoredates, r/PeptideGuide, r/Peptidesource and r/Supplements, and 10 on X. Every one is self-reported by a person you cannot identify or question. Nobody assayed their vial, so the substance in the syringe is unknown in every single case. Nobody was randomly assigned. Almost nobody scanned the injury before and after. People who got better write posts more often than people who did not, so the set is filtered before you even read it.

It is here for one reason. No controlled trial in a human musculoskeletal injury has ever finished, so this is the entire record of people using it for the reasons you are considering it — and it is what you have already read by the time you got to this page.

### The count, with the denominator

Of the 50 accounts, 13 report no personal result at all — they are protocols, questions, general threads about the science, or one person's dosing accident. That leaves **37 accounts that state what happened to the person writing**. Here is the split:

| What they reported | Count | Share of the 37 |
|---|---|---|
| It helped — clear improvement they credit to it | 18 | 49% |
| Partly, or it faded, or they could not separate it from other things | 5 | 14% |
| Nothing happened | 10 | 27% |
| It made something worse | 4 | 11% |

Read that table twice. Half of the people who reported an outcome said it helped, and half did not. If you have seen this compound described online, you have almost certainly seen a version of that record where the 14 accounts reporting nothing or harm were left out. That version is a lie by selection, and it is the standard version.

Four more things the raw count hides.

The 10 "nothing happened" accounts are not shorter courses or smaller doses than the successes. Several ran six weeks or more at the same 500 mcg a day that the successes ran.

The 4 harm reports describe things the rat toxicology gives no reason to expect and the five human studies were far too small to catch: a joint that got worse and inflamed, vision going blurry over weeks, a finger swelling with fluid, and leg pain returning during treatment for a herniated disc.

One account reports a ten-fold dosing accident, which is a safety datapoint of its own and the reason the reconstitution arithmetic earlier on this page matters more than it looks.

And exactly one account in 50 reports an objective check by a clinician. One. Everybody else is reporting pain, movement and confidence — the three things most responsive to time, rest and expectation.

### The 18 who said it helped

[[embed:source:w_xmo3vo5n]]

[[embed:source:w_xypc4fgc]]

[[embed:source:w_ihoinuk1]]

[[embed:source:w_iquapnzf]]

[[embed:source:w_vhlzhg4n]]

[[embed:source:w_mez2amn7]]

[[embed:source:w_z8sd87d2]]

[[embed:source:w_5icolfqk]]

[[embed:source:w_8uy508st]]

[[embed:source:w_e1ub04di]]

[[embed:source:w_as6ue9dv]]

[[embed:source:w_e8sw6xul]]

[[embed:source:w_qqu8pdaq]]

[[embed:source:w_q512lyfs]]

[[embed:source:s82]]

[[embed:source:s83]]

[[embed:source:s93]]

[[embed:source:s101]]

Two of those deserve a note rather than applause. The account crediting a clinician with saying the tear was gone is the single best entry in the whole set, and even that was a re-examination, not a repeat scan. And the account that asks itself "is this placebo?" also added collagen and more protein in the same window, which the writer says outright — that honesty makes it more useful than the confident ones, not less.

### The 5 who got part of a result, or lost it

[[embed:source:w_sg898nqt]]

[[embed:source:w_vljlka3r]]

[[embed:source:w_q3b1i12c]]

[[embed:source:w_iqb7rlvn]]

[[embed:source:w_brwijbo1]]

The last one is a pattern with no counterpart anywhere in the published literature: the effect fading on a steady dose, then not returning when the dose was raised. Nothing in the rat work predicts that. Nothing in the pharmacology explains it.

### The 10 who said nothing happened

These are the entries marketing copy leaves out. They are the same doses, the same durations, and several of them are longer courses than the successes.

[[embed:source:w_jdqqio36]]

[[embed:source:w_fhil2can]]

[[embed:source:w_8dxl599w]]

[[embed:source:w_0t8zcb1s]]

[[embed:source:w_txuoas2j]]

[[embed:source:w_9l5g0ldo]]

[[embed:source:w_8kdirxz8]]

[[embed:source:w_18w5khoc]]

[[embed:source:w_hf6dcwyh]]

[[embed:source:w_mjx06qhj]]

The standard reply offered inside these threads to a negative report is that the person got a bad vial. That reply cannot be checked — nobody in this set tested their product — and it is the exact mechanism by which a grey-market compound builds a record that can never fail. Every success counts as evidence; every failure counts as a counterfeit.

### The 4 who got worse

[[embed:source:w_epyzmnva]]

[[embed:source:w_ucf38h39]]

[[embed:source:w_usaqx7am]]

[[embed:source:w_0d8jnd1s]]

The first of those is the one to read closely if you have a disc problem: leg pain returning and worsening during a course taken specifically to heal a herniated disc. That is the exact situation this page is about, and it is a harm report, not a success.

The second describes one joint improving while another got inflamed and worse in the same person, on the same dose, in the same course.

### The dosing accident, and where the numbers came from

[[embed:source:w_wnund5ki]]

That is ten times the intended dose, caused by misreading a syringe barrel. Nobody was hurt. It is on this page because the numbers everyone uses have nothing under them, and the people using them say so plainly:

[[embed:source:w_o9okgjxa]]

[[embed:source:w_mzg8md2j]]

[[embed:source:w_xk3kn65m]]

[[embed:source:w_1t3oc07y]]

Almost every account in the set describes 250 to 500 micrograms a day, under the skin, sometimes split into two or three shots, run for four to eight weeks. That band converged by copying, not by measurement. It is about a hundredth of the milligram doses used in every published human study.

### The 13 that report no outcome at all — including the six loudest posts here

Thirteen of the 50 accounts state no personal result. Seven are the protocols and dosing arguments already shown above. The other six are X posts, and they are worth looking at separately, because they are almost certainly the format in which most people first meet this compound.

[[embed:source:s88]]

[[embed:source:s89]]

[[embed:source:s99]]

[[embed:source:s100]]

[[embed:source:s95]]

[[embed:source:s96]]

Read what those six actually are. Four are summaries of the animal literature written in the voice of personal endorsement — "repaired 5 different tissues", "no compound heals as many tissue types" — with a dose attached at the end and no report of the writer's own outcome anywhere in them. One is a person asking for an alternative. One is a person saying they never took it but wish they had.

They are in this count because leaving them out would be dishonest, and they are separated out because counting them as successes would be worse. The most confident writing about this compound contains the least first-hand information in it, and that is the single most useful thing this section can tell you.

### Where the accounts contradict the animal work

The animal record is strongest for fresh injuries and weakest — or empty — for long-standing tendon pain and for discs.

The forum record inverts that exactly. Long-standing elbow, wrist and shoulder tendon pain of one to five years' standing is the most common thing people treat. Herniated discs and sciatica — the problem with no animal model whatsoever — generate some of the most emphatic success reports on this page.

The single most emphatic disc account on this page — the sciatica report above, in which pain eased over six to seven weeks of injections after everything else had failed — is also the one with the least behind it, because no animal has ever been given this compound for a disc.

Two readings fit that and the accounts cannot separate them. Either the compound reaches structures the animal work never tested, or long-standing pain that comes and goes was going to improve anyway and the compound arrived during a good month. The disc reports are the clearest case, because a herniated disc shrinks on its own in a large share of people over roughly six to twelve weeks — which is exactly the window these protocols run. Somebody who starts a course at their worst week and finishes it feeling better has described the natural history of the condition, and would have written the same post taking nothing.

The swallowed route contradicts the pharmacology the same way. Surviving stomach acid is proven; getting into a human's blood from the gut is not. People report the two forms doing different jobs, which is precisely what you would expect if the tablet works locally in the gut and never reaches a tendon at all.

[[embed:source:w_1bbc6bfn]]

### The stacking problem, which is the biggest hole in the whole set

Almost nobody takes this alone. TB-500 is combined with it so routinely that a large share of these accounts cannot attribute any outcome to either compound. Others add growth hormone, testosterone, surgery, physiotherapy, diet changes and rest inside the same weeks.

[[embed:source:w_ahk1cevh]]

The three most confident recovery stories on this page — the rotator cuff tear a clinician later called gone, the wrist rebuilt over seven vials, and the shoulder that felt 75% better in five days — were all run as BPC-157 plus TB-500, and two of them alongside structured rehab. Not one of them can tell you which part did the work.

That is not a small caveat. It means a good share of the 18 positive accounts are reports about a combination, run alongside the two interventions with the best evidence in all of musculoskeletal medicine — load management and time.

### What the counted record settles, and what it does not

It does not settle whether it works. Thirty-seven uncontrolled accounts filtered toward success are not weak evidence for a treatment effect; they are a different kind of object, and collecting three hundred more would change nothing about that. A 49% success rate in this set is not a 49% chance it works for you. It is a measurement of what people wrote down.

It does settle three things the published literature does not contain at all, and these are the reason it is worth counting rather than dismissing.

First, the real exposure. People are running 250–500 mcg a day under the skin for four to eight weeks, usually stacked with TB-500. No trial has ever studied that exposure. When somebody eventually does, this is the regimen they should test, and nobody would know it from the papers.

Second, harms at that exposure. Four of 37 accounts report getting worse — local swelling, a joint becoming more inflamed, blurred vision, and returning nerve pain. None of those appear in any published human safety dataset, because those datasets total about 130 people across five studies and would not detect a 1-in-10 problem if it existed.

Third, the mismatch. The two things people actually treat with it — long-standing tendon pain and lumbar disc disease — are the two the animal literature supports least and not at all, respectively.

The Phase 2 hamstring trial reading out in 2027 will answer the works-or-not question for one fresh injury in one muscle. Nothing currently running will answer it for a disc.

## What is settled about BPC-157, and what is not

| Status | Statement |
|---|---|
| Settled | It survives human stomach juice for more than 24 hours |
| Settled | It switches on the VEGFR2–Akt–eNOS chain and increases blood vessel density in a dish and in rodents |
| Settled | It improves mechanical strength and microscope appearance across many fresh rat injuries |
| Settled | It reverses the damage a corticosteroid does to tendon and muscle healing in rats |
| Settled | It blocks diclofenac-caused gut, liver and brain damage in rats |
| Settled | Half of it clears a rat's blood in about 15 minutes; 14–19% of an intramuscular dose reaches the blood in rats |
| Settled | It is on the WADA 2026 Prohibited List under S0, banned at all times, in and out of competition |
| Not shown | That it does anything for a musculoskeletal injury in a person — no controlled soft-tissue trial has finished |
| Not shown | That a swallowed dose reaches the bloodstream of a human |
| Not shown | That it feeds tumours — and equally not shown that it is safe if you have a cancer |
| Unknown | The right human dose. Every published human study used milligrams; everyone taking it uses micrograms |
| Unknown | Long-term safety, interactions with your other medicines, and why clotting time moves in opposite directions in rats and dogs |
| Unknown | Whether any of this reaches a spinal disc. Nobody has looked, in any species |

If you take one line from this page, take this one: the strongest argument for BPC-157 in a degenerating back is a chain of reasoning, and the strongest argument against it is that nobody has ever tested a single link of that chain in a disc. The animal work is real and it is good. It is also about tendons, ligaments, muscles and cut nerves in young rats injured on purpose, and your disc is none of those things.

*BPC-157 is not an approved medicine in any country. Everything sold to the public is grey-market and unverified. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:tb-500]]

[[embed:ara-290]]

[[embed:kpv]]

[[embed:wolverine-stack]]

[[embed:bpc-157-vs-nsaids]]

[[embed:what-are-peptides-herniated-disc]]

[[embed:herniated-disc]]


## Sources

1. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — https://pubmed.ncbi.nlm.nih.gov/30915550/
2. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — https://pubmed.ncbi.nlm.nih.gov/40131143/
3. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pubmed.ncbi.nlm.nih.gov/40789979/
4. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review — https://pubmed.ncbi.nlm.nih.gov/40005999/
5. BPC 157 for Acute Hamstring Muscle Strain Repair — https://clinicaltrials.gov/study/NCT07437547
6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine — https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
7. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity — https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547/
8. Peptide BPC-157 - Does It Work? Breaking Down ... — https://www.youtube.com/watch?v=HIrI8STJPJo
9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
10. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT) — https://pubmed.ncbi.nlm.nih.gov/40759852/
11. SELFTEST graph fn ingest
12. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — https://pubmed.ncbi.nlm.nih.gov/41476424/
13. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
14. Multifunctionality and Possible Medical Application of the Stable Gastric Pentadecapeptide BPC 157 — https://www.mdpi.com/1424-8247/18/2/185
15. What Science ACTUALLY Says About BPC 157 Benefits — https://www.youtube.com/watch?v=gaQwrB8HW4o
16. The Role of BPC-157 in Tissue Repair and Pain Management — https://pubmed.ncbi.nlm.nih.gov/41898733/
17. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review — https://pubmed.ncbi.nlm.nih.gov/41754849/
18. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
19. BPC-157 – No Proof Required! — https://www.mcgill.ca/oss/article/medical-critical-thinking-health-and-nutrition-contributors/body-protection-compound-no-proof-required
20. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management — https://pmc.ncbi.nlm.nih.gov/articles/PMC13026520/
21. Pentadecapeptide BPC 157 and the central nervous system — https://pubmed.ncbi.nlm.nih.gov/34380875/
22. BPC-157: Miracle Healing Peptide or Hidden Danger? — https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger
23. BPC-157 and the Difference Between an Evidence Gap and a Cover-Up — https://wellfounded.health/insights/bpc-157-and-the-difference-between-an-evidence-gap-and-a-cover-up
24. Stable Gastric Pentadecapeptide BPC 157 and Striated, ... — https://pubmed.ncbi.nlm.nih.gov/36551977/
25. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide — https://pubmed.ncbi.nlm.nih.gov/41155565/
26. S808 Oral Peptide BPC-157—An Emerging Adjunct to Gastrointestinal Therapies? — https://journals.lww.com/ajg/fulltext/2025/10002/s808_oral_peptide_bpc_157_an_emerging_adjunct_to.809.aspx
27. Peptides in Orthopedics: BPC-157 — What Patients Should Know About Safety, Efficacy, and Sourcing — https://www.mdorthospecialists.com/2026/04/28/peptides-in-orthopedics-bpc-157-what-patients-should-know-about-safety-efficacy-and-sourcing/
28. How does the Peptide BPC-157 Work? — https://www.youtube.com/watch?v=WjCtQM_rfBE
29. Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ... — https://pubmed.ncbi.nlm.nih.gov/40573323/
30. Stable Gastric Pentadecapeptide BPC 157 as a Therapy of ... — https://pubmed.ncbi.nlm.nih.gov/41832718/
31. Stable Gastric Pentadecapeptide BPC 157 as Therapy ... — https://pubmed.ncbi.nlm.nih.gov/39861766/
32. Protective Effects of BPC 157 on Liver, Kidney, and Lung ... — https://pmc.ncbi.nlm.nih.gov/articles/PMC11857380/
33. Peptides and BPC-157 for Pain: What's the deal? — https://www.youtube.com/watch?v=-rIoG_UF6RI
34. Tracheocutaneous Fistula Resolved by Pentadecapeptide ... — https://pmc.ncbi.nlm.nih.gov/articles/PMC12844668/
35. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection — https://pubmed.ncbi.nlm.nih.gov/38980576/
36. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats — https://pubmed.ncbi.nlm.nih.gov/39861766/
37. Safety of Intravenous Infusion of BPC157 in Humans — https://pubmed.ncbi.nlm.nih.gov/40131143/
38. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — https://pubmed.ncbi.nlm.nih.gov/41476424/
39. The Role of BPC-157 in Tissue Repair and Pain Management — https://pubmed.ncbi.nlm.nih.gov/41898733/
40. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
41. Of all the peptides I've tried BPC-157 is my favorite. — https://x.com/mindpumpsal/status/1751417750806020447
42. BPC-157 post — https://x.com/Breedlove22/status/2071613094540030205
43. PEPTIDE MASTERCLASS: BPC-157 — https://x.com/KingOfVitamins/status/2071610257093145038
44. BPC-157 tendon healing details — https://x.com/KingOfVitamins/status/2071610274843332656
45. TB-500 with BPC-157 for tissue repair — https://x.com/Breedlove22/status/2071613106678337793
46. X post by @mariioo888 — https://x.com/mariioo888/status/2071633910514212931
47. X post by @TakeThiamine — https://x.com/TakeThiamine/status/2071621198287610002
48. X post by @BasedBiohacker — https://x.com/BasedBiohacker/status/2027900122026414320
49. X post by @HealthyAlfred — https://x.com/HealthyAlfred/status/2042931532688494967
50. X post by @WovenDissent — https://x.com/WovenDissent/status/2071612933382037588
51. BPC 157 promotes tendon healing via outgrowth, cell survival, and migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
52. BPC 157, in clinical trials for IBD (PL14736), heals colocutaneous fistulas in rats — https://pubmed.ncbi.nlm.nih.gov/18818478/
53. BPC 157 improves the healing course of spinal cord injury and leads to functional recovery in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/
54. BPC-157 Legal Status 2026: FDA Category 2 Removal, PCAC Review — https://lotilabs.com/resources/bpc-157-legal-status-2026-fda-update/
55. An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition (TIME) — https://time.com/article/2026/07/23/fda-committee-peptides/
56. Gray-Market Peptides: The 'Research Use Only' Fiction — https://rethinkpeptides.com/articles/for-research-use-only-the-legal-fiction-of-gray-market-peptides
57. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide (review commentary) — https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/
58. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation — https://pubmed.ncbi.nlm.nih.gov/27847966/
59. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — https://pubmed.ncbi.nlm.nih.gov/21030672/
60. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts — https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
61. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat — https://pubmed.ncbi.nlm.nih.gov/20225319/
62. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation — https://pubmed.ncbi.nlm.nih.gov/16583442/
63. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application — https://pubmed.ncbi.nlm.nih.gov/20190676/
64. Stable gastric pentadecapeptide BPC 157 as a therapy for the disabled myotendinous junctions in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC8615275/
65. Stable gastric pentadecapeptide BPC 157 as therapy after surgical detachment of the quadriceps muscle from its attachments for muscle-to-bone reattachment in rats — https://pmc.ncbi.nlm.nih.gov/articles/PMC11768438/
66. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs — https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
67. Intra-articular injection of BPC 157 for multiple types of knee pain — https://pubmed.ncbi.nlm.nih.gov/34324435/
68. Phase I, pilot study in healthy volunteers, to assess the safety and pharmacokinetics of PCO-02 (BPC-157) — https://clinicaltrials.gov/study/NCT02637284
69. FDA briefing document, Pharmacy Compounding Advisory Committee: evaluation of BPC-157-related bulk drug substances for inclusion on the 503A bulk drug substances list — https://www.fda.gov/media/193343/download
70. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act — https://www.fda.gov/media/94155/download
71. July 23-24, 2026: meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
72. World Anti-Doping Code International Standard: Prohibited List 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
73. BPC-157: experimental peptide creates risk for athletes — https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
74. BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products — https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products
75. FDA panel votes to loosen restrictions for four peptides — https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
76. FDA advisory panel narrowly votes to allow compounding of unapproved peptides — https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
77. What's changing with peptide regulation in 2026 — https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
78. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review — https://pubmed.ncbi.nlm.nih.gov/40756949/
79. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review — https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
80. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury — https://pubmed.ncbi.nlm.nih.gov/19903499/
81. Novel therapeutic effects in rat spinal cord injuries: recovery of the definitive and early spinal cord injury by the administration of pentadecapeptide BPC 157 therapy — https://pmc.ncbi.nlm.nih.gov/articles/PMC9164058/
82. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions — https://pubmed.ncbi.nlm.nih.gov/21295044/
83. Bulk drug substances used in compounding under section 503B of the FD&C Act — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
84. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/duz790a/
85. Does bpc157 increase recovery between workouts — https://www.reddit.com/r/moreplatesmoredates/comments/1kfp3uf/does_bpc157_increase_recovery_between_workouts/mr860tt/
86. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi6t9l6/
87. Chronic onesided thoracic pain — https://www.reddit.com/r/backpain/comments/1ccysh4/chronic_onesided_thoracic_pain/
88. Hlab27 sacroiliitis on mri vs disc obliteration — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/
89. Compounds to help articular cartilage fissure in — https://www.reddit.com/r/PEDs/comments/173pdv4/compounds_to_help_articular_cartilage_fissure_in/
90. Need help deciding between kpv low dose — https://www.reddit.com/r/Peptidesource/comments/1v6e4g2/need_help_deciding_between_kpv_low_dose/
91. Blend experience — https://www.reddit.com/r/Biohackers/comments/1u7ixcd/blend_experience/
92. Ligament injury repair with bpc157 and tb500 — https://www.reddit.com/r/moreplatesmoredates/comments/phepeu/ligament_injury_repair_with_bpc157_and_tb500/hsp96nl/
93. Bpc 157 and tb 500 for herniated disc — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/
94. Bpc157 gone wrong — https://www.reddit.com/r/PEDs/comments/1qftcul/bpc157_gone_wrong/
95. 1 month of bpc157 tb500 blend reviewblurry vision — https://www.reddit.com/r/Biohackers/comments/1ra2m3p/1_month_of_bpc157_tb500_blend_reviewblurry_vision/
96. Bpc157 for shoulder injury — https://www.reddit.com/r/Biohackers/comments/1tufuie/bpc157_for_shoulder_injury/
97. I know some will disagreebut new batch of bpc 157 — https://www.reddit.com/r/Biohackers/comments/1u7ddu1/i_know_some_will_disagreebut_new_batch_of_bpc_157/
98. Bpc157 and tb4 has it not worked for you — https://www.reddit.com/r/Peptides/comments/1uute3b/bpc157_and_tb4_has_it_not_worked_for_you/
99. De quervains tendonitis recovery — https://www.reddit.com/r/PEDs/comments/1isdmz1/de_quervains_tendonitis_recovery/
100. Finally got around to trying the bpc157 capsules — https://www.reddit.com/r/Supplements/comments/1rcxvm9/finally_got_around_to_trying_the_bpc157_capsules/
101. Need guidance — https://www.reddit.com/r/PeptideGuide/comments/1s4vose/need_guidance/
102. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi9owhr/
103. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/dus0n8q/
104. Compound experience saturday bpc157 — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/dutyok7/
105. And it begins bpc 157 and tb 500 — https://www.reddit.com/r/backpain/comments/1khc6p5/and_it_begins_bpc_157_and_tb_500/nokzab3/
106. Bpc 157 drinking reconstituted injectable vs — https://www.reddit.com/r/Peptides/comments/1u8m20w/bpc_157_drinking_reconstituted_injectable_vs/osdrkbj/
107. Experience with bpc157 and elbow tendinopathy — https://www.reddit.com/r/climbharder/comments/1j4fiij/experience_with_bpc157_and_elbow_tendinopathy/
108. My experience case study recovering from an a2 — https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/
109. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi3v7kp/
110. Compounds healing compounds bpc157 tb500 — https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/js5hfcw/
111. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4eq0n/
112. Compounds bpc157 my experience — https://www.reddit.com/r/steroids/comments/tqsoik/compounds_bpc157_my_experience/
113. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4uao6/
114. Bpc 157 tb500 side effect for 65 yrs old — https://www.reddit.com/r/Biohackers/comments/1u09ium/bpc_157_tb500_side_effect_for_65_yrs_old/oqhs3hp/
115. Compounds healing compounds bpc157 tb500 etc — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4iwuk/
116. Lifting 3 months after a broken wrist — https://www.reddit.com/r/moreplatesmoredates/comments/1l697k3/lifting_3_months_after_a_broken_wrist/
117. Accidentally took 30iu of bpc157 instead of 3iu — https://www.reddit.com/r/Peptides/comments/1teo1c6/accidentally_took_30iu_of_bpc157_instead_of_3iu/
118. Bpc157 and tb500 weekly update — https://www.reddit.com/r/Biohackers/comments/1sgf3q0/bpc157_and_tb500_weekly_update/
119. Is oral bpc157 less effective than injecting it — https://www.reddit.com/r/PEDs/comments/1o3g7qp/is_oral_bpc157_less_effective_than_injecting_it/niwej2s/
120. Pinched sciatic nerve — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/
121. Bpc157 for herniated disc l5 s1 — https://www.reddit.com/r/Sciatica/comments/uk0bhk/bpc157_for_herniated_disc_l5_s1/
122. Bpc157 saved my foot — https://www.reddit.com/r/Supplements/comments/1scedge/bpc157_saved_my_foot/
123. Bpc157peptides in general — https://www.reddit.com/r/climbharder/comments/lvmkqd/bpc157peptides_in_general/kcrhbqv/


---

# The Disc Recovery Stack

slug: the-disc-stack · https://miscsubjects.com/a/the-disc-stack · tags: stack, disc, herniated-disc, degenerative-disc-disease, peptides · updated 2026-08-04T20:35:13.192Z

A disc stack is two or more compounds taken at the same time for a worn or bulging spinal disc — most often BPC-157 with TB-500, sometimes with ARA-290 added for the leg pain, sometimes alongside a weight-loss drug. Each compound is aimed at a different step in how a disc fails.

Underneath all of it is one arithmetic. A disc is being broken down at some speed and built back at some other speed, and how your back feels in six months is decided by which of the two is faster. Every single thing on the list below — walking, smoking, a needle, a tablet, a vial — moves one of those two speeds by some amount. What decides your outcome is not any one of those amounts. It is the sum.

That sum is what almost nothing has been measured on. Nobody with a bad disc runs one variable. They are walking or not walking, sleeping six hours or eight, carrying an extra thirty pounds or not, taking ibuprofen daily or not, and injecting one compound or three — all in the same week. The individual numbers below are real and mostly good. The combined numbers, with three exceptions, do not exist, and where they do exist one of them came back negative.

## A worn disc is two speeds, and the slow one is the blood supply

The disc is the largest structure in the body with almost no blood supply of its own. Small vessels reach the outermost fibres of the tough outer ring and stop there; the soft centre is fed by fluid seeping through the bone above and below it. Every repair process in the body runs on blood delivery, so the disc rebuilds more slowly than any other load-bearing tissue you own.

[[embed:source:s1]]

That does not mean the rebuild side loses. Pooled across eleven cohort studies of people managed without surgery, 66.66% of herniated discs shrank on their own (95% CI 51% to 69%). In the United Kingdom subset the figure was 82.94%; in the Japanese subset, 62.58%.

[[embed:source:s2]]

The shrinking is done by immune cells that treat the displaced fragment as foreign material, digest it, and bring new blood vessels in behind them to carry the debris away.

[[embed:source:s3]]

Two things follow from that pair of facts, and they set up everything else. First, the rebuild side already wins about two times in three with nobody doing anything. Second, the mechanism it wins by is inflammation plus new blood vessel growth — which is precisely the mechanism a daily anti-inflammatory tablet is designed to shut down.

[[embed:degenerative-disc-disease]]

## Genetics puts a number on each thing that wears a disc down

Observational studies of back pain are badly confounded: people who smoke also move less, weigh more and sleep worse, so an association tells you almost nothing about direction. Mendelian randomisation gets around that by using inherited gene variants as the exposure — you are assigned your variants at conception, before any lifestyle exists, so the arrow can only point one way.

A 2026 synthesis pooled twenty such studies in people against disc degeneration and put an odds ratio on each factor. An odds ratio of 1.26 means roughly a 26% higher chance of the outcome per unit of the exposure.

| What moves the breakdown speed | Odds of disc degeneration | How to move it |
|---|---|---|
| Time spent sitting watching television | 1.78 (1.52–2.08) | Stand up and walk; this is the largest lifestyle number in the set |
| Body mass index | 1.26 (1.14–1.38) | Weight loss by any route |
| Waist circumference | 1.26 (1.04–1.53) | Same lever, measured at the belly |
| Smoking, ever having started | 1.22 (1.12–1.33) | Stopping — with a caveat below |
| Triglycerides in the blood | 1.08 (1.03–1.13) | Diet, weight loss, movement |
| Type 2 diabetes | 1.05 (1.03–1.07) | Glucose control |
| Higher bone density | 1.20 (1.15–1.25) | Not a lever — you would not lower it on purpose |

[[embed:source:s8]]

The body-mass row has a second, condition-specific measurement behind it. A meta-analysis of observational studies in people found overweight raised the odds of nerve-root leg pain by 1.23 and obesity by 1.40 — the same direction as the genetic estimate, in the exact symptom most people with a disc actually have.

[[embed:source:s4]]

Read the television row again, because it is the one nobody talks about. Genetically predicted television time carried a larger effect on disc degeneration than smoking, weight, blood fats and diabetes. Sitting still is the biggest modifiable factor in the whole causal set.

On stopping smoking, the honest answer has a limit in it. Rats exposed to cigarette smoke for eight weeks developed cracked, torn, misaligned outer rings and fibrous tissue in the soft centre. After they stopped, the degeneration stopped getting worse and the soft centre regained some of its gel-like material. The physical misalignment of the outer ring did not come back, and the inflammatory signal IL-1beta was still raised eight weeks after the last cigarette.

[[embed:source:s17]]

So stopping smoking halts the slide and buys back part of the chemistry, and does not undo the structural damage already done. That distinction — halting versus reversing — applies to almost every item on this page.

Two more entries on the breakdown side, both self-inflicted by treatment rather than by lifestyle.

Repeated steroid injections into the spine cost bone. Three thousand injected patients were compared with three thousand matched controls; each successive injection raised the risk of a vertebral fracture by a factor of 1.21 (95% CI 1.08 to 1.30). One injection is a small bill. A course of six is a compounding one.

[[embed:source:s14]]

Months of daily anti-inflammatories buy less pain relief than most people assume and work against the clearance mechanism described above. Pooled across 32 trials and 5,356 people with acute back pain, the drugs beat placebo by 7.29 points on a 0–100 pain scale — a difference the Cochrane reviewers called small and probably not clinically relevant.

[[embed:source:s21]]

[[embed:bpc-157-vs-nsaids]]

## Walking is the only item on this page with a hazard ratio behind it

WalkBack randomised 701 Australian adults who had just recovered from a back pain episode into either an individualised, progressive walking programme with six physiotherapist sessions over six months, or no treatment at all. The walking group went a median 208 days before their next activity-limiting episode (95% CI 149–295). The control group went 112 days (89–140). The hazard ratio was 0.72 (95% CI 0.60–0.85, p=0.0002) — meaning that at any given moment, a walker's chance of the pain returning was 28% lower.

[[embed:source:s7]]

Two details in that trial matter for anyone assembling a combination. It cost AU$7,802 per quality-adjusted life-year, which made it cost-effective with 94% probability. And it was not free of harm: lower-limb adverse events ran 100 in the walking group against 54 in the control group.

For pain that is already chronic rather than recurring, structured exercise pooled across 249 randomised trials in people produced roughly a 15-point improvement on a 0–100 scale against no treatment or usual care — about double what an anti-inflammatory delivers for acute pain, and roughly five times what one delivers for chronic pain.

[[embed:source:s10]]

That is the whole evidence-based core of a disc recovery plan, and it is walking and loading. Everything else on this page is added on top of it, and nothing else on this page has a number that comes close.

## Three things sold as the raw material for the rebuild were tested and did nothing

The intuition that a rebuilding tissue needs feeding is reasonable. The intuition has been tested three times and lost three times, and a page that skipped that would be selling something.

Collagen. Thirty-nine recreationally active men took either 15 g of collagen peptides daily or a placebo through 15 weeks of supervised lower-body resistance training. Both groups gained tendon stiffness (+17.3% collagen, +20.9% placebo) and Young's modulus (+17.8% versus +20.6%). Between the groups, nothing: no difference on any tendon measure, with p-values between 0.365 and 0.877. The training built the tendon. The powder added nothing detectable.

[[embed:source:s12]]

Vitamin D. Ten randomised trials in people with chronic low back pain, pooled: standardised mean difference −0.130 (95% CI −0.260 to 0.000), which touches zero. Long-term dosing did not help either, and neither did the active forms. Baseline vitamin D status made no difference to the result.

[[embed:source:s13]]

Weight loss on its own, once exercise is already in place. Across 22 trials and 3,602 people, weight-loss interventions beat minimal care on pain (SMD −0.54) — but head to head against exercise alone, in four trials and 673 people, weight loss was no better (SMD −0.13, 95% CI −0.40 to 0.14). The credibility of the whole body of evidence was rated very low.

[[embed:source:s11]]

That last result is a compounding finding, not a single-factor one, and it is the first of only three real interaction measurements on this entire page. Weight loss and exercise are not additive in the way the arithmetic of the two-speeds model would suggest. They overlap. Buying both does not buy you twice.

## Each peptide is aimed at a different step, and none has been put near a disc

BPC-157 is a fifteen-amino-acid chain based on a sequence found in human stomach fluid. In rats it raises VEGF, the signal that grows new blood vessels into damaged tissue, and drives connective-tissue cells to move into an injury and rebuild it. A cut rat Achilles tendon treated with it came back mechanically stronger than an untreated one.

[[embed:bpc-157]]

TB-500 is a seven-amino-acid fragment of a larger natural protein, thymosin beta-4. In animals it acts on cell movement and on the organisation of collagen laid down in a healing wound. The molecule in the vial and the molecule in most of the published research are not the same thing, which is covered in full on its own page.

[[embed:tb-500]]

The reason a nerve compound is in a disc stack at all is that a large share of the pain is chemical rather than mechanical. Material leaking from a torn disc releases TNF-alpha and IL-1beta onto the nerve root, and those two signals are the ones tied to both the ongoing breakdown of the disc and the pain itself.

[[embed:source:s5]]

ARA-290 is the only one of the three with randomised human evidence of any kind. In a 28-day phase 2b trial, 64 people with sarcoidosis-related small nerve fibre loss and nerve pain took 1, 4 or 8 mg a day or placebo. At 4 mg the corneal nerve fibre area rose by 697 µm² over placebo (95% CI 159–1,236, p=0.012), and regenerating skin nerve fibres rose too (p=0.035). Pain improved in every group including placebo; the placebo-corrected pain difference in the moderate-to-severe subgroup did not reach significance (p=0.157).

[[embed:source:s16]]

[[embed:ara-290]]

Read that carefully, because it is the strongest human result any compound in this stack has, and it is about a nerve in an eye of a person with sarcoidosis. Nobody has run ARA-290 against a nerve root squeezed by a disc. Human evidence in one tissue and one disease does not transfer to another by argument.

Retatrutide is not a disc compound at all. It is a weight-loss drug, and its only relevance here runs through the body-mass row of the table above: less load on the column, no direct action on disc tissue.

[[embed:retatrutide]]

[[embed:what-are-peptides-herniated-disc]]

## The one experiment that tested the pair found no bonus for taking both

This is the single most important result on this page, and it is the one that the phrase "the repair pair" was invented before anybody had.

In 2026, 32 male Sprague-Dawley rats, each about 330 g, had their Achilles tendon cut and repaired, then were split into four groups of eight: control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and both together. Everything was injected into the belly, daily, for four weeks.

Results, arm by arm:

| Arm | Load to failure | Tissue architecture score | Verdict |
|---|---|---|---|
| Control | baseline | baseline | — |
| BPC-157 alone | higher, not statistically significant | numerically better, not significant | signal without proof |
| TB-500 alone | higher, significant (p<0.05) | Bonar p=0.016, Movin p=0.017 | the only arm that moved the mechanical number |
| Both together | not significantly better than either alone | Movin p=0.040 | no bonus for the second compound |

The authors' own sentence: "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone."

[[embed:source:s9]]

Their proposed explanation is that the two compounds converge on the same downstream machinery, so the second one has nothing left to add. They flag it as a hypothesis needing confirmation.

Now negate it properly, because a single result does not settle a question in either direction. Eight rats per arm is small. An additive effect of, say, 15% would very likely be missed at that sample size. The endpoint was a tendon at four weeks, not a disc at six months. The route was into the belly, which is not how anybody takes either compound. And no dose-response work was done, so a different ratio of the two might behave differently. What the experiment establishes is narrow and real: at these doses, in this tissue, on these endpoints, the pair did not beat the better single compound. What it does not establish is that combining them is pointless everywhere.

The claim it does damage to is specific. Anyone who tells you the two compounds are synergistic is describing a mechanism, not a measurement. The measurement exists, it was taken in 2026, and it came back flat.

## Six real combinations, side by side

Nobody chooses one row of the tables above. They choose a whole column of behaviour. Here are six combinations a person with a bad disc actually ends up in, with what is known about each part, what is known about the parts in combination, and where the interaction has never been measured.

| The combination | What each part is measured at, alone | What is measured about the combination | Never measured |
|---|---|---|---|
| **A. Walking 25 min/day + adequate protein + BPC-157 + TB-500** | Walking: hazard ratio 0.72, 701 people, HUMAN. Protein/collagen: no tendon effect over placebo in 39 men, HUMAN. BPC-157: rat tendon repair, ANIMAL. TB-500: rat tendon repair, ANIMAL | The two peptides together: no benefit beyond either alone in 32 rats, ANIMAL | Walking with either peptide, in any species. Any of it in a human disc |
| **B. Smoking + no movement + repeated steroid injections + daily anti-inflammatories** | Smoking: odds 1.22, HUMAN. Sitting: odds 1.78, HUMAN. Each steroid injection: 1.21× fracture risk, HUMAN. Anti-inflammatories: 7.29/100 points of pain relief and suppression of the clearance mechanism, HUMAN | Nothing. Not one study has combined these four | Everything. This is the most common real-world combination and the least studied |
| **C. Walking alone, nothing else changed** | Hazard ratio 0.72 for recurrence; ~15/100 points for chronic pain across 249 trials, HUMAN | This is the measured baseline every other row should be compared against | — |
| **D. Both peptides, no change to movement or weight** | Rat tendon data only, ANIMAL | The pair, in rats: no additive benefit, ANIMAL | Whether peptides do anything at all when the load driving the damage is unchanged |
| **E. Weight loss on a GLP-1 drug + walking, no peptides** | Weight: odds 1.26 per unit of body mass index, HUMAN. Walking: hazard ratio 0.72, HUMAN | Weight loss versus exercise alone, head to head: no added benefit, 4 trials, 673 people, HUMAN | Retatrutide specifically — a 586-person trial is running and reports in 2027 |
| **F. Everything: walking + weight loss + BPC-157 + TB-500 + ARA-290** | Each part as above; ARA-290 has 64-person HUMAN data in a different disease | Nothing whatsoever | The entire combination. No study in any species has given three of these compounds together |

Read column three. Across six combinations, the total measured interaction evidence is three findings: weight loss adds nothing on top of exercise in people, the two peptides add nothing on top of each other in rats, and nothing else has been looked at.

## The interactions nobody has measured, written down so the holes are visible

Naming a gap is a finding. These are the specific pairs and triples that a person assembling a stack is implicitly betting on, with no measurement behind them:

- BPC-157 combined with any form of exercise, in any species.
- Either peptide combined with an anti-inflammatory drug — which matters, because the drug suppresses the same new-blood-vessel step the peptide is proposed to drive. Rats given BPC-157 alongside diclofenac had less gut damage, but nobody measured the tendon.
- ARA-290 combined with either of the other two, in any species.
- Any of the three during active shrinking of a herniation, where the body's own immune clean-up is already running.
- Weight loss combined with either peptide.
- All three peptides together, which is what the popular stack actually is.
- Any of it against the 66.66% background rate of the disc fixing itself. This is the sharpest hole: without a control arm, a person who improves on a stack cannot tell whether the stack did it or whether they were in the two-thirds.

## Every claim above, against the thing that would break it

A claim counts as established only after it has survived its own negation. Here is each substantive claim on this page put against what would falsify it, and whether that test has been run.

| Claim | Tier | What would break it | Has that been tested? |
|---|---|---|---|
| Most herniations shrink without treatment | HUMAN | A cohort where imaging shows no change in most people | Tested repeatedly; 11 cohorts pooled at 66.66% |
| Walking lowers the recurrence rate | HUMAN | A randomised trial where the walking arm relapses as fast as controls | Tested; 701 people; walking arm went 96 days longer |
| Sitting is the largest modifiable driver of degeneration | HUMAN | A causal-genetic study putting television time below smoking or weight | Tested in 20 pooled studies; television time came out highest at 1.78 |
| Supplying raw material speeds tissue rebuilding | HUMAN | A trial where collagen plus training beats training alone | Tested; 39 men, 15 weeks, no between-group difference |
| Vitamin D helps chronic back pain | HUMAN | A pooled result whose confidence interval excludes zero | Tested; 10 trials; interval touches zero |
| Weight loss adds to exercise | HUMAN | A head-to-head trial where the combined arm beats exercise alone | Tested; 4 trials, 673 people; no added benefit |
| BPC-157 and TB-500 are synergistic | ANIMAL | An experiment where the combined arm beats both single arms | Tested once, 2026, 32 rats: the combined arm did not beat either alone |
| BPC-157 rebuilds tendon | ANIMAL | Rat tendons treated with it failing at the same load as controls | Tested; treated tendons failed at higher loads; never tested in a person |
| ARA-290 regrows nerve fibres | HUMAN | A randomised trial where nerve fibre area does not rise over placebo | Tested; rose 697 µm² over placebo at 4 mg, p=0.012, in sarcoidosis |
| ARA-290 relieves nerve pain from a squeezed nerve root | — | Any randomised trial in that population | Never run. This claim is untested, not supported |
| Any peptide here changes a human disc | — | An imaging trial with a placebo arm | Never run in any species |
| Repeated steroid injections are consequence-free | HUMAN | A matched cohort showing no rise in fracture risk with injection count | Tested; each injection multiplied fracture risk by 1.21 |
| Sleep matters to how a disc feels | HUMAN | A crossover trial where cutting sleep does not change pain thresholds | Tested; 39 volunteers; cutting sleep by 40% raised pain sensitivity, with no change in inflammatory blood markers |

[[embed:source:s15]]

One row deserves adding, because it is the only human evidence that a degenerated disc responds to anything regenerative at all. Pooled across trials of stem cell injection into painful degenerated discs, pain and disability scores improved — small studies, early, and the only positive human regeneration signal that exists for this tissue.

[[embed:source:s6]]

The three rows with no tier are the honest edge of this subject. They are not weak evidence. They are absence of evidence, and they sit in a table rather than in the headline because eleven of the fourteen rows above them have real numbers.

[[embed:herniated-disc]]

## Fifteen people who ran a combination, counted

**Fifteen first-person accounts on X, all self-reported, none verified, none from any trial. Ten of them ran two or more compounds together for a spine problem, and five ran BPC-157 on its own. One further account reports harm from the pair at a different site.**

**Of the ten who stacked, seven reported it helped, two reported partial benefit, and one reported none.**

Three weeks on the pair after an L4-L5 herniation, back on a basketball court against two months last time:

[[embed:source:s22]]

A 2017 L4/L5/S1 herniation with a degeneration diagnosis, and this person says he was pain-free within a month on the pair:

[[embed:source:s23]]

ARA-290 plus BPC-157 plus TB-500 for one month after spine surgery, with the sciatica reported 95% gone:

[[embed:source:s24]]

Lower spine degeneration, barely able to stand upright, and this person reports being pain-free on the pair and still dosing:

[[embed:source:s25]]

Retatrutide alongside a BPC-157/TB-500 blend, low back reported much improved — the only account here combining a weight-loss drug with the peptides:

[[embed:source:s27]]

Three compounds at once for severe back pain, reported cleared in three to four weeks:

[[embed:source:s28]]

Severe leg pain, reported 75% better the same evening and gone by day three:

[[embed:source:s30]]

**Partial — 2 of 10.** One month of the pair for lifelong back pain: recovery between flares got faster, and the pain is still there.

[[embed:source:s26]]

Six weeks of the pair for a dried-out lowest disc: biceps and shoulder pain gone, the disc itself only partly better and still needing physiotherapy.

[[embed:source:s29]]

**No benefit — 1 of 10.** One person ran the pair alongside a second stack for joint damage and called the whole thing a waste of money.

[[embed:source:s31]]

**Of the five who ran a single compound, one reported it helped, three reported nothing, and one reported that one compound did nothing for him while a different one worked.**

L5/S1 herniation, BPC-157 alone and deliberately unpaired, 90% pain reduction in two weeks:

[[embed:source:s33]]

The same compound healing a wrist and doing nothing for the same person's disc:

[[embed:source:s34]]

A week of it to avoid neck surgery; the surgery happened anyway:

[[embed:source:s35]]

Oral capsules taken instead of injections, and no help for a back:

[[embed:source:s37]]

One compound nothing for a back injury, the other clearing it in five days — which is the closest thing in this entire set to a within-person comparison, and it points at the two compounds not being interchangeable:

[[embed:source:s36]]

**Harm — 1 report.** Two months of the pair for knees brought slight improvement in the joints, along with badly disrupted sleep and lowered heart-rate variability. Both the sleep and the heart-rate variability went back to normal after stopping.

[[embed:source:s32]]

**What fifteen accounts settle, and what they cannot.** They cannot compare the stack against a single compound, even though the numbers above look like they do. The stacked group reported a better outcome rate than the single-compound group — 7 of 10 against 1 of 5 — and that difference is worthless as evidence. People who buy three vials have spent more, expect more, and are more likely to post a result. People who describe a null outcome tend to be answering somebody else's thread rather than writing their own. And every single one of these people is running against a background rate where two thirds of herniations resolve regardless.

What the accounts do settle is narrower and still worth having. The reported experience is not uniformly positive: four of fifteen describe no benefit for a spine, and one describes a genuine harm. Timelines that people report cluster at two to six weeks, which is faster than any animal tendon study would predict and is exactly the window in which spontaneous shrinking also happens. Nobody in this set reported a serious adverse event.

## Two registry entries that would move a row each, and a third that is only a template

Two entries on ClinicalTrials.gov are marked recruiting and would each convert one row of the tables above from mechanism into measurement. Neither of them is a disc. A third entry is listed below because it circulates as though it were a trial, and it is not one.

| Registry ID | What it tests | Size | Primary endpoint | Reports |
|---|---|---|---|---|
| NCT07035093 | Retatrutide in people with obesity or overweight and chronic low back pain, phase 3, Eli Lilly | 586 | Pain intensity and body weight change, to 72 weeks | Estimated September 2027 |
| NCT07437547 | BPC-157 for acute hamstring strain, phase 2, Hudson Biotech | 120 | Days to unrestricted sport, and MRI injury volume at day 14 under blinded central review | Estimated February 2027 |
| NCT07487363 | Not a trial. A record that declares itself a fictional example, written in the style of a TB-500 study of cardiovascular markers in stable arterial disease, phase 1/2, Hudson Biotech | 80, stated inside the example | Treatment-emergent adverse events at 12 weeks, stated inside the example | Nothing will ever report |

Read the third row against its own record before counting it. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." It is a demonstration template, and any page citing it as proof that TB-500 is being tested in people is citing a placeholder. Its sponsor, Hudson Biotech, filed eight entries of that shape between 2 and 15 February 2026, one of which is the BPC-157 hamstring entry in the row above it.

[[embed:source:s18]]

[[embed:source:s19]]

[[embed:source:s20]]

The BPC-157 hamstring trial is the one worth watching, because MRI injury volume under blinded review is the first objective tissue measurement of this compound in a person. If it comes back flat, the entire rat literature stops transferring. If it comes back positive, the disc question becomes worth running rather than worth arguing about.

## What holds always, what holds never, and what depends on something

**Foundational — true with everything else stripped away.** The disc has almost no blood supply and rebuilds slowly. Immune cells and new blood vessels are what remove a herniated fragment. Load, weight, sitting time, smoking and blood sugar act on the breakdown speed. Movement acts on the rebuild speed. BPC-157 and TB-500 are proposed to act on the rebuild speed by improving blood vessel growth and connective tissue repair. ARA-290 acts on nerve fibres, not on the disc.

**Always true.** Two out of three herniations shrink without treatment, so any uncontrolled personal result is uninterpretable. Every steroid injection adds fracture risk in proportion to the count. Any claim about a peptide in a human disc rests on zero measurements in any species.

**Never true.** No compound named on this page is an approved medicine for a disc anywhere in the world. No published experiment has found a bonus from combining BPC-157 with TB-500 — the one experiment that tested it found none. No trial has combined a peptide with exercise, with weight loss, or with an anti-inflammatory.

**Conditional, with the dependency named.** Walking lowers recurrence risk by 28% — in adults who have recently recovered from an episode, over six months of a progressive programme with physiotherapist contact, not in someone in acute pain today. Stopping smoking halts further degeneration and partly restores the gel in the soft centre — in rats, over eight weeks, and it does not reverse the structural misalignment. ARA-290 regrows nerve fibres — in 64 people with sarcoidosis, at 4 mg a day for 28 days, measured in the cornea. BPC-157 strengthens a healing tendon — in rats, injected into the belly, at 10 µg/kg/day, measured at four weeks. TB-500 improves tendon architecture and load to failure — in rats, at 60 µg/kg/day, on the same schedule. Weight loss reduces back pain — against minimal care, and not against exercise.

Red-flag symptoms are the exception to everything above and are not a matter of weighing evidence: loss of bladder or bowel control, numbness across the area that would contact a saddle, or weakness that is getting worse are emergencies and need a hospital the same day. Nothing on this page is a dose, a schedule or a recommendation to take anything, and every compound named is unapproved for disc disease. TB-500 and BPC-157 are both banned in tested sport at all times.


## Sources

1. Discogenic Low Back Pain: Anatomy, Pathophysiology and Treatments of Intervertebral Disc Degeneration — https://pmc.ncbi.nlm.nih.gov/articles/PMC9820240/
2. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-Analysis — https://pubmed.ncbi.nlm.nih.gov/28072796/
3. Characteristics and mechanisms of resorption in lumbar disc herniation — https://pmc.ncbi.nlm.nih.gov/articles/PMC9396855/
4. Obesity as a Risk Factor for Sciatica: A Meta-Analysis — https://academic.oup.com/aje/article/179/8/929/108237
5. Disc in Flames: Roles of TNF-alpha and IL-1beta in Intervertebral Disc Degeneration — https://pmc.ncbi.nlm.nih.gov/articles/PMC4751407/
6. Mesenchymal stem cells can improve discogenic pain in patients with IVD degeneration: a meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC10313064/
7. WalkBack: individualised progressive walking to prevent low back pain recurrence — randomised trial, 701 adults (Lancet 2024, PMID 38908392) — https://pubmed.ncbi.nlm.nih.gov/38908392/
8. Causal links between multi-domain risk factors and disc degeneration: meta-analysis of 20 Mendelian randomization studies (BMC Musculoskelet Disord 2026, PMID 42243749) — https://pubmed.ncbi.nlm.nih.gov/42243749/
9. BPC-157, TB-500 and the two together on rat Achilles healing — 32 rats, 8 per arm (Jt Dis Relat Surg 2026, PMID 42542926) — https://pubmed.ncbi.nlm.nih.gov/42542926/
10. Exercise therapy for chronic low back pain (Cochrane 2021, 249 trials, PMID 34580864) — https://pubmed.ncbi.nlm.nih.gov/34580864/
11. Weight-loss interventions for pain and disability in musculoskeletal disorders — 22 trials, 3,602 participants (JOSPT 2020, PMID 32272032) — https://pubmed.ncbi.nlm.nih.gov/32272032/
12. 15 g/day collagen peptides plus 15 weeks of resistance training, 39 men — tendon outcomes (Med Sci Sports Exerc 2023, PMID 37436929) — https://pubmed.ncbi.nlm.nih.gov/37436929/
13. Vitamin D supplementation for chronic low back pain — 10 randomised trials (In Vivo 2024, PMID 39477425) — https://pubmed.ncbi.nlm.nih.gov/39477425/
14. Vertebral body fractures after lumbar epidural steroid injections — 3,000 injected vs 3,000 propensity-matched controls (JBJS Am 2013, PMID 23780532) — https://pubmed.ncbi.nlm.nih.gov/23780532/
15. Partial-night sleep restriction and pain sensitivity — 39 healthy volunteers, crossover (Scand J Pain 2025, PMID 41021423) — https://pubmed.ncbi.nlm.nih.gov/41021423/
16. Cibinetide (ARA-290) phase 2b in sarcoidosis-associated small nerve fibre loss — 64 people, 28 days (IOVS 2017, PMID 28475703) — https://pubmed.ncbi.nlm.nih.gov/28475703/
17. Rat discs after 8 weeks of smoke exposure and after stopping (J Orthop Sci 2006, PMID 16568393) — https://pubmed.ncbi.nlm.nih.gov/16568393/
18. NCT07035093 — retatrutide in people with obesity or overweight and chronic low back pain, phase 3, 586 participants (Eli Lilly) — https://clinicaltrials.gov/study/NCT07035093
19. NCT07437547 — BPC-157 for acute hamstring muscle strain, phase 2, 120 participants (Hudson Biotech) — https://clinicaltrials.gov/study/NCT07437547
20. NCT07487363 — a record that declares itself a fictional example, written in the style of a TB-500 (thymosin beta-4 17-23 fragment) study of cardiovascular biomarkers in stable atherosclerotic disease, phase 1/2, 80 participants (Hudson Biotech) — https://clinicaltrials.gov/study/NCT07487363
21. Anti-inflammatory drugs for acute low back pain — 32 trials, 5,356 participants (Cochrane 2020, PMID 32297973) — https://pubmed.ncbi.nlm.nih.gov/32297973/
22. Herniated L4-L5, three weeks on BPC-157 with TB-500, back on the court (anecdotal, X, 2026-07-28) — https://x.com/thebillyboone/status/2082100039707427193
23. Severe L4/L5/S1 herniation and a degeneration diagnosis, pain-free within a month on the pair (anecdotal, X, 2026-07-26) — https://x.com/jasonsvoboda/status/2081426443024961838
24. ARA-290 plus BPC-157 plus TB-500 for one month after back surgery, sciatica reported 95% gone (anecdotal, X, 2026-07-25) — https://x.com/cryptorayray89/status/2081141222719045707
25. Lower spine degeneration, reported pain-free on BPC-157 with TB-500, still dosing (anecdotal, X, 2026-07-25) — https://x.com/KateinMB/status/2080854619593363787
26. One month of the pair for lifelong back pain — recovery faster, pain still present (anecdotal, X, 2026-07-23) — https://x.com/BrandBarons/status/2080279766796562881
27. Retatrutide alongside a BPC-157/TB-500 blend, low back reported improved (anecdotal, X, 2026-07-08) — https://x.com/yakyusenshu23/status/2074846700674674986
28. Three compounds at once for back pain, cleared in three to four weeks (anecdotal, X, 2026-06-03) — https://x.com/mannyjplays/status/2062148959976526143
29. Six weeks of the pair — shoulder and biceps resolved, the disc only partly (anecdotal, X, 2026-07-31) — https://x.com/MuroCrypto/status/2083184469956059529
30. Severe leg pain, reported gone over three days on BPC-157 with TB-500 (anecdotal, X, 2026-08-02) — https://x.com/L0V3lsKeY/status/2083868515438666186
31. The pair called a waste of money for joint damage (anecdotal, X, 2026-05-21) — https://x.com/jakew/status/2057454035855094005
32. Two months of the pair for knees — slight improvement, sleep and heart-rate variability disrupted until stopping (anecdotal, X, 2026-07-28) — https://x.com/franchupardo/status/2082241971582579132
33. L5/S1 herniation, BPC-157 alone and deliberately unpaired, 90% pain reduction in two weeks (anecdotal, X, 2026-07-23) — https://x.com/NewsAsset/status/2080378902984458706
34. BPC-157 worked on a wrist and did nothing for the same person's herniated disc (anecdotal, X, 2026-05-18) — https://x.com/derek_j_scv/status/2056494210963107983
35. A week of BPC-157 to avoid neck surgery, surgery happened anyway (anecdotal, X, 2026-04-30) — https://x.com/NICKELL11b/status/2049997364883030236
36. One of the two did nothing for a back injury, the other cleared it in five days (anecdotal, X, 2026-04-12) — https://x.com/PeptideRookie/status/2043371104731910313
37. Oral BPC-157 capsules did not help a back problem (anecdotal, X, 2026-03-01) — https://x.com/AhaSahhDude/status/2027919309620609260